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1. INTRODUCTION 
 
1.1. Tuberculosis  
 
1.1.1. Mycobacterium tuberculosis 
Robert Koch discovered in 1882 that tuberculosis (TB) is caused by Mycobacterium 
tuberculosis (MTB). MTB is a highly aerobic, non-motile, non-encapsulated, non-
spore-forming slender rod measuring 0.4 x 3 ȝm. The division rate is slow (15-20 
hours). A peptidoglycan wall rich in lipidoglycans makes MTB extremely resistant to 
desiccation as long as it is protected from UV-light,6 and constitutes an important 
survival strategy reflected in the high proportion of the bacterial genome (~30%) 
which is involved in the synthesis or metabolism of lipids.7 MTB is not visible after 
gram staining but can be stained by acid-fast staining and is thus visible by Ziehl-
Neelsen or auramine staining methods. MTB is one of 8 mycobacterial species within 
the MTB complex, which members are causative agents of human and animal 
tuberculosis. Other species capable of causing human tuberculosis are M. bovis, M. 
bovis BCG, M. africanum and M. canetti, but MTB is indeed the most important.6 
 
1.1.2. Infectious spread and clinical presentation 
Pulmonary TB is the most frequent clinical presentation that accounts for 60-90% of 
the TB cases depending on ethnic background, age, co-morbidity and immune status 
as well as the genotype of the MTB strain.8 The classical symptoms of pulmonary TB 
are chronic purulent cough, loss of appetite and weight, fever and night sweats and 
hemoptysis,9 but these symptoms might be less prominent in children <3 years and in 
patients with HIV infection or other immunosuppressive diseases.10-12 Subjects with 
pulmonary TB constitute the infectious source by shedding bacteria while coughing,13, 
14 and such a patient infects on average 10-15 persons each year if left untreated.15 
Close household contacts of the index case have the highest exposure to infected 
aerosols and are very likely to get infected16 as <10 bacilli might be sufficient to 
establish an infection in the lung.6 Corresponding to an evolving delayed-type 
hypersensitivity reaction towards mycobacteria, a primary complex, or Gohn focus 
which consists of a granuloma, usually located close to the pleura in the lower part of 
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the upper lobe or in the upper part of the lower lobe, and enlarged adjacent hilar 
lymph nodes, provides radiologic evidence of an established lung infection.17 
 
About 5-10% of infected subjects develop TB disease during their lifetime,15 half 
within the first 18-24 months of infection.18, 19 Without re-exposure the risk gradually 
declines.20, 21 Bacterial growth is favored in the upper lung-lobes rich in oxygen,4 
explaining the typical localization of TB lesions in adult cavitary disease22. 
Extrapulmonary disease occur in 15-30% of cases and can be localized to virtually 
any organ causing lymphadenitis (30%), TB of the urogenital tract (16-20%), 
osteoarticular TB (7-15%), meningitis or tuberculoma (4%) or pericarditis (0.14-
0.3%).23 Children <2 years at the time of MTB infection and immune compromised 
subjects are at increased risk of progression to TB and more susceptible to severe 
manifestations like disseminated TB and meningitis22, 24-27 (Table 1).  
 
Disease 
manifestation 
<1 year at    
infection 
1-2 years at 
infection 
>10 years 
at infection 
No disease 50% 70-80% 98% 
Pulmonary 
disease       
(3-7 months 
postinfection) 
30-40% 10-20% 30-40% 
(Ghon focus, 
lymph node or 
bronchial) 
(Ghon focus, 
lymph node or 
bronchial) 
(effusion or 
adult type) 
TB 
meningitis 
or miliary     
(1-3 months 
postinfection) 
10-20% 2-5% <0.5% 
*adapted from Marais et al. State of the Art. Int J Tuberc lung dis, 
2004, vol 8 22. 
 
More than 90% of immune competent adults will naturally control the infection and 
develop no symptoms.28 The current paradigm states that few will eradicate the 
bacteria,5, 14, 29  however, some studies raise the possibility that some persons 
eliminate MTB shortly after infection30 or even later if protected from re-exposure.20 
Evidence of previous MTB exposure and latent tuberculosis infection (LTBI) can be 
provided by the presence of a primary complex/Gohn focus on chest X-ray, and/or a 
positive tuberculin skin test (TST/Mantoux) or interferon-gamma-release-assay 
(IGRA).12 Nevertheless, MTB persistence represents a risk of TB progression,31 
Table 1. The 
manifestations of 
TB depend on age 
at infection  
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particularly if the immunity wanes as may be seen by HIV co-infection or by 
administration of immune-suppressive drugs.32, 33 The life-time risk of TB in HIV co-
infected subjects is estimated to 30-40%.15 
 
1.1.3. History of the tuberculosis epidemic 
MTB and man have co-existed since their common origin in Africa.34 Six 
phylogenetic MTB lineages (lineages which share the same ancestor) exist which 
associate with 6 different geographic regions on the globe, and thus constitutes a 
sympatric pattern of host-pathogen co-existence (Sympatric: host and pathogen 
originates from the same geographical region).34, 35 Transmission of MTB is 
facilitated in sympatric host-pathogen combinations compared to allopatric host-
pathogen combinations (host and pathogen originates from different geographical 
regions).35 The earliest evidences of TB in man are provided by lesions in fossil bones 
that date back to about 8000 BC. TB, historically named phthisis or consumption, has 
been a constant threat to mankind, hitting hardest in densely populated urban 
settings.36 TB was the leading cause of death in the western world in the 19th century, 
responsible for up to 20 % of deaths.37 The TB prevalence started to decline as a 
result of general public-health initiatives like isolation of patients in institutions, and 
not as a consequence of vaccination and treatment.37, 38 This can be exemplified by 
London, where the decline started after implementation of the Poor Law (1834) which 
stated that relief for the poor should only be given within the walls of the workhouses. 
After Koch’s discovery of the tubercle bacillus (1882) and the emerging assumption 
of infectivity,39 Prussian physicians introduced strict isolation and treatment of 
patients in sanatoriums.36 This led to a more rapid decline in TB prevalence in Prussia 
compared to other European countries and the United States, despite the fact that 
Prussia had the most crowded living conditions at that time.37 In 1921, a vaccine, 
Bacille Calmette-Guérin (BCG), developed by Calmette and Guérin was introduced, 
and proved to protect children,36 but could not prevent pulmonary disease in adults.40 
Furthermore, the sanatorium treatment by the strict rest cure consisting of “no known 
consumptions” (bed rest, fresh air, sun, healthy foods), optimized the patients capacity 
to fight MTB and supplemented the collapse therapy (1930s) (pneumothorax and 
thoracoplasty).36 Nevertheless, the mortality remained high until the discovery of the 
effect of streptomycin on TB (Waksman 1943). Other anti-TB agents were introduced 
shortly thereafter,36, 41 and Sir John Crofton initiated extensive trials of multi-drug 
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regimens in order to prevent relapses by resistance to drugs used in mono-therapy. In 
the early 1970s, the introduction of rifampicin enabled entirely oral administrations 
for 6 months (short course) compared to the 18-24 months previously required for 
cure. With the introduction of successful treatment, long term sanatorium isolation 
was no longer needed and TB gradually got under control in the western world. 
Subsequently, the scientific and political interest in TB declined and TB surveillance 
was neglected. The burden of TB in the developing world was never addressed.38, 42-44 
In the late 1980s, the emergence of the HIV/AIDS epidemic and multi-drug-resistant 
(MDR) and extensively drug-resistant (XDR) MTB strains became an increasing 
threat to the western world. This proved the necessity for global initiatives to fight the 
TB epidemic. In 1993, WHO declared TB a global emergency.45 
 
1.1.4.  “Cure is the best prevention” (WHO) 
The World Health Organization (WHO) first focused on a global commitment to cut 
transmission by early detection of contagious pulmonary TB cases and effective 
treatment through the framework of Directly Observed Treatment Short-course 
(DOTS).46 DOTS includes governmental commitment to 1) active detection of TB 
cases, 2) standardized treatment directly observed by a health worker for at least 2 
months, 3) drug supply and 4) a standardized recording and reporting system that 
allowed assessment of treatment results. Despite successful implementation of DOTS 
programmes worldwide, the impact on TB incidence have been much less than 
estimated. This is likely attributable to changes in demographic-, epidemiological- 
and social factors which independently or by interaction increase the transmission and 
vulnerability to TB in the population.43, 44, 47 In 2000, United Nations (UN) Member 
States (191) agreed upon 8 Millennium Developmental Goals (MDGs) “for a better 
world”.48 MDG 6, Target C, concerns TB, and states that TB incidence should be 
halted and begin to reverse within 2015. The Stop TB Partnership was established to 
develop a strategy to achieve this goal, but ultimately defined more ambitious goals: 
1) by 2015, half the prevalence and death rates from the 1990 baseline, and 2) by 
2050, eliminate TB as a public health problem (defined as an incidence  1 TB case 
per 100 000). The consensus was that full implementation of The Global Plan To Stop 
TB 2006-2015 (Stop TB Strategy) would be needed for these targets to be met.49 
While simultaneously aiming at addressing social determinants for TB, expansion of 
the DOTS Strategy is still the fundamental basis of the Stop TB Strategy, but the 
15 
 
ultimate goal of elimination of TB cannot be achieved unless new tools (diagnostics, 
drugs and vaccines) are made available.43, 50 Therefore, promotion, support and 
coordination of relevant research are key elements in the Stop TB Strategy.49 
 
1.1.5. The burden of tuberculosis today 
Today, the global TB burden is considerable with an estimated 9.0 million new cases 
and 1.5 million deaths in 2013. HIV co-infection was present in 13% of new cases 
and HIV-patients accounted for 360 000 deaths. India had the largest number of 
incident cases in the world (2.0-2.3 million), which accounted for 26% of the global 
cases. The incidence rate fell at an average of 1.5% per year in the periode between 
2000 and 2013, ensuring that the MDG Target 6.c of halting and reversing the global 
TB incidence by 2015 has been achieved. Notably, an accelerated decline is required 
to achieve the goals of halving TB mortality and prevalence rates, but this is. Of the 
22 high burden countries that accounted for 82% of the world’s TB cases, 10 appear 
on track to meet all 2015 targets for reductions in incidence, prevalence and 
mortality.51 The risk of TB associates with low socio-economic status, but are affected 
by migration, increased urbanization and changes in demographics and life-style. The 
ongoing financial crisis already hinders tuberculosis-control programmes,28 and might 
therefore change the estimates of the TB burden by 2015 alone, or together with other 
political- and/or climate changes.44, 47 Furthermore, the promising gains in TB control 
are threatened by MDR- and XDR-TB, which constitutes 3.5% of new cases.51  
 
Latent TB infection is widespread and an estimated  2 billion individuals are latently 
infected around the globe.52 These subjects constitute a huge reservoir for TB disease 
and transmission,15 but the proportion of exposed/infected subjects who clear the 
infection is unknown.53 Pre-existing immunity in subjects with latent infection (or as a 
result of BCG vaccination) is likely to mediate accelerated containment of MTB in 
the case of re-infection, but does not provide full protection and might even cause a 
more violent tissue-destroying hypersensitivity reaction.53 Transition from latent TB 
to active TB is facilitated by factors which impair the host immunity. In 22 high 
burden countries which together have 80% of the estimated total TB burden, Lönnroth 
and Raviglione estimated the proportion of TB cases that could be attributed to 
specific risk factors (population attributable fraction (PAF)): malnutrition; 34%, 
smoking; 23%, HIV; 7%, diabetes; 6%, harmful alcohol use; 13% and indoor air 
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pollution; 26%. The relative importance of these factors depends on their prevalence, 
which differ between countries and regions.43 In addition, genetic variety in MTB 
strains affects virulence and transmission, and genetic variations between populations 
and individuals affect the susceptibility to TB.8, 44  
 
1.1.6. The diagnosis of MTB infection and disease 
The epidemiological situation and health resources differ considerably around the 
globe. In order to optimize the management of TB in the local setting, WHO has 
recommended the elaboration of national- or regional guidelines for diagnosis of 
MTB infection (latent TB) and disease (active TB).54-57  
 
1.1.6.1. MTB infection (latent TB) 
The diagnosis of MTB infection is relevant in assessing risk of TB in recently 
exposed contacts of infective TB cases, particularly in children aged <5 years,58 in 
screening of immigrants from TB high-endemic countries, HIV patients, and patients 
selected for immunosuppressive therapy. MTB infected subjects at risk of developing 
TB should generally be considered for isoniazid preventive therapy (IPT).58-60 The 
diagnosis relies on immunological tests (TST and/or IGRAs) which detect prior 
sensitization with mycobacterial antigens. The validation of both tests is complicated 
by the lack of a gold standard for latent MTB infection. Their performance depend on 
the population at risk and both tests have shortcomings in terms of sensitivity and 
specificity.61-64 Notably, Both TST and IGRAs are unable to conclude on 1) whether 
live MTB bacilli are present – a strict requirement for reactivation, and 2) the time-
point of infection, an important risk factor for TB progression.53 The ability of the 
tests to predict TB progression largely depends on the context: in low incidence 
settings the positive and negative predictive value of IGRAs seems better than TST, 
and the negative predictive value of IGRAs in this setting is very good. Notably, these 
findings are not valid in high incidence settings, making TST and IGRAs 
inappropriate tools to rule out TB.65-67 Importantly, the negative predictive value of 
IGRAs remains to be established in children and immunocompromised individuals.67 
 
1.1.6.1.1. Tuberculin Skin Test (TST) 
TST is an ancient tool which measures the in vivo delayed type hypersensitvity (DTH) 
in response to intradermally injected purified protein derivate (PPD) from an 
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attenuated M. bovis strain. The standard TST consists of 0.1ml with 2 tubercular units 
(TU) of Statens Serum Institute (SSI) tuberculin RT23. Some countries/regions use, 
PPD manufactured from other laboratories resulting in some variation in the M. bovis 
strain used. The test is read by recording the degree of induration measured in mm 48-
72 hours later. The induration results from a local inflammation triggered by memory 
T cells recognizing mycobacterial antigens presented by antigen-presenting cells 
(APCs) at the injection site (see 1.2 for further elaboration). TST conversion occurs 
about 6 weeks after exposure.68 The cut-off for a positive test depends on the 
epidemiological setting (mycobacterial exposure), BCG-vaccination and host 
immunity (Table 2).  
Table 2. The interpretation of TST depend on  risk of exposure and clinical factors 
Induration of  5 mm is considered 
positive in 
Induration of  10 mm is 
considered positive in 
Induration of  15 mm 
is considered positive in 
Ɣ Human immunodeficiency virus 
(HIV)-positive persons. 
Ɣ Recent contacts of TB patients. 
Ɣ Persons with fibrotic changes on 
chest radiograph consistent with prior 
TB. 
Ɣ Patients with organ transplants and 
other immunosuppressed patients 
(receiving the equivalent of 15 mg/d of 
prednisone for 1 month or more.  
Risk of TB in patients with 
corticosteroids increases with higher 
dose and longer duration.) 
Ɣ Recent immigrants (i.e., within the 
last 5 years) from high-prevalence 
countries. 
Ɣ Injection drug users. 
Ɣ Residents and employees† of the 
following high-risk congregate 
settings: prisons, nursing homes and 
other long-term facilities for the 
elderly, hospitals and other health 
care facilities, residential facilities for 
patients with acquired 
immunodeficiency syndrome (AIDS), 
and homeless shelters. 
Ɣ Mycobacteriology laboratory 
personnel. 
Ɣ Persons with the following clinical 
conditions indicating higher risk: 
silicosis, diabetes mellitus, chronic 
renal failure, some hematologic 
disorders (e.g., leukemias and 
lymphomas), other specific 
malignancies (e.g., carcinoma of the 
head, neck, or lung),weight loss of 
10% of ideal body weight, 
gastrectomy, and jejunoileal bypass. 
Ɣ Children < 4 years of age, or 
infants, children and adolescents 
exposed to adults at high-risk 
Ɣ Persons with no known 
risk 
Center for Disease Control and Prevention, 2013. 69 
PPD contains antigens widely expressed by mycobacteria. Subsequently, BCG-
vaccination after infancy and exposure to NTMs might affect the TST response, 
resulting in loss of specificity.65 As TST is an in vivo test has been concern of a 
boosting response by repeated testing.54  
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1.1.6.1.2. Interferon-gamma-release assay (IGRA) 
IGRAs measure the IFNȖ-release after in vitro stimulation (16-24 h) of whole blood 
with the antigens ESAT-6 (6 kDa Early Secretory Antigenic Target), CFP-10 (Culture 
Filtrate Protein 10) expressed by the region of difference (RD-1 region) of the 
mycobacterial genome and secreted by MTB during active replication.70 The RD-1 
region is present in a few mycobacterial species only (M. tuberculosis, M. africanum, 
M. kansasii, M. marinum leprae, M. marinum, M. smegmatis and M. szulgai)71 which 
increases the test specificity compared to TST both with regard to prior BCG-
vaccination and NTM exposure.65 Two IGRAs are currently commercially available: 
x QuantiFERON Gold In-tube (QFT), Cellestis, includes the antigens ESAT-6, 
CFP-10 and TB7.7 (RD-11 antigen53) and measures the amount of IFNȖ 
released from whole blood (ELISA platform).72 
x T-SPOT.TB, Oxford Immunotec, includes the antigens ESAT-6 and CFP-10 
and measures the number of effector T-cells that respond with IFNȖ-
production (by ELISPOT). The individual PBMC count is corrected for.73 
 
1.1.6.2. Tuberculosis (active TB) 
When active TB is clinically suspected at least two early morning (fasting) specimen 
should be obtained from sputum, gastric lavage or adequate tissue aspirates (ex: 
lymphadenitis). Specimens are stained with Ziehl-Neelsen (light microscopy) or 
auramine (fluorescence microscopy) to enable detection of acid-fast bacilli by direct 
microscopy. In addition, all specimens should be cultured for confirmed identification 
of MTB (designated confirmed TB) when adequate facilities and resources are 
available.74 Liquid culture systems are recommended, but solid culture medium 
(Lövenstein-Jensen) is more cost-effective in resource-limited settings. Drug-
susceptibility testing is recommended.52 Adequate specimens can be difficult to obtain 
in extrapulmonary- and paucibacillary disease which are more frequent in the 
immunocompromised patient74 and in children <5 years12. As a consequence, the 
diagnosis remains unconfirmed in 70-80% of young children (designated probable 
TB).75-77 A new molecular diagnostic test (Xpert MTB/RIF assay) detects the  MTB 
complex (defined in section 1.1.1) and rifampicin resistance (proxy for MDR) within 
2 hours but is more resource intensive and less sensitive than liquid culture.52, 75  
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Therefore, in clinical settings involving children <5 years and/or immune-
compromised patients the diagnosis of TB also relies on:58 
x a history of known TB exposure (contact with an infectious index case). 
x symptoms10 
x radiologic lesions consistent with TB (chest, spine/bone or brain).  
TST or IGRAs might be tempting to use as evidence of a previous encounter with 
MTB, but neither test can be used as a rule-out test, nor distinguish latent from active 
TB, and are therefore not recommended in the diagnosis of active TB.54, 56, 57, 74, 78 
Nevertheless, in smear-negative symptomatic children with a chest X-ray consistent 
with TB, either known exposure or a positive TST/IGRA was until recently 
recommended for the diagnosis of active TB.74 Reduced sensitivity of TST/IGRAs in 
young children can therefore result in under-diagnosis of TB. New recommendations 
for the diagnostic approach in young children include a broader clinical evaluation.12 
 
1.2. The host immune response to Mycobacterium tuberculosis infection and host-
pathogen interaction 
 
The outcome of MTB infection; immediate progression to TB, latent infection (with 
or without later re-activation resulting in TB) or clearance (with or without induction 
of adaptive immune responses) depends on the host-pathogen interaction.1, 79 The host 
response is also influenced by BCG-vaccination or exposure to other mycobacteria,80 
age (young children81 or elderly82), genetic factors,83, 84 malnutrition85 and vitamin 
deficiencies (vitamin A86, vitamin D87, 88, co-infections (HIV15 and helminthes89, 90), 
immune-modulating diseases (diabetes91, 92), behavior (indoor pollution, smoking,92, 93 
alcoholism94) and drugs (TNFĮ-antagonists33).  
 
1.2.1. Some basic concepts in immunology  
Before proceeding further, some basic concepts often referred to in immunology are 
introduced: 1) Innate versus adaptive immunity and 2) Primary versus secondary 
immune responses. The innate immune system consists of epithelial cells, immune 
cells residing in the particular tissue (e.g. macrophages, dendrittic cells (DCs), mast 
cells) or recruited from blood (neutrophils, monocytes, NK-cells), and provides a 
rapid first line of defense against pathogens which probably eradicates many 
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infections without the need for deploying the adaptive immune system. Activation of 
the complement cascade further potentiates the efficiency of innate immune cells. 
When the innate immune system is overwhelmed by a new pathogen, a primary 
immune response develops. A primary immune response is characterized by innate 
responses which aim at keeping the pathogen sufficiently under control while more 
efficient adaptive immune responses by specific T- and B-cells evolve and enable 
pathogen clearance or dormancy. Later exposure to the same pathogen either by re-
infection or re-activation activates immunological memory exhibited by memory T- 
and B-cells and enables a more rapid deployment of adaptive immune responses, 
characteristic of a secondary immune response.95  
 
1.2.2. The immune system of the lung – an overview in the context of MTB 
infection 
MTB’s site of entry is the lung alveoli, thus herein, the focus is on immunological 
mechanisms within the lung parenchyma and lymph nodes draining this tissue. The 
mucosal surfaces of the respiratory tract are constantly exposed to inhaled antigens. 
Efficient immune responses which are vital in the context of invading pathogens 
might be devastating if induced by ubiquitous harmless antigens. Therefore, the 
immunological homeostasis in the human lung is biased towards an anti-inflammatory 
or regulatory phenotype in the steady-state. 96 While not the scope of this thesis, this 
aspect is important to keep in mind during the ensuing discussion of the host immune 
response to MTB infection.  
 
1.2.2.1.The first pathogen encounter activates innate host immune 
responses  
Whereas the conducting airways are protected against invaders by ciliated bronchial 
epithelium and secretory goblet cells which together enables mucociliary clearance of 
inhaled antigens, this robust barrier is lacking in the alveoli; MTB’s main port of 
entry. Both in conductive airways and in the alveoli, macrophages and DCs are 
strategically positioned close to the epithelial surface to serve their functions of 
antigen capture and pathogen killing by phagocytosis (macrophages)96 (Figure 1).  
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Macrophages and DCs express a large range of pattern recognition receptors (PRRs) 
on their surface that recognizes different components of microorganisms. Some PRRs 
that recognize components of MTB are given in Table 3.  
 
Figure 1. Initiation of a primary immune responses in the conductive airways (1) and in the lung 
alveoli (2). Panel a) and b) illustrate the location of immune cells and antigen (Ag) in 1 and 2 
respectively. Resident DCs activated by Ag recognition travel  through the afferent lymphatics to  
the draining lymph nodes where naive Ag-specific T-cells are activated to differentiate and 
proliferate (3) before they enter the circulation  by the efferent lymphatics..Effector T cells 
subsequently home to the infected airways (4) whereas memory T cells are systemically distributed 
(5) to assure renewal of the effector T cell pool and immunological memory.  Adapted from Frode 
L. Jahnsen. 
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Table 3. Examples of consequences by engagement of various pattern recognition receptors (PRRs) 
PRRs MTB ligand Pathway Cytokine spectrum/     other effects Ref. 
Scavenger receptors     
 MARCO trehalose dimycolates with TLR2 Stimulate the formation of foamy macrophages 
4 
C-type lectins         
 DC-SIGN 
mannose-capped 
lipoarabinomannan 
(LAM) 
RAF-1 IL-10  97, 98 
 Dectin-1 MTB glycolipids CARD9 IL-1ȕ, IL-6, IL-12p40, IL-17A, IL-23, TNFĮ 
99.98 
  Mincle trehalose dimycolates Syk-FcRg-CARD9 IL-1ȕ, IL-6, IL-12p40, IL-12p70, IL-23, TNFĮ 
99 
Toll-like Receptors         
membrane-bound     
 TLR2 MTB lipomannan 
My88D-IRAK-NFțB 
activation or TRAF6-
MAP 
IL-12p40, IL-12p70, IL-
23, downregulation of 
MHCII  
97, 99 
 TLR4        Liopteichoic acids with MD-2 and CD14. RAF-1  
97, 98 
 TLR9   IL-12p40 99 
intracytoplasmatic     
  NOD2/CARD15 MTB mycolylarabino-galactan peptidoglycan   IL-12p40, TNFĮ 
97, 99 
 
Depending on the PRR engaged, binding induces 1) enhanced phagocytosis 
(mannose-binding lectins and scavenger receptors), 2) NFțB-activation and secretion 
of cytokines and chemokines (Toll-like receptors) and/or 3) up-regulated expression 
of MHC class II and co-stimulatory molecules required for antigen-presentation to 
lymphocytes. In the alveoli, an additional macrophage subset; residing alveolar 
macrophages provides a first line of defense through pathogen capture before 
epithelial invasion.96  
 
Epithelial cells contribute by secretion of neutralizing antimicrobial peptides. In 
addition, they respond to direct- or indirect pathogen-induced damage by secreting 
inflammatory mediators capable of increasing the activation status of adjacent 
macrophages and DCs. Furthermore, activated by pathogenic products and/or the 
inflammatory state itself, the endothelial cells of pulmonary capillaries start 
expressing selectins (P-selectin and E-selectin) and integrins (ICAM-1, ICAM-2) 
required to recruit more leucocytes from the blood to the infected tissue.95  
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Neutrophils are the first innate immune cells to arrive from blood.2, 95 Neutrophils 
possess anti-mycobacterial properties and can kill extracellular bacteria directly by 
reactive oxygen species,95 or indirectly by empowering macrophages through 
degranulation of proteolytic enzymes.100 Neutrophils are attracted to the infective site 
in the lung dependent on secretion of IL-8 (CXCL8) by macrophages and/or 
endothelial cells.95, 101  
 
The next cells to be recruited from the blood are monocytes which differentiate into 
tissue macrophages or DCs depending on the cytokine milieu (M-CSF or GM-CSF 
and IL-4, respectively).95 
 
Activated endothelial cells become leaky, permitting plasma proteins to enter the 
tissue. Plasmatic precursor enzymes of the complement system directly (C1q) or 
indirectly (C-reactive protein or Mannose-binding lectin) activated by pathogenic 
products can initiate the complement cascade further amplifying the recruitment and 
efficiency of immune cells.95 Altogether, these early events of innate immunity 
produce a range of inflammatory mediators at the infectious site which subsequently 
shapes the adaptive immune responses as described in the next section. The 
inflammatory phenotype at the infectious site is thus critical for the efficiency and 
success of adaptive immune responses to prevent overt TB following MTB-infection.  
 
1.2.2.2.Induction of adaptive immune responses 
Activation of DCs residing in the lung parenchyma through PRRs, enhance their 
migration to the draining lymph nodes102 where the DCs initiate adaptive immune 
responses by their interaction with T- and B-cells (Figure 1). Antigens presented by 
incoming DCs on MHC class I or II molecules are recognized by CD8+ and CD4+ T 
cells, respectively, specific for the antigen presented.95 Given the intra-vesicular 
residence of MTB in arrested phagosomes, presentation by the conventional vesicular 
pathway is straight forward,14, 103 and can also be induced by IFNȖ-induced 
autophagy,104 CD8+ T cells are activated by MHC class I presentation of 
cytoplasmatic antigens. Intra-vesicular MTB proteins reach the MHC class I loading 
compartment in infected or bystander APCs by cross-presentation.105-109 CD4+ T cells 
differentiate into distinct functional subsets depending on the activation status of the 
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DC and the surrounding inflammatory phenotype (see section 1.2.3), demonstrating 
the importance of the innate immunity on the ensuing adaptive immune response.  
 
B cells recognize a part of the three-dimensional structure of un-processed antigen by 
the B-cell receptor (BCR). Cross-linking of BCRs on the membrane or help from 
CD4+ T cells (T helper cells) mediated by TCR recognition of antigen presented on a 
B-cell MHC II molecule, is required for activation of B cells.95  
 
The recognition of antigen by T and B cells triggers their differentiation and 
proliferation. Mature effector lymphocytes exit the lymph node through the efferent 
lymph and reach the circulation through the thoracic duct. Specific homing properties 
acquired by lymphocytes activated in the lymph node enables their migration back to 
the infected lung96 (Figure 1). At the infectious site, effector T cells combat the 
bacteria in several different ways depending on the subset (see section 1.2.3). B cells 
differentiate into antibody-producing cells, designated plasma cells, that mediate 
humoral immunity by the secretion of antibodies. The arrival of effector lymphocytes 
at the infective site represents the onset of targeted and efficient adaptive immune 
responses.95  
 
Importantly, long-lived T- and B cells are generated in parallel to effector 
lymphocytes during their differentiation in the lymph nodes. These cells, called 
memory lymphocytes, continue to circulate after the eradication/quiescence of the 
infectious agent providing the host with immunological memory. By re-exposure to 
the same antigen through re-infection or re-activation, memory lymphocytes assure a 
rapid generation of effector lymphocytes termed a secondary immune response that 
often prevents clinical disease.  
 
1.2.3. Differentiation of T cell subsets and their mode of action 
Following antigen recognition, naive CD4+ T cells differentiate into functionally 
distinct phenotypes (Th1, Th2, Th17 or Treg) depending on the activation state of the 
antigen-presenting cell (APC) and the cytokine milieu13, 95, 99 (Figure 2). 
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In primary infected mice, it takes about 20 days before effector T cells are generated 
in sufficient numbers to limit bacterial growth.110 In humans, the kinetics of effector 
responses in the lung after MTB exposure is not easily assessed.  
 
1.2.3.1.CD4+ T cells 
The requirement of CD4+ T cells in host protection to MTB is well established in 
various mouse models,79 in cynomolgus macaques111 and in humans in the context of 
HIV-infection, which is the most powerful risk factor for TB at a population level.32, 
52 Still, the mechanisms behind the protective effect of CD4+ T cells are not fully 
understood.79 The discovery of CD4+ T cell subsets which differ in functional 
capacity necessitates a description at the subset level:  
 
CD4+ Th1 cells 
APCs with an activated phenotype secreting IL-12, IL-18 and IL-27, favor activation 
of the transcription factor T-bet required for differentiation of Th1 CD4+ T cells.95, 112 
Figure 2. Presentation and recognition of MTB antigens, and factors involved in 
the differentiation of T cell subsets. 
 
Reprinted by permission from Elsevier Ldt: [Cell Host & Microbe] Kaufmann and Parida, 20085. 
Hyperlink: Sciencedirect/elsevier 
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In the setting of MTB-infection, IL-12p40, the product of MTB antigen ligation with 
different PRRs, is required for Th1 development.113 Th1 cells are defined by their 
secretion of Th1 cytokines, notably IL-2, IFNȖ, TNFĮ and GM-CSF.95 IFNȖ and 
TNFĮ are required for macrophage activation and are both crucial in host protection 
against MTB13, 14, 103 as activated macrophages restrict MTB replication by various 
mechanisms103 which eventually overcome the phagosomal arrest104, 114.  
 
The importance of Th1 cells in human MTB infection has been demonstrated by 
various gene deficiencies in the cytokine-mediated macrophage activation pathway.83, 
115 Th1 cells co-producing 2 cytokines (polyfunctional T cells) are more potent 
cytokine producers,116 and have been suggested to provide superior protection against 
TB progression in infected subjects.13, 117, 118 Therefore, vaccine candidates are 
evaluated by their capacity to induce polyfunctional T cells.119-121 
 
CD4+ Th17 cells 
The differentiation and proliferation of Th17 cells is dependent on IL-6 or IL-21 in 
the presence of low amounts of TGF-ȕ, which induces the transcription factor RORȖt, 
both required for the expression of IL-23 receptor and hereby sustained Th17 
responses.99 Th17 cells secrete IL-17, IL-21 and IL-22,122 IL-17 trigger release of IL-
8 (CXCL8) and GM-CSF from endothelial and epithelial cells required for neutrophil 
expansion and recruitment101, 123 probably important for the initial granuloma 
formation124, 125, (see section 1.2.2.1). 
 
Evidence suggests a protective role for Th17 cells in the early mycobaterial host 
defense: Vaccines inducing Th17 memory cells in the lungs induce IL-17 dependent 
CXCR3 ligands (CXCL9, CXCL10 and CXCL11) which accelerate the recruitment of 
MTB-specific Th1 cells resulting in reduced bacterial burden in WT compared to IL-
17 deficient mice.110, 126 Th17 cells/IL-17 also seem to protect against MTB infection 
by mechanisms independent of IFNȖ.127, 128 Once the Th1 response is adequate, the 
cytokine milieu will favor further Th1 delineation and suppress Th17 delineation.99 
 
MTB-specific Th17 cells in TB patients predominantly express either IL-17 or IL-22 
(few co-producers), unlike Th1 cells which mostly display an effector phenotype, 
Th17 cells display a central memory phenotype.129 In progression to TB, Th17 cells 
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might no longer be protective, as IL-17 is associated with severe neutrophil 
inflammation in the human lung.130 Supporting this, mice repeatedly exposed to 
mycobateriae exhibit necrotic lesions rich in neutrophils131-133 Th17 cells seem less 
susceptible to suppression by regulatory T cells (defined and discussed in the next 
paragraph) than Th1 cells in vitro,134 and it has been suggested that a skewing in the 
Th1/Th17 balance towards Th17 cells, promotes neutrophil inflammation, tissue 
necrosis and progression in TB pathology.79  
 
CD4+ regulatory T cells 
CD4+ T cells expressing the transcription factor FoxP3 are termed regulatory T cells 
(Tregs).135 These cells seem crucial in limiting autoimmune diseases136 and tissue 
damage following acute infections.135 Tregs act directly (TCR-ligation) or indirectly 
(alterations in the cytokine milieu) on the delineation and/or activation of other T cell 
subsets.137 FoxP3+ Tregs consist of 2 subsets: 1) Natural Tregs induced in the thymus 
by appropriate TCR-recognition and affinity of self-antigen (potential of cross-
reactivity with microbial antigens), and 2) Induced Tregs which arise when FoxP3 is 
induced in conventional T cells in the periphery (favored by chronic antigen 
stimulation, limited co-stimulation and TGF-ȕ).138 Induction of Tregs by MTB might 
represent a pathogen evasion strategy for the pathogen3, 137, 139 as Tregs reduce the 
induction of protective effector T cells by a contact-dependent inhibition of APCs 
(CTLA-4, LAG, NRP1 and surface-bound TGF-ȕ).140  
 
In early MTB infection, there is an unspecific recruitment of Tregs to the lung which 
result in reduced Treg numbers in peripheral blood.135, 141 Tregs are present within 
granulomas.142 There is abundant evidence from in vitro and in vivo models to support 
that Tregs expand during MTB infection and subsequently reduce and delay 
protective effector T cell responses.3 The effect seems to be mediated by natural Tregs 
specific for MTB antigens by cross-reactivity.135 Pre-existing specific Tregs generated 
by oral exposure to NTMs could have an impact on vaccine take and the delayed 
induction of adaptive immunity. This delay likely has an impact on bacterial load and 
subsequently the resistance to TB progression.79 
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In TB patients, there is a positive correlation between bacterial 
load/immunopathology and Treg numbers, but whether Treg expansion in this setting 
is a cause or a consequence of TB disease is still unknown.135 
 
FoxP3 negative CD4+ T cells with regulatory properties through their cytokine 
secretion, can also have an impact on the host immune response to TB,143-147 but are 
not further discussed here. 
 
1.2.3.2.CD8+ T cells 
Following TCR-ligation, MTB-specific CD8+ T cells restrict bacterial growth by 
granulysin- and perforin mediated apoptosis of MTB infected macrophages or by 
macrophage empowerment through IFNȖ and TNFĮ secretion.14, 103 No data support a 
non-redundant role of CD8+ T cells in the control of early or latent MTB infection 1, 
but their importance might increase in later phases of infection148 when IFNȖ-
secretion dominates compared to the cytotoxic activity.149 Some results indicate that 
CD4+ T cells might be required for the expansion of MTB-specific CD8+ T cells.111 
 
1.2.3.3.Prolonged T cell responses 
Rapid expansion and maintenance of short-lived effector T cell pools (CD4+ T 
including Tregs, and CD8+) depend on IL-2.150 In a state with continued exposure to 
antigen, as in MTB infection, IL-2 seems to be produced mainly by effector memory 
T cells (TEM), but IL-2 production and the ability to replicate is lost when the cell 
further differentiate towards terminal effectors (TTE). Therefore, without the 
generation of long-lived central memory T cells (TCM) which exhibit high 
proliferative capacity by repeated antigen exposure, the pool of effector T cells cannot 
be sustained.13, 117 Effector T cell responses are also self-limiting through IFNȖ- and 
TCR dependent up-regulation of inhibitory molecules (CTLA-4, PD-1) and down-
regulation of co-stimulatory molecules, which result in T cell inhibition and 
apoptosis.5, 151 MTB-specific T cells in TB patients are predominantly TEM cells,152 
and some suggest that progression to TB is proceeded by exhaustion of the memory T 
cell pool by sustained exposure to MTB antigens.13, 117, 153 Progression to TB might 
thus be a consequence of waning immunity. 
 
29 
 
The generation of TCM is the goal of vaccination, as these subsets ensure rapid 
deployment of high-affinity adaptive immunity at primary or secondary exposure to 
pathogen (due to re-exposure or re-activation) 13. IL-7 and IL-15 are crucial in the 
generation of memory T cells.150, 154 TCM, TEM and TTE have different homing 
capacities and can therefore be distinguished by phenotypic markers (Table 3). 155, 156 
Table 3 Markers of T cell differentiation 
  marker naïve 
central 
memory 
(CM) 
effector 
memory 
(EM) 
terminal 
effector 
(TE) 
T cell 
differentiation 
CD45RA + - - +/- 
CD45RO - + + - 
homing to 
lymph node 
CCR7 + + - - 
CD62L (L-selectin) + + - - 
activation 
marker 
CD27                           
(TNF-receptor family) - + + - 
? KLRG1 ? - - + 
 
1.2.4. How MTB interferes with host immune responses 
The downstream events induced by antigen recognition depend on the affinity of the 
PRR:MTB ligand-binding which is subject to genetic variation in both host and 
pathogen. This could be factors which contribute to the observed differences in host 
susceptibility and MTB virulence.  
 
Being incorporated in early endosomes, MTB are targeted for intravesicular 
destruction within the engulfing macrophage, but MTB has evolved to prevent 
phagosome maturation and endolysosomal fusion arresting phagosomal degradation. 
Within this arrested phagosome MTB ensures the acquisition of nutrients (iron and 
lipids) within the arrested phagosome, by interfering with intracellular trafficking 
pathways.14, 157, 158 By now, MTB have exploited the phagocytic properties of an 
alveolar macrophage to establish a protected niche for replication until adaptive 
immune responses are put into play.79 Evidence suggests that MTB interferes with 
additional properties of the host macrophage: 
x inhibits IFNȖ-activated genes and antigen-presentation.159-161 
x inhibits autophagy which can kill MTB regardless of the phagosomal arrest 
(induced by IFNȖ, inhibited by IL-4 and IL-13).104, 162 
x increase the production of anti-inflammatory cytokines.163 
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x favors necrosis to apoptosis of infected macrophages either through inhibition 
of TNFĮ-dependent apoptosis,164, 165 membrane repair166 or interference with 
the eicosanoid metabolism.167 This delays the DCs uptake of MTB and their 
subsequent activation and migration.168  
x exaggerated production of IFNȖ and nitric oxide (NO) which subsequently 
lead to suppression of cell-mediated immune responses.169 
These examples illustrate how MTB subverts host immune responses by promoting 
the production of anti-inflammatory cytokines and delaying activation and antigen-
presentation by DCs, permitting bacterial replication within the macrophage. In vitro 
studies suggest that MTB is unable to prevent endolysosomal fusion in pre-activated 
macrophages,158 but the anti-inflammatory alveolar macrophages are probably easily 
subverted. Furthermore, in a setting with both resting and activated macrophages, 
MTB seem to inhibit uptake by activated macrophages by mannose derivatives on the 
surface.170  
 
Macrophages seem to undergo necrosis at a certain threshold of bacterial load 
resulting in the release of viable bacilli which can infect neighboring mononuclear 
cells171 and neutrophils.172 Studies in mice suggest that a mechanism for genetic 
susceptibility to MTB is an increased tendency of infected macrophages to undergo 
necrosis instead of apoptosis.173 Importantly, IFNȖ can reverse some of these 
effects.104, 114 MTB also seem to impose changes in uninfected bystander DCs through 
shedding of immune-modulating antigens in apoptotic blebs.107, 108 
 
MTBs immune modulating properties together with the slow replication rate keeps the 
inflammation down, but either a high inoculation dose or release of viable bacilli 
following macrophage necrosis, will sooner or later activate other players of innate 
immunity and induce an inflammatory reaction.  
 
The onset of adaptive immune responses is delayed in MTB infection compared to 
other infections3, 174 (Figure 3).  
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This is likely due to insufficient activation and migration of DCs due to multiple 
factors: 1) the regulatory environment in the alveoli (alveolar macrophages and 
tolerogenic DCs),3, 96 2) the slow MTB replication rate,6 3) the capacity of MTB to 
suppress inflammation by a) inhibition of co-stimulatory molecules and induction of 
anti-inflammatory cytokines79, 163 or b) Treg activity135 (Regulatory T cells in MTB 
infection; section 1.2.3.1). How the DCs capture antigen also seems important: by 
phagocytosis of free MTB bacilli (after necrosis of infected macrophages)109 the DC 
itself will become infected and exhibit reduced antigen-presenting capacity,102 
whereas engulfment of MTB containing vesicles from live or apoptotic macrophages 
will leave the DC uninfected and retain their antigen presenting capacity.109 In the 
setting of MTB infection, the importance of migrating DCs is unclear as 
dissemination of viable bacilli to the draining lymph nodes seems required for 
induction of adaptive immunity in mice. This dissemination occurs 8-9 days after 
challenge and corresponds to necrosis of infected macrophages.174-176 In mice with 
primary infection, it takes 15-18 days post infection before MTB-specific T cells are 
present at the primary site.175 Thus MTB delays the kinetics of effector T cell 
proliferation and migration by altering the DCs phenotype as described above, and a 
direct effect of induced MTB-specific regulatory T cells135, 177 (Regulatory T cells in 
MTB infection; section 1.2.3.1.).  
 
1.2.5. Granuloma formation – a result of the host-MTB interplay  
1.2.5.1.Early granuloma formation 
Sooner or later infected alveolar macrophages start secreting TNFĮ and other 
inflammatory chemokines (CCL2, CXCL10, IL1-Į, IL1-ȕ, IL-18).2 As described, 
neutrophils and monocytes are recruited first, and become important sources of TNFĮ 
and CXCR3 ligands required for T cell recruitment and granuloma formation.125, 178 
Figure 3. The adaptive 
immune responses are 
delayed in MTB infection 
compared to other 
infections.  
 
Reprinted by permission from 
Macimillan Publishers 
Ltd:[Mucosal Immunology], 
Urdahl et al., 20113. Hyperlink: 
Mucosal Immunology 
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The arrival of MTB-specific lymphocytes contributes to the broad production of 
cytokines and chemokines (TNFĮ, CXCL9, CXCL10, CXCL11, CCL2, CCL3, 
CCL4, CCL5). Adaptive immunity is increasingly put into play, a mounting IFNȖ-
production provides a negative feed-back which will gradually down-regulate the pro-
inflammatory innate responses (Figure 4). The net result is rearrangement of the 
micro-anatomy at the infectious site to a granuloma2 in which MTB is confined within 
a hostile environment exposed to NO, CO and low pH. In response to this, MTB up-
regulates 1) the DosR-regulon, which constitutes 48 genes which induces a dormant 
or slow-replicating state179, 180 and other transcriptional regulators which result in  2) 
nutrient-switch from glucose to fatty acids/cholesterol and 3) increased fortification4 
to ensure its survival. Notably, these dynamics in the MTB gene expression profile is 
likely to affect the MTB antigens available for T cell recognition.5 
 
With lack of CD4+ T cells in the context of HIV/AIDS or in mouse models, the 
immunopathology of MTB infection is shifted from granulomatous lesions to 
neutrophil inflammation and necrosis.132, 181 Even though neutrophils might provide 
protection in early MTB infection, their inflammatory properties might enhance 
MTB-related pathology at later stages.99 Recently, Berry et al, have provided evidence 
which indicate that neutrophils are more important in TB pathogenesis than earlier 
anticipated. The transcriptional profile of peripheral blood of TB patients was 
dominated by up-regulation of both IFNȖ and type I IFN-inducible transcripts, to 
which neutrophils contributed the most.182 
 
Findings of MTB-containing APCs surrounded by proliferating B cells and T cells in 
the outer mantel of lung granulomas, suggest the formation of secondary lymphoid 
structures.183, 184 B-cell deficient mice are more susceptible to TB disease185 and have 
more severe immunopathology with increased neutrophil accumulation,186 effects 
which might be mediated by FcȖ-receptors.187 Based on this, B-cells are suggested to 
play a role in the formation and maintenance of granulomas.79 In humans, a recent 
study reported a reduction in B cell transcripts in peripheral blood of TB patients.182 
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1.2.5.2.Evolution of the granuloma and emergence of overt TB  
The structure of the initial human granuloma is highly vascularized but if it develops 
further, the vascularization decreases and the core of MTB infected macrophages 
becomes increasingly surrounded by different morphotypes of differentiated 
macrophages (giant cells, epithelioid cells and foamy macrophages) and a fibrous 
layer which physically seem to isolate MTB from the surrounding mantle of MTB 
specific CD4+ and CD8+ T cells. Subsequently, excessive granuloma formation 
ensures caseation, necrosis and MTB transmission4 (Figure 5).  
 
Figure 4. The  successive 
recruitment of immune 
cells is driven by 
cytokines and chemokines 
secreted by the infected 
macrophage.  
 
Reprinted by permission from 
Macimillan Publishers 
Ltd:[Nature Reviews 
Microbiology], Russell, 20072. 
Hyperlink: Nature Reviews 
Microbiology
Figure 5. The  formation 
and destabilization of the 
human tuberculosis 
granuloma.  
 
Reprinted by permission from 
Macimillan Publishers 
Ltd:[Nature Immunology], 
Russell et al., 20094. Hyperlink: 
Nature Immunology  
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In humans and non-human primates (NHP), tubercular granulomas exhibit a broad 
spectrum of histological and functional features within the same individual.2, 188 
Furthermore, repeated CT/PET-scans in NHPs and human TB patients provide 
evidence that granulomas are highly dynamic and act independently from each other1, 
189 (personal communication, Clifton E Barry at the Keystone Symposia “Host 
Response in Tuberculosis”, March 13-18, 2013, Whistler, BC, Canada). Whether the 
integrity of the granuloma persists or destabilizes, resulting in caseation, seem to be 
determined locally by a complex interplay of host chemokines, cytokines, immune 
cells as well as MTB characteristics.1, 4, 178, 190 The mechanisms involved are not yet 
fully understood, but the bacterial load within the granuloma seems to be an important 
factor in granuloma destabilization.79, 189 Furthermore, MTB-bacilli are localized in 
different parts of the granuloma; from the necrotic center to outside the fibrotic 
capsule. Depending on the localization, the balance between the pathogen and the host 
immune response is likely to represent a broad spectrum: while bacilli might be kept 
dormant or slow-replication outside the fibrotic capsule of the granuloma, other 
bacteria in the granulomatous center could be replicating.1, 2 The determinant 
factors/mechanisms in granuloma destabilization and progression to overt TB are not 
fully understood but might include: 
x Oxygen restriction facilitates breakdown of the granulomatous structure to 
caseation and necrosis. This is consistent with reduced vascularization and 
levels of the macrophage-derived vascular epithelial growth factor (VEGF) in 
caseous granulomas compared to non-progressive granulomas2.  
x Recent evidence suggest that MTB and/or hypoxia induces matrix 
metalloproteinases (MMP) which induces collagen destruction and drives 
tissue pathology in TB.191, 192  
x Some argue for a role of MTB induced pro-inflammatory foamy 
macrophages,4 which so far have been identified in necrotic lesions only.4, 193  
x A shift from apoptosis to necrosis of infected macrophages at a certain 
bacterial load could be an important mechanism171 and provides an argument 
that MTB are slowly replicating rather than fully dormant inside the 
granuloma-residing macrophage. The threshold is likely to be dependent of 
MTB strain and a number of host factors.171, 173  
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x A shift in the balance of CD4+ T cell subpopulations (Th1/Th17/Treg) 
promoted by factors in the microenvironment might proceed increased 
inflammation and progression to granulomatous caseation and necrosis. A 
simplified hypothesis build on the documented plasticity of T cell subsets: 
Tregs can be converted into Th17 cells by pathogen components  and IL-6194 
and steadily increasing bacterial load could be permitted by the presence of 
Tregs impairing Th1 function. Alternatively, increased bacterial load could 
have a broader impact on the cytokine milieu through DC or MMP-mediated 
tissue-destruction and hereby the delineation of CD4+ T cells. Once Th17 
cells have reached a certain level (permitted by local IL-2399), they become 
resistant to regulation by Th1 cell133 and the vicious cycle of neutrophil 
inflammation and tissue destruction accelerates.  
 
To summarize, the granuloma is the hallmark of established MTB-infection, and 
actually represents a favorable outcome for both host and pathogen.4 For the host, the 
granuloma confine MTB in a hostile environment required for initial bacterial control 
whereas lack of granuloma formation results in bacterial dissemination and rapid 
disease progression. For MTB, persistence within the granuloma exhibits a potential 
for caseation and necrosis - a niche for later replication, bacillary spread and 
transmission.2, 79 The emerging consensus is that MTB infection result in a broad 
spectrum of pathological manifestations closely related to the balance between MTB 
and the host immune response. TB occurs when the pathology result in symptoms 
(Figure 6).  
 
Figure 6. The inter-
relationship between 
bacterial load, host 
immune responses and 
clinical manifestations.  
 
Reprinted by permission from 
Macimillan Publishers 
Ltd:[Nature Reviews 
Microbiology], Barry III et 
al., 20091. Hyperlink: Nature 
Reviews Microbiology 
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The rapidity in the onset of efficient adaptive immune responses following infection is 
crucial in controlling bacterial replication. The bacterial load at the time of 
equilibrium between host immune responses and MTB (containment inside a 
granuloma) seems to be a crucial determinant for the fate of the individual granuloma 
and the subsequent risk of TB progression in the host.79, 176  
 
1.3. Readouts of the host immune response 
 
As indicated above, the host immune response towards MTB is tightly linked to the 
immune-pathology. Therefore, following a global initiative for biomarker discovery49, 
different components of the host immune response to MTB have been extensively 
studied for their potential as diagnostic and prognostic biomarkers.195 A biomarker 
marker is “a characteristic feature that is objectively measured and evaluated as an 
indicator of a normal or pathological process or of the response to intervention. 196 
(MTB derived biomarkers have been studied in parallel, but are not a subject for this 
thesis.) In MTB infection, single biomarkers seem to be of little value, whereas a 
profile of combined biomarkers, termed a biosignature, is probably more appropriate 
due to the complexity in host immune response.195  
 
The selection of specimens for biomarker studies depending on disease localization, 
availability and risk related to sampling. Peripheral blood has obvious advantages 
when it comes to availability and risk compared to other specimen (sputum, broncho-
alveolar lavage (BAL), gastric aspirate, tissue biopsy). Invasive procedures in the 
diagnosis of MTB infection in absence of active TB are hardly ethical. Evidence 
suggests that biomarkers in peripheral blood reflects environmental, physiological and 
pathological events occurring in different tissues of the body,197 and this is supported 
by correlative data on transcriptional biomarkers and the radiological extent of TB 
disease.182 Peripheral blood has also been regarded appropriate when it comes to T 
cells; the hallmark mediators of protective immunity towards MTB, as they circulate 
in peripheral blood prior to recruitment to the site of infection.53 
 
Biomarker discovery can be assessed by un-biased approaches of gene signatures 
(micro-array/transcriptomics), protein signatures (proteomics) or metabolic signatures 
(metabolomics) or by analysis of specific transcriptomes, proteins or metabolic 
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metabolites, or cell populations pre-selected because of their documented role and 
relevance in the host immune response to MTB.5, 198 Analyses are performed both 
direct ex vivo (unstimulated) or after in vitro stimulation depending on the approach.  
 
1.3.1. The need for TB biomarkers and improved diagnostics 
Biomarkers in TB are crucial in the development of new therapeutics and vaccines 
and current research focuses on four areas:5, 31, 195, 199 
1. Improve the diagnosis of active TB. 
2. Prediction of treatment efficacy and cure. 
3. Prediction of reactivation/progression to TB in MTB infected healthy subjects. 
4. Prediction of protective immunity by vaccine candidates/surrogate end-points 
in vaccine trials. 
In children <3 years the need for better tools in the diagnosis of MTB infection and 
active disease is urgent. With regard to MTB infection, children this young have 
increased risk of rapid and more severe TB manifestations12 which have led to 
recommendations of preventive treatment.58 With regard to active disease, adequate 
management is challenged by a high proportion of unconfirmed cases (70-80%),75 as 
sputum negative TB cases are not prioritized for treatment by many national TB 
control programmes. TST and QFT are used both to diagnose MTB infection and as 
supplements in the diagnosis of pediatric TB12, 71, 200 despite proper validation in 
young children.63, 64, 201 Data on TST and QFT performance in different cohorts of 
young children are needed in order to ameliorate the interpretation of test results. In 
addition, new biomarkers have the potential to increase the diagnostic accuracy and 
thereby contribute to a better management of TB in this vulnerable age group.31, 71, 200 
Notably, a rapid biomarker-based, instrument-free test for non-sputum samples that 
also detects childhood and extrapulmonary TB, ranked second in recent ranking of 
diagnostic needs.202  
 
For biomarkers to become true tools in the global management of TB, they need to be 
confirmed in populations heterogeneous with regard to genetics, endemics of HIV, 
mycobacteria and helminthes as well as socioeconomic determinants.195 
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2. AIMS OF THE STUDY 
 
The general aim of this thesis was to contribute to a better understanding and 
interpretation of immunological tests developed to diagnose Mycobacterium 
tuberculosis infection, and to explore the diagnostic potential of new immune 
biomarkers in Mycobacterium tuberculosis infection and disease in children.  
  
2.1. Specific aims  
 
Paper I:  To evaluate the performance of TST and QFT, and their association 
with clinical, demographic and nutritional (intra-uterine and post-natal) characteristics 
in a cohort of BCG-vaccinated young children in Southern India. 
 
Paper II:  To explore the diagnostic potential of new immune biomarkers in 
Mycobacterium tuberculosis infection and disease in BCG-vaccinated young children 
in Southern India. 
 
Paper III: To characterize immune biomarker profiles associated with concordant 
or discordant TST and QFT results in BCG-vaccinated young children in Southern 
India.  
 
Paper IV: To explore the quality and/or magnitude of mycobacterial-specific T-
cell responses associated with QFT reversion and persistent QFT-positivity in 
adolescents in Southern India.  
. 
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3.2. Study populations, enrollment, randomization and data collection 
 
The study participants included in this thesis are drawn from the study population of 
the Neonatal Cohort Study (NCS) and the Adolescent Cohort Study (ACS). These 
prospective population-based observational cohort studies were set up in the source 
population described in section 3.1, as part of the process for preparing Palamaner as 
a field site for future TB vaccine trials. Conducted by the TB Trials Study group 
(contributors listed in the papers), NCS and ACS were designed to establish the 
incidence of TB disease during a 2-year follow-up period of 
x children in one annual birth cohort (NCS) and  
x randomly selected school clusters of adolescents aged 12-18 years (ACS). 
A field study site was established at Emmaus Swiss Hospital, coordinated from the St. 
John’s Research Institute,205 funded by AERAS206 and the Research Council of 
Norway (TB Trials 179342 and 192534). All clinical TB cases identified during the 
studies, were referred to the TB public programme203 for initiation of anti-TB 
treatment.  
 
Families who planned to move from Palamaner during the follow up period were not 
eligible. Written informed consent was obtained from participants aged >18 years or 
from each participant’s legally authorized representative. In addition, a written assent 
to participation was obtained for adolescents aged <18 years. The consent process in 
the NCS study is described and evaluated by Rajaraman et al.207 
 
Data were captured in clinical research forms and entered into a database following 
Good Clinical Practice (GCP) guidelines.208 Further inclusion criteria, data collection 
and sampling of specimens are described below, separately for the NCS and the ACS. 
Individual HIV status was not assessed as part of the NCS or ACS, but data from a 
house-hold contact study conducted in the same study area in the period 2010 to 2012, 
found a HIV prevalence <1% (TB Trials Study Group, unpublished data). 
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3.2.1. Neonatal Cohort Study (NCS) (paper I-III) 
3.2.1.1. Enrolment 
Neonates were eligible if BCG vaccine was administered by study staff within 72 
hours of birth and written informed consent was obtained within 15 days of birth. The 
BCG strain used by public health facilities in the study area is a strain originating 
from Danish 1331, manufactured by either the BCG Laboratory in Guindy South 
India or the Serum Institute, Pune. Of 7 424 women identified antenatally in the study 
area, 4 872 fulfilled the inclusion criteria (eligible population). The majority of 
neonates that did not meet the inclusion criteria were not available during the 15 days 
post-delivery since it is common practice for women to travel to their mothers home 
to deliver. Of the eligible population, 4 382 (89.8%) were enrolled in the NCS. 
Parents were provided a Study Identification Card with the study physician’s contact 
details, to keep track of important health information, and were encouraged to contact 
the study office if their child was ill, exposed to a known TB case, diagnosed with 
TB, admitted to hospital or died. In addition, all primary health centres and referral 
hospitals within and around the study area, were visited weekly by study staff to 
determine if any study participants were admitted or treated with a presumptive 
diagnosis of TB or related diagnoses like HIV/AIDS. 
 
3.2.1.2. Randomization and follow-up 
The 550 population units were first stratified according to the type (semi-urban; rural, 
high development, rural, low development) and the size of the population (<500, 500-
1000, >1000). This stratification was done because the TB incidence is likely to be 
different between these communities. Population units within each stratum were 
subsequently randomly assigned into active or passive surveillance. Thus, all neonates 
within a population unit were assigned to the same surveillance group. This was to 
avoid cross-over between the surveillance groups in the follow-up process.  
x Infants with active surveillance (2 215) had bimonthly home visits by a study 
team member.  
x Parents of infants with passive surveillance (2 167) received health education 
about TB symptoms at enrolment, and were encouraged to bring their children 
to the case verification ward (CVW) if they developed such symptoms. The 
only home visit was at study closure.  
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3.2.1.3.Data obtained by surveillance per-protocol  
x At baseline, time of birth, clinical data of pregnancy length and delivery were 
registered by medical records and/or interview. Weight were measured by 
spring balances and height measured recumbent (lying down) on a length 
board and read according to standard guidelines (Figure 8). Age of the mother 
and socio-economic variables (parental education (6 levels), caste (3 levels), 
religion (7 levels), type of housing (7 levels) and cooking fuel (7 levels)) were 
obtained in interview by study staff.  
       
x Data obtained by interview at the regular per-protocol visits (see section 
3.2.1.2) included known contact (>8 hours) with a TB case without or on 
treatment, symptoms (longstanding cough, fever and/or weight loss) and 
weight measurement as described above.  
x At study closure, TST was performed on all study subjects. 
Detailed description of data acquisition is given in section 3.4-3.8. 
 
3.2.2. Adolescent Cohort Study (ACS) (paper IV) 
3.2.2.1.Enrolment 
Adolescents aged 12-18 years attending high schools or junior colleges in Palamaner 
Taluk, were eligible (estimated to be 17 818 students in 2006) for the enrolment 
study-target set to 8 000 subjects. Enrolment required written informed consent from 
each subject’s legally authorized representative or from participants aged 18 years. 
In addition, written assent from participants aged <18 years was required.    
 
 
Figure 8. A) Spring 
balances were used for 
measuring child weight. 
The balances were 
calibrated with standard 
weights once a month. 
B) Correct recumbent 
height measurement on a 
length board (fixed 
headboard, movable foot 
board) requires 2 trained 
staff. 
A 
B 
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3.2.2.2.Randomization and follow-up 
The schools were stratified into public- or private schools and further sub-stratified 
according to size (public high schools) or type (private high school, private junior 
college, public junior college). This stratification was done because the TB incidence 
is likely to be different between the different strata. Subsequently, the schools within 
each stratum were randomly assigned for either  
x active surveillance (3 102) with clinical evaluation every 3rd month and 
sampling of PBMCs every 6th month. QFT was included from study day 360 
and repeated at day 720. 
x passive surveillance (3 542)  with clinical evaluation and sampling of PBMCs 
at baseline and study closure.  
Adolescents with active surveillance only, were eligible for paper III. 
 
3.2.2.3.Data obtained by surveillance per-protocol  
x At baseline, gender, age, socioeconomic determinants, known TB exposure, 
presence of a BCG scar, previous TB disease and on-going symptoms were 
obtained in interview by study staff. Anthropometric measures (weight, 
height), the hemoglobin level and TST (repeated within 1-4 weeks if <5mm; 
using the larger of the two measurements) were registered. Subjects with 
respiratory symptoms were assessed for TB through clinical investigations 
(section 3.4), a TST (section 3.5), chest X-ray(s) (section 3.6) and 
microbiological analyses (section 3.7 and 3.8.1)  A diagnosis of TB required: 
1) one sputum culture positive for MTB, or 2) one AFB-positive sputum 
smear and one positive PCR for MTB.  
x Every 3rd month (active surveillance only), data from the clinical evaluation 
including recent exposure to a TB patient within the house-hold or class 
(without or on treatment), symptoms (unexplained cough, weight loss, fever 
and/or night-sweats for >2 weeks, and/or haemoptysis) and anthropometrics 
were captured. This assessment was done on all study subjects at study 
closure. 
x Every 6th month (active surveillance only), blood for banking of PBMCs and 
other exploratory immunological purposes. 
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x Data on TST repeated at study day 360 and 720 (study closure), and QFT 
(added to the study protocol during the study) at day 360/540 and 720 were 
registered. 
Detailed description of data acquisition is given in section 3.4-3.8. 
 
3.3. Selection of study participants and study outcomes 
 
3.3.1. Neonatal Cohort Study (paper I-III) 
During the follow-up, study staff evaluated the children within the active surveillance 
group with regard to defined criteria which led to referral to the Case Verification 
Ward (CVW) at the Emmaus Swiss Hospital: 
1) more than 8 hours of exposure to a known TB case (without or on 
treatment) within the last year,  
2) symptoms suggestive of TB (longstanding cough and/or fever and/or loss of 
weight)  
3) failure to thrive (FTT) defined as any of the following;  
a) loss of weight or no weight gain for two consecutive visits,  
b) down-ward crossing of two percentile lines on the weight for age 
growth chart, or  
c) weight that tracked consistently below the 3rd percentile in the WHO 
Child Growth Standards209 or  
4) a TST 10 mm at study closure. 
Children in the passive surveillance group were referred to the CVW by general 
health services informed of the NCS study, directly and/or indirectly (through the 
caretakers) if TB was confirmed or suspected.  
 
All children referred to the CVW during the 2-year follow-up were eligible for 
inclusion in the studies described in papers I-III. At the CVW, a clinical assessment of 
each child was performed, with an aim of classifying the children according to pre-
defined TB outcomes (Table 4). 
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Table 4. Outcomes/endpoints Definition Paper I Paper II Paper III 
Clinical outcomes (diagnostic 
algorithm, Figure 9)         
  Clinical TB 
Definite or Probable TB according to 
diagnostic algorithm, Figure 9. X X   
   Definite TB MTB confirmed in culture or by PCR X (X)*   
    Probable TB symptoms and radiological changes (chest AP view) suggestive of TB X  (X)*   
Outcomes based on 
diagnostic tests         
  TST result cut-off 10mm (pos/neg) X   X 
  QFT-GIT result cut-off 0.35 IU/mL (pos/neg/indeterminateª) X  X 
  MTB infection TST+ and/or QFT-GIT+   X   
*In paper II, children with definite and probable TB was designated as clinical TB, not assessed and 
discussed as distinct groups. ªChildren with indeterminate QFT were not included in paper III. 
 
 
 
 
 
Clinical entry criteria
1. Known TB exposure > 8 hours
2. Fever and/or cough  2 week
3. Failure to thrive*
4. TST  10mm.
MTB culture 
and/or PCR 
positive
Definite TB Probable TB Not TB
No  
Chest X-ray suggestive of 
TB as judged by 2/3 
independent radiologists 
Yes
 1 of the listed 
clinical criteria
No  
Yes No  
Yes
 
TB was suspected in 746 children who accounted for 803 referrals during the study 
period. 38 children were referred twice, 2 were referred 3 times, and one child 4 
times. According to the outcome definitions, the flowchart of study participants in 
paper I-III is given in Figure 10. Supplementary details for each paper are given in the 
text below. 
 
Figure 9. Diagnostic algorithm for pediatric TB. The categorization was done by the 
treating clinician who was blinded to the QFT result. 
*Failure to thrive, defined in section 3.3.1, point 3).
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Neonatal Cohort Study (NCS)
4382 neonates
Active 
2215
Passive 
2167 Randomly assigned to 2 years follow up
638 108
Clinical outcomes 
705
Categorized according to TB 
diagnostic algorithm 
Unlikely/Not TB
692
653 (1st visit data), 37 (2nd visit 
data), 2 (3rd visit data)
Clinical TB 
13
9 Probable, 4 Definite
10 (1st visit data), 3 (2nd visit data)
Eligible
BCG within 72 hours of birth
Consent within 14 days of birth
MTB infected        
90
TST and/or QFT 
positive, normal CXR 
Controls     
107
TST-QFT-, normal 
CXR 
Study subjects for paper I-III were drawn from the pool of children (746) with 
suspected TB investigated at the Case Verification Ward
Test outcomes 
210
Categorized according to TST 
and QFT results 
Mixed outcomes        
210
Categorized according to TB 
diagnostic algorithm, TSTand QFT
TST+QFT+ 
21
TST+QFT-
54
TST-QFT+ 
19
TST-QFT-
116
Paper I Paper II Paper III
The same 
subjects
 
Paper I  
Of the 746 children, 705 were classified by the diagnostic algorithm for pediatric TB. 
Forty-one of the 746 children were not classified according to the diagnostic 
algorithm and subsequently excluded from the data analyses; 40 children because of 
lack of data from sputum/gastric aspirate, CXR and/or TST, and 1 child because he 
was lost to follow-up. Among the 40 children, only 1 child had known TB exposure, 
but the CXR in this child was normal. For children with multiple visits, the latest visit 
was included in the dataset as follow-up observations are highly relevant in the 
diagnosis of clinical TB. If QFT and/or TST were lacking at the latest time-point, data 
from the previous time-point was included if the clinical TB diagnosis remained 
unchanged (Figure 9). Visits lacking data on clinical TB category were also excluded.
  
Figure 10. Flowchart for study participants in paper I-III. 1TST10mm, 2QFT0.35IU/mL 
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Paper II 
Of the 746 children, the clinical TB cases (13) as well as 90 children assumed to be 
MTB infected (positive TST and/or QFT and normal CXR), had adequate specimen 
available for biomarker analysis. In addition, 107 uninfected children were randomly 
selected amongst TST/QFT negative children with normal CXR and adequate 
specimen for biomarker analysis. The random selection of un-infected controls aimed 
at getting similar distribution of sex and age within the categories by age and gender 
matching.  
 
Paper III 
The 210 subjects selected for paper II were reclassified exclusively dependent on their 
TST and QFT results. 
  
3.3.2. Adolescent Cohort Study (paper IV) 
Adolescents randomized to active surveillance who did not develop TB disease during 
the 2-year follow-up, were eligible if they had valid QFT test results and PBMCs in 
storage at 2 time-points: study day 360; hereafter referred to as the QFT baseline, and 
1 year later (study day 720). The adolescents were identified based on their QFT 
result at the 2 time-points and classified as: consistent positives, reverters or 
consistent negatives (controls). Then computerized random selection within the 
groups was undertaken (Table 5). 
Table 5.  
Study participants in paper IV 
QFT-GIT result 
cut-off  0.35 IU/mL 
Baseline 1 year later n 
Consistent positive + + 21 
Reverter + - 21 
Consistent negative - - 10 
Total     52 
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3.4. Clinical assessments (paper I-IV)  
Table 6. Clinical assessments relevant to the study 
NCS ACS 
Paper I- III Paper IV 
Surveillance  
      Description Active Passive Active 
When assessed         
  Baseline and study-closure per protocol X X X 
  Every 2 (NCS) or 3 (ACS) months per protocol in active surveillance X   X 
  At the CVW* after self-referral or referral by study staff X X   
Medical history       
  History of TB in study subject (ACS subjects only) TB previously suspected in study subject? X   
  Symptoms  
NCS: Fever, cough or FTT**/weight loss. 
ACS: Fever, cough, weight loss, night 
sweats, hemoptysis.                                          
Duration of these symtoms 
X X 
  TB exposure  
Known exposure to a TB patient                  
NCS: with/without active treatment >8h.         
ACS: within the household or classroom 
X X 
Examination          
  Antropometric data Height, weight X   X 
Examinations (only at the CVW*)       
  Antropometric data Height, weight X   
  Palpation lympnodular enlargement, abdomen X   
  Ausculation lung and heart X   
*Case Verification Ward 
**Failure to thrive. Defined in section 3.3.1, point 3. 
 
3.5. Tuberculin skin test (TST) (paper I-IV) 
 
Tuberculin Skin Test (TST) was performed by a trained nurse/doctor; 2 TU/0.1 mL 
tuberculin; Span Diagnostics Ltd, India were injected intra-dermally on the volar part 
of the lower arm and read after 48 hours. A cut-off of 10mm was chosen according 
to the Indian recommendations for childhood TB.210 
 
3.6. Chest X-ray (paper I-IV) 
 
Interpretations were done by 3 independent expert radiologists blinded to clinical 
symptoms and classified as 1) normal, 2) abnormal not TB and 3) abnormal 
consistent with TB. Consensus by 2/3 was required to classify the radiographic 
findings as abnormal TB.  
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Paper I-III (NCS) 
A chest radiograph (CXR), anterioposterior (AP) view, was performed on all referred 
children.  
 
Paper IV (ACS) 
Adolescents with symptoms or known TB exposure at baseline had a CXR AP view 
performed to exclude active TB. 
 
3.7. Sampling and handling of specimen 
 
3.7.1. Acquisition of microbiological specimen (paper I-IV)  
Paper I-III (NCS) 
Induced sputum (collected in a 20 ml tube using an infant mucous extractor after 
nebulisation with  hypertonic saline (3 %) and gastric aspirate (50ml tube containing 
10% sodium carbonate) were collected in the mentioned order on two consecutive 
mornings for M. tuberculosis smear and culture (see 3.8.1.). If no sample was 
obtained through the mucous extractor, the child was given chest physiotherapy and 
the nebulisation was repeated once before proceeding to gastric aspiration. The 
rationale for doing induced sputum first, was that if sputum was swallowed instead of 
expectorated it would be recovered in the gastric aspirate. A minimum of 4 hours 
fasting was required before the procedures. 
 
Paper IV (ACS) 
Two sputum specimens were collected at baseline from adolescents with symptoms or 
known TB exposure. Induced sputum as described above was performed if naturally 
produced sputum could not be obtained.  
 
3.7.2. Peripheral blood (paper I-IV) 
Peripheral blood for: 
x Hemoglobin (Hgb) measurements (capillary blood from heel-prick) 
(paper I-III) 
x QFT (~3 ml, see 3.8.2) (paper I-IV) 
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x PAXgene tubes (1-2.5 ml, see 3.8.3.1) (paper II-III) 
x 2 Cell Preparation Tubes (CPT) (16 ml, see 3.8.5.1) (paper IV) 
 
3.8. Laboratory methods (paper I-IV) 
 
3.8.1. Identification of mycobacteria (paper I-III) 
Sputum and gastric aspirate smears were heat fixed, stained with Auramine O dye, 
destained using acid alcohol and counterstained with potassium permaganate before 
fluorescent microscopy was performed by trained personnel. For mycobacterial 
culture the same specimen were digested and decontaminated using the NALC-
sodium hydroxide method, and inoculated onto Löwenstein Jensen medium (L-J) (300 
ȝl) and Mycobacterial Growth Indicator Tube (MGIT) (500 ȝl). The cultures were 
followed for 8 weeks. Positive smears and cultures were confirmed by Ziehl-Neelsen 
staining and speciated using the HAIN kit (GenoType® MTBC, Ver1, Hain Life 
Sciences, Germany). Direct PCR (The COBAS® TaqMan® MTB Test, Roche 2007) 
was done on culture negative specimen for infants with CXR suggestive of TB. 
Positive cultures were tested for drug susceptibility (streptomycin, isoniazide, 
rifampicin, ethambutol).  
 
3.8.2. QuantiFERON®- TB Gold In-Tube (paper I-IV) 
The QuantiFERON®- TB Gold In-Tube (QFT) assay (Cellestis) was carried out 
according to the manufacturer’s instructions. Briefly, venous blood was collected 
directly in the three kit tubes; Nil Control, TB Antigen and Mitogen control. 
Immediately after drawing of blood, the tubes were vigorously shaken before 
incubation at 37oC for 16-24 hours. Plasma from the tubes was harvested before 
storage at -20 ºC, and transport in cryoshippers to the laboratory at the St- John’s 
Research Institute, Bangalore, for the ELISA assay. As recommended by the 
manufacturer,72 the standard curve for reading of the optical density (OD) values was 
based on 4 standards (S1-S4) prepared by dilution of the Kit standard. Triplicates of 
S1-S4 were analyzed in the middle of every 96-well plate which also contained a 
batch of 28 study samples (triplicates). OD values were read on an automated 
photometer. Every plate was assessed with regard to established quality criteria 
acquired by the QuantiFERON-TB Gold In-Tube Analysis Software: 
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x S1: mean OD 0.600 
x Coefficient of variance (CV%) for S1 and S2 15% 
x S3 and S4: variation between replicates 0.040 OD from their mean. 
x The correlation coefficient calculated from the mean absorbance (=OD) of S1-
S4 must be 0.98. 
x Zero Standard: mean OD 0.150 
The test results were interpreted as positive, negative or indeterminate as 
recommended by the manufacturer (Table 7). 
Table 7. Interpretation of QuantiFERON-TB Gold In-Tube results 
Nil 
(IU/mL) 
TB Antigen minus Nil      
(IU/mL) 
Mitogen minus 
Nil (IU/mL) 
QuantiFERON-
TB (IU/mL) 
8.0 
<0.35 0.5 
Negative 0.35 and <25% of Nil 
value 0.5 
0.35 and 25% of Nil 
value Any Positive 
<0.35 <0.5 
Indeterminate 0.35 and <25% of Nil value <0.5 
>8.0 Any Any 
Retesting at higher dilutions of samples with QFT result >10 IU/mL was not 
performed and is not required by the manufacturer.  
 
Paper I-III (NCS) 
Children referred to the CVW had blood drawn for QFT if capillary Hgb 10 g/dL. 
 
Paper IV (ACS)  
Initially, QFT was not included in the study protocol. A protocol change was made to 
include repeated QFT testing at study day 360 and day 720.  
 
3.8.3. Dual color Reverse Transcriptase-Multiplex Ligation dependant Probe 
Amplification (dcRT-MLPA) (paper II and III) 
As the amount of blood which can be obtained from infants is limited, we used a 
novel high-throughput technique developed and described by Joosten et al,211 which 
requires only 130-150 ng of total RNA for analysis of a predefined panel of 49 genes 
consisting of four housekeeping genes, used as internal controls, and 45 genes 
identified by the partners in the Bill and Melinda Gates foundation Grand Challenge 
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project #6 consortium as differentially expressed during M. tuberculosis infection 
and/or disease in adults, by screening of different populations by qPCR and 
microarray. For each target sequence, two half-probes were designed and ligation of 
these probes is required to get the PCR product. This, together with placing the probe-
ligation sites close to an exon boundary, minimizes detection of contaminating DNA 
fragments. Known splice variants and single-nucleotide polymorphisms were also 
taken into account in probe design. Validation of the assay as well as the threshold 
value, were established by serial dilutions of chemically synthesized oligonucleotide 
templates using a validation probe set of 8 genes. The detection threshold was 20 
copies of any oligonucleotide, corresponding to log2 transformed peak area of 7.64. 
The results from the dcRT-MLPA assay proved highly comparable to Taqman real-
time PCR. The inter-assay correlation was found to be excellent (0.998) when 
independent duplicate samples were compared. The variance in the assay was 
analyzed by setting the total variation to 100% and determining the contribution by 4 
components; donor variation (the variation within a cohort of healthy individuals), 
collection variation (the variation within the same individual over time), tube 
variation (the variation between 5 separate PAXgene tubes collected from the same 
healthy donor) and assay variation (the variation between temporarily different RT-
MLPA assays). The contribution to the variance by these components varied 
somewhat from gene to gene, but the predominant factor for all genes was the donor 
component, underlining the adequacy of the method to detect differences between 
subjects classified by disease state. The standard deviation for dcRT-MLPA patient 
samples is normally in the range 35-45% (personal communication by Marielle Haks, 
Leiden University Medical Center, Netherlands). 
 
All required regents for the dcRT-MLPA assay were obtained from the Department of 
Infectious Diseases, Leiden Medical University, Leiden, The Netherlands: 
x Probes: right-hand and left-hand 5’ phosphorylated half probes 
x Primers: Reverse transcription gene target specific primers, FAM 
labelled MLPA primers, HEX labelled MAPH primers 
x Positive control: synthetic template oligonucleotides (hybridization templates)  
x Human Universal Reference RNA  
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3.8.3.1.RNA extraction 
Total RNA was extracted from blood collected on the PAXgene Blood RNA Tubes 
using the ‘PAXgene Blood RNA kit’ with RNase free DNase on-column digestion 
(both PreAnalytiX, Hilden, Germany) according to the manufacturer’s instructions. 
The total RNA concentration and purity (A260/280 nm ratio) were measured using a 
Nanodrop spectrophotometer (Thermoscientific, Wilmington, Delaware, U.S.A) and 
ranged between 0.4 - 24.5 ȝg (average 6.6 ± 4.85 ȝg). The RNA quality was further 
assessed by agarose gel electrophoresis. 
 
3.8.3.2.The dcRT-MLPA assay 
Samples with a concentration <50 ng/ȝl were concentrated at 45ºC using a speed 
vacuum concentrator (Eppendorf AG, Hamburg, Germany), before the transcription 
step. The dcRT-MLPA experiment protocol is described in detail by the inventors of 
the assay.211 In brief, the assay includes the following steps: 1)reverse transcription, 
2)hybridization of gene-specific probes, 3)ligation of half-probes, 4)PCR reaction and 
5)fragment analysis. All samples for paper II and III were run in duplicates. The 
human reference RNA and syntetic oligonucleotide were included on each 96-well 
plate. Reference RNA served as positive control for reverse transcription, whereas the 
oligonucleotide was positive control for the PCR-reaction. The amplified PCR 
products were diluted 1:10 with nuclease-free H2O and added to a mixture of Hi-Di-
Formamide with 400HD ROX size standard. The PCR fragments were analyzed on a 
3730 capillary sequencer in Gene scan mode (Life Technologies, Carlsbad, 
California, USA). 
 
3.8.3.3.Processing of dcRT-MLPA data 
Data was analyzed using GeneMapper software version 4.0 (Life Technologies, 
Carlsbad, California, USA) according to the GeneMapper version 4.0 manual. The 
default peak detection settings were inspected and adjusted if necessary. The peak 
area (in arbitrary units) of duplicates were averaged, and amongst four reference 
genes included in the assay (ABR, B2M, GAPDH and GUSB), GAPDH showed the 
least variance. (GUSB or ȕ-glucuronidase, is a lysosomal enzyme which could also 
play a role in the immune response towards TB212). All other genes where thus 
normalized against GAPDH using Microsoft Excel spreadsheet software and 
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subsequently log2 transformed as described by Joosten SA et al. Of the 45 genes, 7 
genes had expression levels below the cut off value of 7.64 (peak area < 200 arbitrary 
units) and one gene, CD14, co-localized with a primer-dimer peak and was therefore 
omitted from further analysis. 
 
3.8.4. Multiplex bead array – Bio-Plex assay (paper II and III) 
For the Bio-Plex assay, we used supernatants from the QFT assay (the Nil and TB 
Antigen tubes). A pilot study was conducted using 52 samples randomly selected 
from the study subjects included in paper II: children with TB disease (11), MTB 
infected children (29) and uninfected controls (12). The samples were screened by the 
‘Human cytokines 27-plex’ kit (Bio-RAD Laboratories Inc., Hercules, California, 
USA) according to the manufacturer’s instructions and measured by fluorescent 
intensity (FI) by the Bio-Plex 200 System empowered with Luminex xMAP 
technology. With each assay set-up, dilutions of a multiple standard (S1-S8) 
containing all the 10 proteins were set-up in duplicates on each plate together with 
patient samples. Due to sample availability patient samples were run in single wells. 
Analyses comparing the three clinical groups revealed discrete differences in 5/27 
biomarkers (IL-5, IL-13, IP-10, IFN-Ȗ and TNF-Į). These 5 biomarkers were selected 
for inclusion in a customized 10-plex kit together with 5 biomarkers (IL-2, IL-6, IL-8, 
IL-10 and MCP-1) added because of findings in previous TB biomarker studies.213-215 
All the samples (210) were then tested by the 10-plex kit and analyzed both in the 
setting of paper II and paper III. The cytokine/chemokine concentrations (pg/mL) in 
the unstimulated (Nil) and stimulated (TB Antigen) tubes were analyzed individually. 
 
3.8.5. 9-color flowcytometric assay on PBMCs (paper IV) 
3.8.5.1.Isolation, storage and transport of PBMCs  
At the study field-laboratory at Emmaus Swiss Hospital, peripheral blood 
mononuclear cells (PBMC) were isolated from 16 ml peripheral blood collected on 2 
CPT tubes per subject, according to the manufacturer’s instructions. Briefly, within 2 
hours of venipuncture the CPT tubes were inverted 8-10 times prior to centrifugation 
(25 min of 1750g at room temperature (RT)). Following aspiration of plasma, cell 
layers from both CPTs (same individual) were collected into a 15 ml centrifugation 
tube, before 2 repeated washings with RPMI 1640 (Gibco 11875 or Sigma R8758) 
with 1% Fetal Bovin Serum (FBS) (Gemcell 100-500 or Gibco 16000-044)) and 
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centrifugations (370 g for 10 min at RT). The cells were resuspended and frozen in -
80ºC immediately after adding an equal amount of 80% FBS with 20% DMSO 
(Sigma D2650). After 12 hours at -80ºC, the samples were transferred to -152 ºC for 
typically a week, before transport and banking in to the Biorepository liquid N2 
freezers at St. John’s Research Hospital. Selected samples were shipped 
simultaneously in liquid N2 (MVE Vapor Shipper) to Oslo University Hospital, 
Norway, where the samples were randomized for processing in 7 batches, each 
containing a maximum of 24 samples. 
 
3.8.5.2.Thawing  
PBMC were thawed by drop-wise resuspension in preheated RPMI 1640 
(BioWittakre) with 10% FBS (Sigma) and 1% L-glutamine (Lonza, BioWhittaker), 
and left over-night. Cell counts and viability were assessed on Tryphan Blue stained 
cells (Countess, Invitrogen), and in some samples confirmed by manual counts after 
staining with Acridin Orange (Sigma). Samples with cell viability >70% were set up 
for further analysis. 
 
3.8.5.3.In vitro stimulation  
PBMCs were assessed for ex vivo responses to peptide pools of 1) Ag85b (2 ȝg/mL), 
2) Early Secretory Antigen Target-6 (ESAT-6) (2 ȝg/mL), 3) Rv 2660c (10 ȝg/mL) 
and 4) Purified Protein Derivate RT50 (PPD) (10 ȝg/mL), all provided by Statens 
Serum Institutt, Copenhagen, Denmark. Staphococcal Enterotoxin B (SEB) (Sigma) 
was used for positive control and PBS served as negative control, all in the presence 
of the co-stimulants ĮCD28 (10 ȝg/mL, clone L293, BD) and ĮCD49d (10 ȝg/mL, 
clone L25, BD). Samples from the same subject (QFT baseline and after 1 year) were 
set up side by side on a 96-well round bottom plate (Corning Life Sciences. Brefeldin 
A (BD GolgiPlug) (1.0 ȝl/well) and monensin (BD GolgiStop) (0.7 ȝl/well) were 
added before the 6 hour incubation (37ºC, 5% CO2). 
 
3.8.5.4.Simultaneous staining of membran and intracellular proteins 
As CD107 (BD) is a degranulation marker, CD107a-FITC (BD) was added together 
with the Golgi inhibitors prior to incubation. Stimulated samples were washed in PBS, 
stained with LIVE/DEAD Violet Fixable Dead Cell Stain (L34955, Invitrogen), 
incubated for 10 min, washed with PBS, then stained for the following surface 
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markers; CD3-APC Alexa Fluor 750 (Beckman Coulter), CD4-PerCP Cy5.5 (BD), 
CD14-PacBlue (BD), CD16-PacBlue (BD), CD19-PacBlue (Invitrogen) and 
CD45RO-PE Cy5 (BD), and incubated  for 25 min. The cells were subsequently 
washed twice with FACS buffer (PBS with 2% FBS and 0.01% sodium azide), fixed 
and permeabilized by a 10 min incubation using Cytofix/Cytoperm (BD) and 
subsequent wash with Perm/Wash Buffer (BD). Intracellular markers were added; 
IFNȖ-Alexa Fluor 700 (Invitrogen), IL2-APC (BD), TNFĮ-PE Cy7 (BD), and 
perforin-PE (Diaclone), before a 30 min incubation followed by two washes with 
Perm/Wash Buffer. Stained samples were stored in 1% formaldehyde at 4ºC until 
flowcytometric analysis (within 48 hours). All staining steps and incubations were 
done at room temperature.  
 
3.8.5.5.Flowcytometric analysis 
The samples were run on a LSR II flowcytometer (BD Biosciences) using the 
configuration and set-up given in Table 8. 
 
 Table 8. Configuration and set-up of the "Yellow LSRII", 
Montebello 
Laser Marker Flurochrome Filter 
Violet 405  Dump/viability Pacific Blue 450/40 
Blue 488  
CD107a FITC 525/50 
CD4 PerCP-Cy5.5 720/40 
Yellow 561  
Perforin PE 582/15 
CD45RO PE-Cy5 670/14 
TNFa PE-Cy7 780/60 
Red 640  
IL2 APC 670/14 
CD3 APC-Alexa750 780/60 
IFNg Alexa 700 730/45 
 
To avoid high pressure in the high-throughput sample platform due to many 
fluorochromes, samples were transferred to FACS tubes, diluted in PBS and manually 
loaded. Single stained BD CompBeads were used for automatic compensation. For 
each individual sample, 20 000 events were recorded ungated for sample quality 
assessment, before the storage gate was set to a wide lymphocyte gate based on 
forward- and side scatter properties. FACS Diva Software (BD) was used for data 
acquisition. 
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3.8.5.6.Gating strategy and data extraction 
After transfer of data to FlowJo Software, version 9.4.11, the compensation matrices 
were manually inspected an adjusted if appropriate. The expression of cytokines after 
specific short-time (18h) stimulation is reported very low within the CD45ROlow 
subsets,216 thus we gated on the CD3+CD4+CD45RO+ and CD3+CD4-CD45RO+ 
cell populations followed by cytokine gates. The gating strategy is given in Figure 11. 
 
 
Boolean gates were created based on combinations of single cytokine gates. Both a 
cytokine panel (IFNȖ, IL-2, TNFĮ) and a cytotoxic panel (CD107a, IFNȖ, perforin) 
was analyzed; the cytotoxic panel was assessed within CD3+CD4-CD45RO+ cells 
only. Samples excluded from data analysis (Figure 12) had either 
x a poorly defined lymphocyte population,  
x CD3+CD4+ or CD3+CD4- cell counts <5000 or  
x lacked a valid positive control. (Valid positive control defined as >1% 
cytokine-producing cells when stimulated with SEB.) 
Figure 11. Example of a representativ sample after stimulation with positive control (SEB). Singlets were 
gated based on forward- and side scatter properties; CD3 high cells not within the dump gate (CD14, 
CD16, CD19); verification of the lymphocyte population; CD4 high population; CD45RO high (memory) 
population; single cytokine gates (upper pane) and two-dimentional cytokine gates (lower pane) were 
used to correctly draw the gates according to the “natural break”.
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When assessing cytokine-positive cells, the background response to PBS was 
subtracted. A threshold for positive cytokine response was set at a 2-fold increase in 
cell count above the background, and samples that did not meet this requirement were 
set to zero. Subjects producing any of the cytokines were considered responders to the 
respective antigens. About 50% of the consistent positives responded to ESAT-6 and 
Ag85b, but as the frequencies of cells responding to Ag85b were considerably lower, 
data on Ag85b-responses was not included in paper IV. Neither was data on Rv2660c-
responses as only 25% of the consistent positives responded to this antigen.  
 
3.9. Statistical analysis 
 
All p-values were calculated using two-tailed tests and a p-value of <0.05 was taken 
to be significant. When not stated otherwise, Microsoft Office Excel 2003 were used 
for data handling, analyses were conducted using the PASW Statistics version 18.0 
and GraphPad Prism version 5 was used for statistical figures. 
 
Paper I 
Sociodemographic, clinical and nutritional characteristics were assessed in the 705 
children classified according to the diagnostic TB algorithm, as follows: Low 
birthweight (<2500g) and being small for gestational age (SGA: Weight-for-
gestational age <10th percentile)217 were used as indicators of intra-uterine nutritional 
status. Birthweight was also assessed as a continuous variable. The WHO child 
growth standard Z-scores were dichotomized using the cut-off <-2, which defines 
wasting (weight-for-height (WHZ)), stunting (height-for-age (HAZ)) and underweight 
(weight-for-age (WAZ) and BMI-for-age (BAZ)).209 Equal to the WHO definition, 
hemoglobin <10 g/100ml defined the cut-off for moderate-severe anemia.218 Age was 
categorized into 3 levels (<12 months, 12-23 months, 24 months and also assessed 
as a continuous variable. Data on mother’s and father’s education were captured in 6 
levels, but recoded into three categories for data analysis (illiterate, primary or 
secondary school, high school or higher). Housing material and cooking fuel were 
dichotomized in order to identify higher socioeconomic status (bricks versus others; 
electricity or gas versus others, respectively). TST and QFT were handled as 
categorical variables; TST dichotomized around the cut-off 10mm as recommended 
in local guidelines,210 and QFT was divided into 3 categories as recommended by the 
61 
 
manufacturer: positive (0.35 IU/mL), negative (<0.35 IU/mL) and indeterminate.72 
For QFT, exact measurements >10 IU/mL were not available, due to the technical 
restriction imposed by the test’s standard curve. Differences in the distribution of the 
variables between children with clinical TB and children without TB were assessed: 
Continuous variables by T-test (normally distributed) or Mann Whitney U test (not 
normally distributed); Categorical data by Pearson’s chi-squared with Yates 
Continuity Correction or Fisher’s exact test, where appropriate.  
 
Kappa statistic (ț) was used in the concordance analyses of TST and QFT results for 
individuals with valid results for both tests, and evaluated in accordance with McGinn 
et al..219 Spearman’s Rank Order Correlation was used to assess the relationship 
between the mitogen response and age. (The result from this analysis is not included 
in paper I, but in section 5.2). 
 
Because we observed a considerable left-skewing in the distribution of the nutritional 
Z-scores, the nutritional variables WHZ, HAZ, WAZ and BAZ were reassessed to 
optimize the definition of these variables before inclusion in univariate and 
multivariate logistic regression analyses. The Z-score variables were analyzed in 
different ways: 1) as continuous variables, 2) as categorical variables defined by the 
standard WHO cut-offs; <-2 (moderate to severe malnutrition); <-3 (severe 
malnutrition), 3) after re-standardization of the cut-off (mean minus 1.96*St.dev), 4) 
binned by quartiles and 5) dichotomized around cut-offs corresponding to the lowest 
quartiles (new cut-offs: WHZ <-2.61; HAZ <-2.16; WAZ <-2.65; BAZ <-2.51).  
Variables which turned out significant when continuous did not do so when 
categorized as in alternative 2) and 3). Based on this, we concluded that dichotomous 
variables with a cut-off corresponding to the lowest quartile, best reflected the 
information in the dataset. The left-skewing in Z-score distributions and new cut-offs 
used in logistic regression analyses are illustrated in Figure 12. 
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Associations with the following outcomes were assessed by univariate and 
multivariate logistic regression analyses: 
1. a positive TST versus a negative TST 
2. a positive QFT versus a negative QFT 
3. concordant TST and QFT positive versus concordant negative or discordant 
positive for TST and QFT. 
4. an indeterminate QFT versus a valid QFT result (positive or negative) 
 
Unadjusted odds ratio estimates for the variables: surveillance arm (active or passive), 
gender, birthweight, SGA, age, socioeconomic factors (mothers/fathers education, 
housing, cooking fuel), known TB exposure, symptoms, nutritional status (WHZ, 
HAZ, WAZ, BAZ, anemia) and isolated NTMs, were performed by logistic 
regression. 
 
Variables with significant univariate associations with the TST and/or QFT outcomes 
were considered for inclusion in the multivariate model if they, based on the 
literature, could be assumed to have a casual impact on the outcomes. These assumed 
causal relationships were based on the literature and drawn by principles of a directed 
Figure 12. Left-skewed WHO Z-scores in the study population. In each plot, 
the mean Z-score in the study population is marked with a blue line 
compared to the WHO Z-score means (dashed blue line). New cut-offs 
corresponding to the lowest quartile is marked with a red line.  
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acyclic graph (DAG).220 Notably, as the positive TST and/or QFT outcomes are 
imperfect read-outs of the clinical TB outcome (clinical TB disease, MTB infection or 
no infection/disease) for which there is no gold standard, we chose to illustrate the 
variables relationship both to the clinical TB outcome and the positive TST and/or 
QFT outcomes (Figure 13) (Causal relationships are indicated with arrows.) The 
variables’ impact on clinical TB influence on the child’s susceptibility for MTB 
infection and disease, whereas the variables impact on a positive TST and/or QFT 
result influence on the ability of the tests to correctly reflect the clinical TB outcome 
(test performance). Following the DAG principle, ancestor variables (variables that is 
a cause of another variable more closely linked to the outcome) and descendants of 
the outcome, were not included in the multivariate models.220 These considerations 
left age, TB exposure, WHZ, HAZ and NTM presence in the multivariate model 
together with gender which is routinely included. WHZ and HAZ represent different 
entities of malnutrition, and important colinearity or interaction was not found when 
all possible 2-way interactions in each of the multivariate models were tested. 
Nevertheless, their inter-relationship both as continuous and categorical variables was 
investigated with regards to correlation (Spearman’s rho=-0.06, p=0.14), colinearity 
(Tolerance=1, Variance Inflation Factor=1) and interaction. Analyses suggested a 
higher correlation between weight-for-age Z-score (WAZ) and either of WHZ 
(Spearman’s rho=0.49, p<0.0005) or HAZ (Spearman’s rho=0.37, p<0.0005). A slight 
interaction between WHZ and HAZ (p=0.048) for a positive QFT was found. The 
model including the interaction gave a better fit (Likelihood Ratio test Statistics: 
X²=5.34, p<0.025), but did not change the coefficients.  
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MTB exposure
(Known TB contact)
NTM exposure
(NTM 1in specimen)
Sex
SES*
(Mother/father’s 
education, housing, 
cooking fuel)
Clinical TB outcome
Clinical TB disease, 
MTB infection, 
No disease or MTB infection Positive 
TST/QFT
Symptoms
Fever and/or cough 2 weeks,
Failure to thrive
Malnutrition
(WHZ, HAZ, WAZ, 
BAZ, anemia)
Age 
(Months, 3 categories: 
0-11;12-23;24)
 
 
 
 
 
 
Regarding the indeterminate QFT outcome, the assumed causal relationship is 
different (Figure 2). Being primarily the result of inadequate mitogen responses, this 
outcome is not specific for clinical TB outcome, but rather affected by all 
physiological conditions interfering with T-cell responses in general. Accordingly, 
known TB was not considered relevant whereas symptoms of any duration (categories 
defined in Table 1, paper I) were included because of previous reports.221 Notably, 
age was used as a continuous variable in the multivariate model as categorization 
gave statistical problems due to no indeterminate results in the oldest age group. As 
inclusion of variables which measure the same thing can cause statistical problems 
related to co-linearity, we chose to exclude the symptom FTT and instead use the Z-
score to facilitate the interpretation in relation to the positive TST and/or QFT model. 
In addition, FTT in our study was a composite variable including 3 different aspects 
related to the weight-for-age Z-score. Applying “clean” Z-scores makes comparison 
with other studies easier (Figure 14).  
Figure 13. A Directed Acyclic Graph (DAG) illustrating the causal relationships between the 
determinants for the outcomes clinical TB and positive TST and/or QFT. A causal relationship 
between a determinate (variable names listed in parenthesis) and an outcome is indicated with 
arrows. Ancestors (variables that is a cause of another variable more closely linked to the outcome) 
and descendants of the outcome not included in the multivariate models, are in italic. Variables 
significantly associated to the outcomes in univariate analysis are in bold. Dashed arrows indicate 
more uncertain relationships. 
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As WAZ and BAZ are alternative markers of nutritional status and indicate 
underweight if the Z-score is <-2),222 exchanging WHZ and HAZ for WAZ or BAZ in 
the multivariate models was also explored.  
 
The amount of variation explained by the final multivariate models (Nagelkerke R 
Square) for the different TST/QFT outcomes is given in (Table 9).  
Table 9. Explained variation (Nagelkerke R²) by 
the multivariate model 
Outcome analyzed R² 
TST positive (10mm) 0.385 
QFT positive (0.35IU/mL) 0.102 
Combined TST/QFT positive 0.267 
Indeterminate QFT  0.193 
 
Age was the most important factor and contributed with 60-80% of the explained 
variation in all models, whereas sex and NTM presence did not contribute in any 
model. Known TB contact contributed more to the explained variation for the 
Figure 14. A Directed Acyclic Graph (DAG) illustrating the causal relationships between the 
determinants for the outcome indeterminate QFT. A causal relationship between a determinate 
(variable names listed in parenthesis) and an outcome is indicated with arrows. Ancestors 
(variables that is a cause of another variable more closely linked to the outcome) and descendants 
of the outcome not included in the multivariate models, are in italic. Variables significantly 
associated to the outcomes in univariate analysis are in bold. Dashed arrows indicate more 
uncertain relationships. 
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outcomes QFT positive and Concordant TST/QFT positive (both ~20%) than for TST 
positive (~4%). The contribution by nutritional variables (WAZ for TST positive and 
HAZ for QFT positive and Concordant TST/QFT positive) were as important as 
known TB contact in all these models. For the outcome Indeterminate QFT, 
symptoms contributed more than the nutritional variables, but overlap between these 
variables is likely as 3 different models including sex, age and either 1)symptoms, 
2)WHZ or 3)HAZ all explained ~80% of the explained variation in the final model. 
 
Paper II 
Differences in baseline characteristics were identified by the Pearson’s chi-squared 
test (with Yates continuity correction) or Fisher’s exact test, where appropriate. dcRT-
MLPA (gene expression) and bio-plex (cytokines/chemokines) data were analysed 
separately following the analysis strategies given below: 
1. The global test was performed to determine whether the global expression 
pattern of the selected genes was related to any of the clinical outcomes (pair-
wise comparison).223 
2. Binary logistic regression was applied for the identification of single 
biomarkers differentially expressed between the clinical groups. These 
analyses were performed with and without adjustments for age (months), 
nutritional status (WHZ and WAZ) and NTM in specimen (categorical 
variables as given in Table 1, paper II). These factors were regarded possible 
confounders based on their differential distribution between the clinical 
groups. Later, the adequacy of adjusting for these factors was re-evaluated by 
the principles of a DAG diagram (defined and described in section 3.9, paper 
I) (Figure 15), and confirmed. No correction for multiple testing was 
undertaken due to the exploratory nature of the study.  
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Read-outs
MTB exposure
(Known TB contact)
NTM exposure
(NTM 1in specimen)
Sex
Clinical TB outcome
Clinical TB disease, 
MTB infection, 
No disease or MTB infection
Host immune 
response
Symptoms and findings
Fever and/or cough 2 weeks,
Failure to thrive, CXR
Malnutrition
(WHZ, HAZ, WAZ)
Age 
(Months, 3 categories: 
0-11;12-23;24)
TST
QFT
Biomarkers
Transcriptomes
Cytokines/chemokines
 
 
 
 
 
 
3. The “lasso” (Least Absolute Shrinkage and Selection Operator) is a regression 
model which penalizes the absolute size of the regression coefficients, 
shrinking them towards zero. This can be an appropriate approach if the 
predictors are likely to be highly correlated or interdependent. In either case, 
standard regression may generate overly-generous regression coefficients 51. 
It is an alternative to backwards stepwise elimination of non-significant terms, 
not relying on statistical significance tests. As a result, lasso is useful for 
establishing a prediction model at an individual level (i.e., identifying 
important predictors), but not for summarizing average trends in the data.224 
The optimal lasso model is the one with optimal lambda value or penalty. For 
the biomarker data, this was determined using leave-one out cross-validation. 
This method replaces the classical adjustment for multiple testing.224 The lasso 
model corresponding to the lambda value which resulted in the smallest 
Figure 15. A Directed Acyclic Graph (DAG) illustrating the assumed causal 
relationships between the determinants for clinical TB outcomes and host immune 
response for which biomarkers, TST and QFT were the available read-outs in our setting. 
A causal relationship between a determinate (variable names listed in parenthesis) and an 
outcome is indicated with arrows. Dashed arrows indicate more uncertain relationships. 
Variables significantly associated with the clinical TB outcome in univariate analysis was 
adjusted for when assessing differences in biomarker profiles between the clinical TB 
outcome groups are in bold. Ancestors (variables that is a cause of another variable more 
closely linked to the outcome) and descendants of the outcome not adjusted for, are in 
italic.  
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prediction error was considered the optimal model and the non-zero estimated 
coefficients were reported. Next, the prediction performance of this model in 
terms of probabilities and ROC curves, was based on the performance on the 
test data 
The statistical environment R was used for the global test223 and for the lasso 
regression (add-on package “glmnet”).225 
Paper III 
Differences in baseline characteristics and single biomarkers between subjects 
classified according to TST and/or QFT results were analyzed as described for paper 
II. Biomarker signatures using the global test and/ or lasso regression were not 
considered relevant in this setting.  
Paper IV 
The distributions of age, sex and BCG-status between the QFT categories were 
assessed by ANOVA and Fisher’s Exact test where appropriate. For TST, QFT and 
absolute frequencies of T-cells subsets (flowcytometric data), non-parametric 
statistics were applied as the data were not normally distributed. As the 
flowcytometric data on relative frequencies are normalized, parametric statistics 
(unpaired T-test with Welch’s correction) were applied.226 The study was designed to 
have paired measurements for all immunological read-outs. For TST and QFT data, 
paired analyses on repeated measurements by the Wilcoxon Signed rank test was 
performed, whereas differences between groups (unpaired data) were assessed by 
Mann-Whitney U test. High quality demands for flowcytometric samples resulted in 
too many missed samples (section 3.8.5.6) to allow for paired statistical analyses 
(Friedman’s test). Therefore, pair-wise comparisons by the Mann-Whitney U test 
were done. Correlations were assessed by Spearman’s Rank Order Correlation. A 
two-tailed Į-level of p<0.05 was considered significant. Microsoft Office Excel 2003 
and GraphPad Prism version 5 were used for data handling and statistical analyses.  
 
3.10. Ethical considerations 
 
The NCS and ACS were conducted according to the principles of the Declaration of 
Helsinki (4th revision), and approved by the institutional review board at St. John’s 
National Academy of Health Sciences, and an independent ethics review committee 
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contracted by the Aeras and the Ministry of Health Screening Committee, 
Government of India. 
x NCS: No. 5/8/9/60/20006-ECD-1 dt.10.11.2006 
x ACS:  No. 5/8/9/52/2006-ECD-I dt. 10.11.2006  
Confidentiality of patient identify was maintained by assigning each subject with a 
coded number used to identify all documents and specimens. All source documents 
are stored in a secured location, and except for monitoring and auditing of the study, a 
written assent is required for any dissemination. The informed consent process for the 
NCS is described an evaluated in detail by Rajaraman et al.207 
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4. MAIN RESULTS – summary of papers 
4.1. Paper I 
Influence of Age and Nutritional Status on the Performance of the Tuberculin 
Skin Test and QuantiFERON®-TB Gold In-Tube in Young Children Evaluated 
for Tuberculosis in Southern India 
Jenum S, Mahelai D, Selvan S, Jesuraj N, Vicky Cardenas, Kenneth J, Hesseling AC,  
M Pai, Doherty TM , Vaz M, Grewal HMS, TB Trials Study Group. 
 
A reliable identification of young children with Mycobacterium tuberculosis (MTB) 
infection or tuberculosis (TB) is vital to assure adequate preventive and curative 
treatment. As pediatric TB often remains unconfirmed, evidence of a previous 
encounter with MTB by a positive Tuberculosis Skin Test (TST) or IFNȖ-release 
assay (IGRA) are used as a supplement in the diagnosis, but data on the performance 
of these tests are scarce in children aged <5 years. Whereas an increasing number of 
studies have addressed how immune suppression in the context of HIV infection 
affects the performance of TST and IGRAs in young children, the impact of immune 
suppression by malnutrition is far less studied. Therefore, our aims were to evaluate 
the performance of TST and QuantiFERON-TB Gold In-Tube (QFT) and their 
association with clinical-, demographic- and nutritional (intra-uterine and post-natal) 
characteristics in a cohort of children aged <3 years in a setting with high TB burden 
and low HIV prevalence. 
Nested within a prospective cohort study of 4382 neonates in Southern India, this 
study included 705 children aged 1-35 months (mean 14.8) evaluated for TB during 
the 2-year follow-up. 13 children were diagnosed with clinical TB, in whom MTB 
was confirmed in 4. Isolated isoniazid resistance was detected in 1 out of 3 children 
with culture confirmed TB. The sensitivities of TST and QFT for clinical TB were 
equally poor (31% and 23%, respectively). Based on adjusted logistic regression of 
TST and QFT outcomes, the poor sensitivity of these tests in this population seems, at 
least in part, attributable to young age and malnutrition. More specifically, children 
aged <2 years were less likely to have a positive TST and/or positive QFT and more 
likely to have an indeterminate QFT. Children within the lowest quartile for the 
height-for-age Z-score, indicative of chronic malnutrition, were more susceptible to 
MTB infection and more prone to indeterminate QFT results. TST was less reliable in 
children with a weight-for-height Z-score within the lowest quartile.  
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4.2. Paper II 
Identification of biomarkers for Mycobacterium tuberculosis infection and 
disease in BCG-vaccinated young children in Southern India. 
S. Dhanasekaran, Synne Jenum, Ruth Stavrum, Christian Ritz, Daniel Faurholt-Jepsen, 
John Kenneth, Mario Vaz, Harleen M. S. Grewal, T. Mark Doherty, TB Trials Study 
Group (Genes Immun 2013;May 16) 
 
There is an urgent need for better diagnostic tools in the diagnosis of MTB infection 
and disease in young children. Our aim was to explore biomarkers with a potential to 
discriminate between clinical TB (n=13), MTB infection (n=90) and neither (controls 
, n=107) in children <3 years with suspected TB. mRNA isolated from unstimulated 
peripheral blood mononuclear cells was examined for the transcription of 45 genes. A 
10-plex assay was applied to analyze the level of cytokines/chemokines in QFT 
supernatants (TB Antigen and Nil tube). The clinical groups were compared pair-wise 
with and without adjustments for age, nutritional status and the presence of non-
tuberculosis mycobacteria, both with regard to single gene expression (logistic 
regression) and with regard to biosignatures (Global test and lasso regression). 
 
In adjusted analyses of single gene transcripts in unstimulated peripheral blood, we 
found lower levels of RAB33A in clinical TB compared with MTB infection and 
controls, whereas mRNA for SEC14L1, GUSB, BPI, CCR7, and TGFB1 were reduced 
in TB patients compared to MTB infected children or controls. Children with MTB 
infection displayed higher levels of CD4, TGFB1 compared to controls. Lasso 
regression was applied to identify the biomarker signatures which best predicted the 
clinical outcomes. RAB33A alone discriminated between clinical TB and MTB 
infection (AUC 77.5 %), whereas a biosignature of RAB33A, CXCL10, SEC14L1, 
FOXP3, and TNFRSF1A effectively discriminated between clinical TB and controls 
(AUC 91.7 %). This supports, also in young children, the diagnostic potential of 
RAB33A for clinical TB and in the discrimination between MTB infection and 
disease. The 5-biomarker signature and CD4 and TGFȕ-1 might provide clues to the 
identification of clinical TB cases among children with symptoms for other reasons. 
The 10-plex cytokine assay on TB Antigen supernatants revealed little difference 
between the clinical groups, but increased levels of IL-2 and IL-13 was found in 
children with MTB infection compared to controls. 
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4.3. Paper III  
Concordant or discordant results by the tuberculin skin test and the 
QuantiFERON-TB test in children reflect immune biomarker profiles. 
S. Dhanasekaran, Synne Jenum, Ruth Stavrum, Christian Ritz, John Kenneth, Mario Vaz, 
T. Mark Doherty, Harleen M. S. Grewal, TB Trials Study Group 
 
Young children have an increased risk of progression to TB following MTB infection. 
Therefore, evidence of MTB infection, as indicated by a positive TST and/or positive 
QFT, should initiate preventive treatment in children aged <3 years when active TB 
has been excluded. However, TST and QFT often give discordant results in this 
population. How to interpret discordant results in terms of TB risk and preventive 
treatment is unclear. We hypothesized that a preselected panel of TB immune 
biomarkers could provide some insight into the immunological mechanisms 
underlying concordant and discordant TST and QFT results. Children were classified 
according to TST and/or QFT result and the expression of 45 gene transcripts in 
peripheral blood (direct ex vivo) and 10 cytokines/chemokines in QFT supernatants 
(Nil and TBAntigen tubes from the QFT assay) within these groups, were compared 
pair-wise by logistic regression, with and without adjustments for age, nutritional 
status and the presence of non-tuberculous mycobacteria. 
 
Comparing test positive children to concordant negative (TST-/QFT-) children, 
concordant positive (TST+/QFT+) children only, had differentially expressed 
transcriptomes of FPR1, TNFRSF1A (both up-regulated) and BPI (down-regulated), 
and increased levels of IFNȖ (TB-Ag tube). Contrary, all test positive children (TST 
and/or QFT positive) had up-regulation of the transcriptomes CD4 and TGFB1, and 
increased levels of the cytokines IL-2 and IL-13. The only difference between the 
TST+/QFT- and TST-QFT+ discordant children was a down-regulated transcription 
of SEC14L1 and an elevated level of IP-10 in TST-/QFT+. IP-10 proved to be more 
differentially expressed between concordant/discordant groups than IFNȖ, and seemed 
in fact to be a better marker for a positive QFT. 
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4.4. Paper IV 
The frequencies of IFNȖ+IL2+TNFĮ+ PPD-specific CD4+ memory T-cells 
correlate with the magnitude of the QuantiFERON® Gold In-tube response in a 
prospective study of healthy Indian adolescents. 
Jenum S, Grewal HMS, Hokey D, Kenneth J, Vaz M, Doherty M, Jahnsen FL, TB 
Trials Study Group. 
 
MTB infected subjects who do not progress to tuberculosis (TB) are assumed to 
possess natural protective immunity. Their immune responses have been extensively 
studied to identify immune correlates of protection from TB progression, highly 
needed for TB vaccine trials and more targeted preventive treatment. The 
QuantiFERON® Gold In-tube assay is an IFNȖ-release assays used to identify MTB 
infected subjects. Evidence suggests a positive correlation between the magnitude of 
specific IFNȖ-responses and TB risk, but studies on the single cell level suggest that 
the quality (polyfunctionality) of the T-cell response is more important for protection 
than the quantity of IFNȖ-release. This assumption has not been supported by 
prospective, longitudinal studies. We hypothesized that the quality and magnitude of 
MTB-specific T-cell responses in peripheral blood would differ between two groups 
of healthy subjects with different TB risk, as judged by their longitudinal 
QuantiFERON®-TB Gold In-Tube (QFT) results. As part of a prospective cohort 
study in Indian adolescents, we assess, by multicolour flow cytometry, the cytokine 
production by mycobacterial-specific T cells in PBMCs of 42 QFT positive 
adolescents of whom 21 became QFT negative (reverters) within 1 year. Ten QFT 
consistent negatives were included as controls.  
 
Relative frequencies of PPD-specific polyfunctional (IFNȖ+IL2+TNFĮ+) CD4+ T-
cells were high but similar in both QFT groups at baseline. Reverters displayed lower 
absolute frequencies of these cells, which were further reduced 1 year later. Notably, 
the polyfunctional subset was most efficient in terms of cytokine production and their 
absolute frequency correlated well with the magnitude of the QFT-response. Our data 
do not support that higher relative or absolute frequencies of PPD-specific 
polyfunctional CD4+ T-cells in peripheral blood can explain the reduced risk of TB 
progression observed in QFT reverters. Contrary, absolute frequency of these cells 
correlated with the QFT-response, suggesting that this readout reflects antigenic load. 
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5. GENERAL DISCUSSION 
 
5.1. Discussion of methods 
 
5.1.1. Study design of NCS and ACS 
The strength of these studies is the prospective design, the considerable number of 
enrolled subjects and the population based setting in a low- to middle income country 
with low prevalence of HIV. This design was required to establish the true incidence 
of TB in children <3 years and adolescents in order to prepare the study area for 
future vaccine trials. The study design and data acquisition within NCS and ACS 
constitutes a fixed framework with possibilities and limitations when it comes to 
answering other relevant research questions in the field of TB research. Nested within 
NCS and ACS, the study designs in paper I-IV were chosen to make the results and 
findings transferable and relevant to clinical decision making in the diagnosis and 
treatment of MTB infection and disease. Paper I, III and IV shed light on current 
diagnostic tools, whereas potential future diagnostics and predictive markers are 
explored in paper II and IV.  
 
A limitation by the NCS/ACS design is the per protocol pre-scheduled follow-up 
assessments. This implies that the time since TB exposure is likely to be more 
heterogeneous than in household contact studies. The accuracy of exposure data is 
likely to decrease with the time elapsed from the encounter with an index case, and 
the pre-scheduled follow-up. The heterogeneity of exposure intensity will also be 
broader in a population-based versus a household contact setting. Nevertheless, the 
kinetics of the host immune response read-outs included in the papers (TST, QFT, 
biomarkers and MTB-specific T cell responses) are largely unknown,30, 227 and is 
practically unachievable to establish in humans. Subsequently, optimized timing for 
testing is difficult to assure in study protocols.  
 
Paper I-III 
It is a strength that the study setting resembles a “real-life” context where parents 
present their ill child for diagnosis and treatment. This makes the conclusions 
clinically relevant. The proportion of children with malnutrition and the high 
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background presence of NTMs may limit the generalizability to other settings, but 
these conditions are typical for many areas with high-to-moderate TB burden.  
 
Ideally, data on the gradient of TB exposure should have been recorded. As a gold 
standard for MTB infection is lacking, data on the exposure gradient and/or the 
infectivity of the index case is often used as a surrogate of MTB infection. If the 
magnitude of TST or IGRA results corresponds to the gradient of exposure, 
interpretation and validation of these diagnostics would be facilitated.62, 63, 228-233 
Many argue that TB exposure is a better surrogate of MTB infection in TST/IGRA 
validation than confirmed cases of active TB, as active disease by itself likely affects 
the host immune response and the performance of immunological tests.62  
 
Furthermore, data on helminth infection were not available. Co-infection with 
helminths influences host immunity90, 234 resulting in increased susceptibility to MTB 
infection.235 In addition, the likelihood of an indeterminate QFT seems to be 
increased.89 The prevalence of helminth infection in the NCS study population is 
presumably high as a similar but older Indian population had a prevalence of 35%.236 
Acquisition of data on helminth infection is laborious and requires trained personnel. 
Therefore, in the context of NCS, we were unable to collect stool samples. 
 
Paper IV 
In the context of MTB infection and disease, repeated data on the cytokine profile of 
specific T cell subsets are limited to settings related to treatment response. To our 
knowledge, polyfunctional mycobacterial-specific T cell responses have not been 
assessed in healthy subjects repeatedly tested by QFT outside a contact investigation 
setting. Furthermore, by assessing groups with different risk of TB progression as 
judged by repeated QFT results, our study design had the potential to provide 
polyfunctional T cell data relevant to TB risk assessment.   
 
5.1.2. Definition of clinical outcomes 
5.1.2.1. Clinical TB (paper I and II) 
In real-life, clinical TB cases comprise both cases confirmed by the finding of MTB 
in culture or by PCR (definite TB), and bacteriologically unconfirmed cases 
(probable/possible TB).12 The validation of diagnostic tools requires a gold standard, 
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which in the setting of TB, can only be provided by confirmed TB cases. This is why 
the performance of TST and IGRAs in the diagnosis of MTB infection have been 
evaluated using confirmed TB cases.61 At the same time, it is broadly accepted, also 
in adults, that a proportion of TB cases are smear/culture negative,74, 237 thus these 
cases are systematically left out of evaluations on TST and IGRA performance. In 
young children, TB remains unconfirmed in 70-80%.75-77 Therefore, the strict 
requirement for confirmed TB cases in the evaluation of diagnostic tests is rarely 
applied in studies of pediatric TB. Instead, clinical TB is the commonly applied 
outcome.63 Whereas confirmed (definite) TB is clearly defined, the criteria for 
bacteriologically unconfirmed TB cases vary across studies238-243 with consequences 
for the number of incident TB cases reported.244 
 
The diagnosis of TB in this study relied on an a priori diagnostic algorithm (see 
figure section 3.3.1) with hierarchical classification of clinical TB outcome, as this 
approach seems to be most accurate in the assessment of incident TB cases.244 
Clinical TB was present in 13 of 746 (1.7 %) referred children. Despite throughout  
evaluation at the CVW, only 4 children (31%) had their diagnosis of active TB 
confirmed by MTB in culture or PCR, but this proportion is similar to other studies. 75 
9 children were classified as probable TB (see section 3.3.1, Figure 9). The diagnostic 
algorithm did not include 1) lack of response to broad-spectrum antibiotics (not 
fluoroquinolones) as suggested in some practical guidelines to reduce over-diagnosis 
of bacteriologically unconfirmed TB cases,74 or 2) response to TB therapy used by 
others.245 The definition of probable TB in NCS relied on the approach used by South 
African Tuberculosis Vaccine Initiative (SATVI), which have conducted multiple 
large-scale studies on TB incidence and vaccine trials (http://www.satvi.uct.ac.za/). 
The estimated incidence of TB in South Africa is 993 per 100 00052 and probably 
even higher in densely populated Cape Town which constitutes the field for SATVI. 
This is about 5-fold the incidence of TB in India (176 per 100 000 population per 
year).246 Subsequently, the same diagnostic algorithm is likely to produce more false 
positives in our setting. On the other hand, both the diagnostic algorithm and the 
diagnostic procedures focused on pulmonary TB with a subsequent risk of under-
diagnosing extra-pulmonary TB. Whereas all children were palpated for enlarged 
cervical lymph nodes, extensive and often invasive investigations might be required in 
the diagnosis of other forms of extra-pulmonary TB. This was not done in NCS, and 
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would hardly be ethical on study participants without reasonable indications for extra-
pulmonary manifestations. In South African children, extra-pulmonary TB were 
reported in 8.2% of non-HIV-infected children aged <3 years. Cervical lymphadenitis 
and TB meningitis accounted for 84%. Miliary TB was defined as intra-thoracic TB 
and occurred in 3.9%.26 Children with severe manifestations like miliary TB and TB 
meningitis are severely ill and therefore likely to have been brought in for health care 
in an area where the consciousness of TB was high due to increased awareness caused 
by the on-going study. Osteoarticular TB in children is most likely to occur 1-3 years 
after the primary infection22 and is therefore rare in young children.26  
Children assessed at the CVW had a mean follow-up time of 8.5 months (range 0-22 
months) after discharge, and 85% (paper I) and 77% (paper II) had active surveillance 
(visited by study staff bimonthly). 39 children came for repeated evaluations at the 
CVW without being diagnosed with TB. The mean follow-up time and large 
proportion of children with active surveillance make it unlikely that severe TB cases 
were missed. Notably, 5 children died after dismissal from the CVW. Verbal autopsy 
(questionnaire modified from an earlier published Indian study247), was performed for 
all these children (Table 10) without TB being considered a plausible cause of death. 
Nevertheless, these children could theoretically represent lost TB cases.   
Table 10. Causes of death according to verbal autopsy in referred children.  
Sex 
Diagnosis Data from the CVW 
ICPC  Description 
Time between 
admission and 
death 
Age 
(mo.) Results from TB assessments WHZ HAZ WAZ 
girl N17 Acute Renal failure 1 month 2 
Cough 2 weeks. CXR/TST/QFT 
negative. MOTT (indeterminate) 
in 1/2 induced sputum samples.  
-3.68 -1.02 -3.30 
girl A09 Infectious gastroenteritis  9 months 3 Culture/CXR/TST/QFT negative. 0.27 -2.56 -2.05 
girl 
J22 
Unspecified 
acute lower 
respiratory 
tract 
infection 
3 weeks 4 Fever 2 months, cough 2 weeks. Culture/CXR/TST/QFT negative. -4.12 -6.79 -7.16 
boy 17 months 6 Culture/CXR/TST/QFT negative. Exposed to TB case on treatment -2.62 -1.00 -2.51 
girl 3 1/2 months 12 TST 17mm. Culture/CXR/QFT negative. -0.43 -4.55 -3.10 
 
In exploring and evaluating potential biomarkers in TB diagnosis (paper II), all TB 
cases should ideally be confirmed by the identification of MTB in specimen. Even 
though there will always be uncertainty about the correctness of a bacteriologically 
unconfirmed TB diagnosis, it seems unreasonable to omit unconfirmed TB cases in 
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exploratory studies in pediatric settings. This group is after all the most difficult when 
it comes to decision to treat. Ideally, confirmed and unconfirmed cases should be 
explored as separate groups, but little can be done about the small number of 
smear/culture positive TB cases in the NCS. Therefore, we decided to club 
smear/sputum confirmed (definite TB) and bacteriologically unconfirmed (probable 
TB) TB cases when exploring biomarkers in paper II. We acknowledge that this is 
likely to have reduced the discriminatory power of single biomarkers and biomarker 
profiles. 
 
5.1.2.2. MTB infection (latent TB) and uninfected controls (paper II) 
In paper II children positive for TST and/or QFT but without CXR changes consistent 
with TB, were categorized as latent TB. The term used for these children should 
preferably have been MTB infection without overt disease. Calcification of TB lesions 
is generally regarded as an indication of clinical quiescence or latency, which usually 
occurs 12-24 months following primary infection (even though it might come earlier 
in young children).22 All children in this study are <3 years, and subsequently, the 
large majority of infected children can be assumed to be in the course of primary 
infection and unlikely to have reached a stage of latency.  
 
A positive TST and/or QFT were used in the classification of MTB infected children. 
As discussed in 1.1.6.1, neither tests can be validated due to the lack of a gold 
standard. Furthermore, the tests might give discordant results (explored in paper III). 
Therefore, we acknowledge the uncertainty of the classification of the MTB infected 
children, but the diagnostics we used are the best tools available (as well as T-SPOT) 
and generally accepted to diagnose MTB infection.54, 248  
 
There are some additional evident pit-falls when it comes to classification of MTB 
infected children without overt TB disease. First, as the sensitivity of TST and QFT 
for active TB was low, there is a fair risk that some TST/QFT negative children were 
truly infected and wrongly classified as uninfected controls. Second, it is a risk that 
some of these children may have true TB disease without the typical CXR changes. A 
low threshold for referral could have resulted in children undergoing investigations 
before evident disease manifestations had occurred, or the TB foci could be 
extrapulmonary. Interestingly, 2 out of 4 of the smear/culture positive TB cases came 
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from the passive surveillance group compared to 1 out of 9 smear/culture negative 
(probable) TB cases. This may indicate that culture negative smear/culture negative 
TB cases passed undiagnosed in children with passive surveillance. Alternatively, 
there was an over-diagnosis of clinical TB in children with active surveillance. We 
think the first scenario to be the most likely as under-reporting of TB cases in children 
is very common.249  
 
We are aware that misclassification for any reason is likely to have reduced the 
statistical power of our analyses and hereby reduced the true differences in 
biomarkers between the groups. Nevertheless, major misclassification would tend to 
produce a null result when comparing groups. 
 
5.1.3. Random and systematic errors in data collection (paper I-IV) 
Random and systematic errors can cause false estimates and/or confounding.  
The methods used for data collection in paper I-IV, possible errors that can arise, and 
measures taken to minimize them, are listed in the Table 11: 
Table 11 Possible errors Means of assessment 
Random error Systematic error 
Common for all   Data collected during NCS/ACS were 
doubled entered applying Standard 
Operating Procedures (SOPs). All staff 
members were certified after going through 
a Professional Development Programme 
including clinical research and management, 
consent, basic epidemiology and infectious 
diseases. Staff members were also trained 
and certified according to standard SOPs for 
relevant procedures    
Errors in 
typing/registration 
Systematically less/more errors by 
some staff 
Data from health/study documents See Common for all  
Data from interview  See Common for all. In addition use of the 
local language and structured questions. By 
interview, the ability to verify whether the 
questions are correctly understood was 
maintained.   
Misunderstandings 
by the respondent 
and/or observer 
Misunderstandings dependent on 
the educational 
level/communication skills of the 
respondent and/or observer 
   
Under-reporting of low 
socioeconomic class (education, 
income, housing, fuel) 
Using staff from the local community 
(outreach workers and field supervisors) to 
obtain this information and the informed 
consent.  
  
Inaccurate report 
of 
duration/character 
of symptoms/TB 
exposure 
 
 
inaccuracy in reports of  
symptoms/TB exposure is likely to 
increase with time 
Nurses/doctors were used for interviews 
regarding clinical history and symptoms. 
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Data from anthropometric measurements  See Common for all. 
  
Errors in devices 
for measuring 
weight 
Error in calibration of devices used 
for measuring weight.   
  
 
Weight rounded off 
upwards/downwards/to the nearest 
100g 
Training and certification in relevant SOPs  
    
Errors in the 
application of the 
method for 
measurement  
Observer-related differences in the 
application of methods (e.g. 
weight with/without diapers, time 
of day, relation to meal, etc) 
Training and certification in relevant SOPs 
Performance of the TST Observer-related differences in the 
application and reading  technique 
of TST 
See Common for all.  
Training and certification in relevant SOPs 
Laboratory methods (described in more detail in the text) 
  Regular standardization (of the mean/peak 
area/standard curves). Calculation of CV%* 
gives an indication of the accuracy 
  
Inaccuracy in 
measurements 
Drift in the automatic readers used 
(ELISA, sequencer, LSR II) 
 Microbiological samples   
 
 
Random 
contamination 
Non-random contamination due to 
different batches (ex: hypertonic 
saline/ medium) or staff on duty.   
Training and certification in relevant SOPs. 
Procedures of quality assurance in the 
sampling and handling of lab specimen 
 QFT and 10-plex assay Non-random differences in the 
sampling and handling of 
specimen 
Training and certification in relevant SOPs 
(QFT, n=x, 10-plex, n=1)    
 dcRT-MLPA  All samples were handled by the same 
person and supervised by another person 
(less strict for RNA isolation)   
Technical errors 
throughout the 
protocol 
Non-random differences between 
batches/personnel 
 Flowcytometry   
  
Technical errors 
throughout the 
protocol 
Batch- or personnel related 
differences 
All samples were handled by the same 
person 
  
Errors in the 
readings of LSR II 
(plugging, 
software) 
 Continuous supervision of flow runs 
    
Errors in gating 
and/or handling of 
data  
Drift in gating cut-off with time Gating on all batches were synchronized 
*CV% or the coefficient of variance, is defined as the variance in percent for repeated measurements of 
the reference sample compared to the standard curve 
 
5.1.3.1.Microbiological samples (paper I and II) 
A relatively high number of children had positive NTM cultures. The TB Trials Study 
Group was greatly concerned that this was due to contamination, for example of the 
water used for gastric lavage. Therefore, an extensive review of the samples and 
sampling procedures were conducted in cooperation with a visiting US-based quality 
assurance team. These investigations, together with the non-random distribution of 
positive NTM cultures supported our conclusion that NTM presence was not a result 
of contamination: Firstly, NTM were isolated from both induced sputum and gastric 
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lavage samples. Secondly, NTMs were less likely to be isolated at younger ages 
(adjusted OR 0.21, CI 0.09-0.49 for 0-5 months, OR 0.49, CI 0.30-0.79 for 6-11 
months, and OR 0.71, CI 0.47-1.01 for 12-17 months), which likely reflects an 
increasing interaction with the environment with age, since NTMs are ubiquitously 
found in soil and water. Our data provided no evidence that the presence of NTMs 
were related to disease (as defined by ATS/IDSA250 in the referred children. 
 
5.1.3.2.QuantiFERON Gold In-Tube (paper I-IV) 
The processing of tubes and ELISA plates was performed manually by a limited 
number of trained technicians (3). No kit independent control was analyzed to assess 
the variability/reproducibility between plates or personnel. The coefficient of variance 
(CV%, defined as the variance for repeated measurements of the reference sample 
compared to the standard curve in percent) is likely to be greater in peripheral 
wells.251 While this phenomenon may affect the interpretation of individual samples, 
it contributes to random error in a study-context with a high number of samples 
analyzed in randomized order. Accordingly, such variation is unlikely to have caused 
systematic bias affecting study results. 
 
Studies on the QFT assay which elucidate the contribution to the total sample 
variability caused by 1) the manufacturer (between-lot variation), 2) preanalytical 
sources (time of day for blood draw; blood volume; intensity of shaking the tubes; 
delay in incubation; incubation time), 3) analytical sources (within/between-run, 
between operator and between laboratory imprecision), and 4) immunological sources 
(boosting by PPD; modulation by PAMP) have recently been reviewed by Pai et al.65 
The authors conclude that the manufacturer and the users of the test can minimize the 
systematic sources of variability by standardization, whereas random sources of 
variability are unavoidable and must be accounted for when interpreting the results. 
Notably, the total variability in the test needs to be determined in order to establish an 
appropriate test cut-off and borderline zones.65 Regarding boosting of the QFT 
response by intradermal injection of PPD as part of the TST, evidence suggests a 
potential for boosting if blood is drawn from 7 days to 3 months after PPD 
administration. Boosting does not seem to occur within 3 days post-TST (equals the 
time point for TST reading) or later than 3 months, but interestingly seems more 
prevalent among subjects who are already QFT positive.252, 253 To avoid the effect of 
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boosting, the NCS/ACS study protocols assured that blood for the QFT assay was 
drawn on the same day as the administration of the TST.  
 
Paper I-III 
In the NCS TST was performed per protocol at study day 360 (active surveillance, 
only) and at study closure (day 720). In addition TST was part of the diagnostic 
procedure at the CVW. If TST and QFT were performed within 3 months either as 
part of the pre-scheduled follow-up or at a previous visit at the CVW, the tests were 
not repeated. Visits including TST and QFT results were preferred for inclusion in the 
data sets if the clinical diagnosis remained unchanged from the previous visit (see 
section 3.3.1, paper I). We therefore conclude that the risk of false positive QFT 
results as a result of TST boosting was minimal in paper I-III. 
 
Paper IV 
In this paper the study participants selected from the ACS were classified based on 
repeated QFT measurements. All ACS participants had a TST performed at inclusion, 
mid-study (day 360, termed QFT baseline in paper IV) and at study closure (day 720, 
termed after 1 year in paper IV). None of the study participants included in paper IV 
had TST performed outside the pre-scheduled follow-up, thus the time interval 
between TST and the subsequent QFT was 12 months. Boosting of QFT by TST 
therefore seems unlikely. 
 
Another question relevant for paper IV is whether subjects classified as reverters had 
true QFT reversion or just minor fluctuations around the test cut-off due to variability 
in the QFT assay itself (personnel and equipment) or biological within-subject 
variability as discussed above. In a review addressing within-subject variability in the 
QFT-response, only 3 studies fulfilled the inclusion criteria.253 Two of these studies 
were conducted in high endemic settings where absence of MTB re-exposure was 
assumed because of short test intervals (1-3 weeks). Highest variation in IFNȖ-release 
(± 80%) was found by van Zyl-Smit et al who measured QFT in the same subjects 3 
times at 1-week intervals.252 Among consistent positives, 19 of 21 had QFT values 
0.70 IU/ml, a suggested upper limit for a “grey-zone” (0.35 to 0.70 IU/mL) in test 
interpretation,254 whereas 18 of 21 reverters had either a baseline value 0.70 IU/ml 
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or a reduction in IFNȖ-release of 80% from baseline to the reversion one year later, 
suggestion true test reversion.252  
 
5.1.3.3.dcRT-MLPA (paper II and III) 
All samples were run in duplicates and averaged, to reduce the risk of outliers 
affecting the result. The standard deviation of the reference gene (GAPDH) in all 
study subjects was 52%, thus slightly above the normal range for the standard 
deviation (35-45%) (see section 3.8.3). The least standard deviation was found for 
B2M (36%) but we chose not to use this as the high signal intensity in sequencing the 
HEX (green) labeled PCR products caused some problems in the definition of the 
peak. Anyway, we did conduct all analyses using B2M as the reference gene without 
any consequences for the results. To further evaluate the assay in our hands, the CV% 
of every gene from the PCR 6 runs were calculated based on peak area data of the 
positive control (synthetic oligonucleotide) after normalization to GAPDH CV% = 
St.dev/Average*100) (Table 12). 
FAM labeled HEX labeled 
 Gene CV% Gene CV% 
CD8+A 10,6 IL10 28,8 
CXCL10 14,2 BPI 13,0 
CD4+ 30,6 CCR7 22,5 
IL4d2 16,3 SPP1 24,8 
BLR1 12,5 CCL22 30,1 
SEC14L1 17,0 MMP9 20,3 
GUSB 8,9 RAB24 24,1 
TIMP2 8,5 CD163 23,5 
CCL19 5,4 TGFB1 23,5 
FPR1 12,7 TNFRSF1B 27,4 
IL4 13,6 FCGR1A 24,6 
NCAM1 9,3 TNFRSF1A 21,5 
FOXP3 24,4 RAB13 29,1 
CTLA4 30,8 CD3E 14,8 
TNF 11,4 CD19 16,9 
RAB33A 7,1   
ABR 13,3   
TGFBR2 7,3   
IL7R 14,1   
BCL2 8,8   
CASP8 3,7   
TNFRSF18 33,7     
Notably, for diagnostic tools a CV%>15% might not be acceptable, but with an 
exploratory purpose as in our studies, a higher CV% can be tolerated as long as the 
uncertainty in the results are taken into account in the interpretation of the results.  
Table 12. CV% of 
the genes included in 
the dcRT-MLPA 
assay. %CV >15 is 
bolded. 
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5.1.3.4.10-plex ELISA assay 
No reference sample was included in the 10-plex ELISA assay. Therefore, the CV% 
based on independent controls cannot be measured. As a proxy for variation of the 
measurements on the six plates, the mean fluorescent intensity (FI) from duplicates of 
every of the eight dilutions of the kit standard which included each of the 10 
cytokines/chemokines, was analyzed (Table 13). 
Table 13. CV% of the standard dilutions (S1-S8) across 6 plates. Duplicates of each standard run on 6 plates 
were averaged before the averaged values from the 6 plates were used to calculate mean and standard 
deviation. For cytokines reported to be significantly or borderline differentially expressed between groups in 
paper II and/or paper III, the CV% value for standards with concentrations most closely matching the median 
concentration of the cytokines in the study samples are boldfaced to facilitate interpretation. 
Standard 
Hu 
IL-2 
Hu 
IL-5 
Hu 
IL-6 
Hu 
IL-8 
Hu IL-
10 
Hu IL-
13 
Hu 
IFNȖ 
Hu IP-
10 
Hu 
MCP-1 
Hu 
TNFĮ 
S1 3,9 6,9 17,8 7,6 9,9 8,8 17,5 34,1 20,8 12,0 
S2 6,0 99,6 16,7 13,1 9,6 5,0 5,5 23,7 10,9 15,4 
S3 4,5 12,6 16,5 14,2 10,4 5,1 5,0 20,4 10,0 12,4 
S4 20,5 27,4 69,7 49,1 37,3 14,3 52,6 78,2 30,5 48,2 
S5 6,2 10,7 16,6 14,3 9,9 5,5 27,3 21,3 8,9 13,9 
S6 4,0 7,6 15,3 10,2 10,6 1,7 57,4 20,3 8,4 11,6 
S7 10,2 11,0 19,4 15,5 9,2 5,2 48,3 21,0 9,0 13,4 
S8 21,6 8,2 15,5 31,0 9,9 2,8 24,5 59,9 10,0 12,6 
 
As illustrated in Table 13, CV% of the standards with a concentration most closely 
corresponding to the study samples was 15% for IL-2, IL-5, IL-8, IL-10 and IL-13 
whereas the CV% for IFNȖ and TNFĮ was as high as 50%. CV% calculations based 
on more than 6 samples could have given a more satisfying CV%. We feel that the 
exploratory nature of paper II and III permits less stringent criteria with regard to 
assay validation, but high variability is likely to have reduced the power of statistical 
analyses, and must be taken into account in the interpretation of the results. In future 
studies, CV% should certainly be evaluated through kit-independent controls.  
 
5.1.3.5.Flow cytometry (paper IV) 
As flow cytometric data were obtained in batches within a period of 8 weeks, a drift 
in the LSR II flowcytometer could cause systematic errors. During the study period 
the laser alignment, laser area scaling and parameter voltages on the LSR II 
flowcytometer were calibrated according to standard beads as part of the standard 
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routine, by the chief manager Kirsti Landsverk at the core facility at Oslo University 
Hospital, Montebello. The CV% for the standard beads are given in Table 14.  
Month CV% for standard beads LSR II, 2012 
FITC APC PE Pac 
Blue 
January 2,1 3,8 1,9 2,8 
May 2,2 2,4 1,8 1,6 
June 1,8 2,8 2,0 1,7 
August 1,8 3,0 2,1 2,0 
September 1,8 2,6 2,5 2,6 
October 1,3 2,8 1,7 2,1 
 
In addition, compensation controls (separate beads for all included fluorochromes) 
where run before every experiment. While voltages for all channels were left 
unchanged after calibration, acceptable variability was registered for fluorochromes 
with 15% spectral overlap (Table 15). 
 
5.1.4. Selection bias and confounding 
Selection bias is a systematic error which occurs when subjects are systematically left 
out of the study or drop-out, because of the procedures used for study inclusion or 
participation.255 With regard to establishing the incidence of TB, which was the 
primary aim of the NCS and ACS, selection bias could have been introduced if for 
instance; literacy was required to get adequate information about the study and/or 
complete questionnaires; information was given and/or interview undertaken  in 
another language than the local or; only neonates having a supervised birth were 
included. All these factors disfavors enrollment of subjects from low socioeconomic 
classes. As the TB incidence is highest in underprivileged populations this selection 
bias can cause wrong estimates of TB incidence. Another possible selection bias 
Table 15. Spectral overlap >15% after automatic calculation of compensation 
Fluorochrome minus % fluorochrome 30.4.12 15.5.12 22.5.12 29.5.12 7.6.12 11.6.12 13.6.12 
Variability 
(%) 
Alexa 700 PerCP-Cy5.5 27 27 22 32 32 32 33 16,6 
PE-Cy 5 PerCP-Cy5.5 27 27 27 29 27 27 27 0,6 
Alexa 700 APC 31 31 30 29 31 31 32 0,9 
PE-Cy 5 APC 31 33 36 28 26 26 27 15,0 
APC Alexa750 Alexa 700 27 27 27 27 28 28 28 0,3 
PerCP-Cy5.5 PE-Cy 5 39 40 40 39 40 41 40 0,5 
APC PE-Cy 5 27 26 22 33 33 32 32 18,6 
APC Alexa750 PE-Cy7 18 17 14 21 22 22 23 11,0 
Table 14. CV% for 
standard beads run 
on all 4 lasers on the 
LSR II, Montebello 
in 2012. The period 
for analyses of the 
samples for paper IV 
is marked in grey. 
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would be if a sub-group sharing genetic background with higher or lower 
susceptibility for TB than the remaining population, systematically rejected 
enrollment due to a cultural reluctance to give blood or undergo certain examinations. 
 
Confounding can be explained as “a confusion of effects”. This implies that the 
measured effect or association is not related to the analyzed variable but totally or in 
part, related to other unknown factor(s) differentially distributed between the groups 
compared.255 
  
Considerations on possible selection biases and confounding are addressed separately 
for paper I-III and paper IV. 
 
Paper I-III 
Of eligible neonates, 90% were enrolled in the NCS (section 3.2.1.1). This 
corresponds to the upper goal for enrolment set in the study protocol (80-90%). Of 
enrolled subjects ~90% participated throughout the study. The frequency of 
participants who did not complete the study was similar within the active and passive 
surveillance groups (no significant differences between the groups), as well as for the 
whole NCS cohort, are listed in Table 16. 
Table 16. Study adherence 
Surveillance 
NCS cohort 
Active  Passive 
Participants not completing 
the study due to:       
  Death 49 (2.2) 71 (3.3) 120 (2.7%) 
  Lost to follow-up 38 (1.7) 60 (2.8) 98 (2.2%) 
  With-drawn 93 (4.2) 111 (5.1) 204 (4.7%) 
Fulfilled the study 2034 (91.9) 1925(88.8) 3959 (90.4) 
 
The 746 children referred to the CVW during the 2-year surveillance constitute the 
source population of paper I-III. 10 (1.3%) of these children withdrew from the study 
after the first visit to the CVW and additionally 9 (1.2%) children were lost to follow-
up. These numbers are small, but could have a confounding impact on our results if 
these children were predominately TB cases. We find it unlikely that symptomatic 
children should predominately be lost to follow-up as these are most likely to profit 
by the health care provided by the study. 
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Some data values are missing as sampling was omitted as a consequence of clinical 
evaluation (e.g.: blood-draw in very anaemic or seriously ill children), whereas other 
variables might be missing due to technical errors or because the procedure/question 
were missed by the staff. Nevertheless, the number of missing values within each 
variable were marginal (<2%) except for haemoglobin values (104, 13.9%). 
Systematic analyses to clarify systematic differences in socio-demographic or clinical 
variables between drop-outs and the remaining study population are currently being 
conducted as part of a manuscript in preparation by the TB Trials Study Group on TB 
incidence in the study area.  
 
It is evident that most of the children referred to the CVW were from the active 
surveillance group, demonstrating a reduced threshold for seeking health care in 
children under active surveillance. While there were no difference in the proportion of 
children under active and passive surveillance for children with and without clinical 
TB (Table 1, paper I and II), the proportion of probable TB was higher in children 
under active surveillance consistent with a lower threshold for referral (Table 2, paper 
I). This is further discussed in section 5.2.  
 
TST 10mm outcome was both a referral criteria and 1 of 4 diagnostic criteria (1 
criteria in addition to characteristic CXR changes) required for a diagnosis of clinical 
TB. The TST estimates could therefore be subject to selection bias, which is a 
limitation in paper I. This compromise in design was required in order to avoid losing 
TB cases; the primary aim of the NCS was to establish the true incidence of TB. This 
selection bias could result in an overestimation of the TST’s sensitivity for clinical 
TB, but as none of the probable TB cases depended on a positive TST for their 
diagnosis, this does not affect the TST sensitivity estimate. Furthermore, compared to 
the OR estimates of the associations between a positive TST and the assessed 
variables, the OR estimates for a positive QFT outcome may be overestimated 
because TST-QFT+ discordant positives children within the NCS were only referred 
if they had known TB exposure or were symptomatic, whereas TST+QFT- children 
might have had no other referral criteria. Notably, the effect is probably limited as 
referral based on a positive TST only was present in 51 (6.8%) of 746 children of 
whom 44 (86.3%) were referred at study closure. 
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In paper II and III, uninfected controls were selected in order to make the clinical 
groups in paper II as equal as possible with regard to sex and age. For each child with 
clinical TB and for each child with MTB infection, a sex matched subject as similar in 
age as possible, was selected. Opposing this age- and gender matched selection, 
differences between the 3 clinical groups were analysed by pairwise comparison, not 
with matched statistical methods. This approach could theoretically have introduced a 
systematic selection bias. From a statistical point of view it might have been better to 
pick the uninfected controls randomly since analyses adjusted for sex and age were 
applied anyway. 
 
Paper IV 
Possible selection biases in the ACS is not included herein, as paper IV represents an 
exploratory laboratory study in which this has little direct relevance. Study subjects 
for paper IV were picked by computerized randomization among subjects enrolled in 
ACS with available PBMCs. We argue that this was the best method to select study 
participants to avoid selection bias. Nevertheless, there might be systematic reasons 
for PBMCs not being available. Similarly, as we experienced problems with bacterial 
contamination in about 20% of the vials, this might have resulted from a systematic 
error in the collection of specimen, which could theoretically result in a selection bias.  
 
5.1.5. Statistics 
 
5.1.5.1. Presentation and definition of independent variables (paper I) 
In paper I, Table 1, the distributions/proportions of independent variables are 
presented for all children referred and classified according to the TB diagnostic 
algorithm. Some variables are presented both as continuous and categorical variables 
to get a better picture of the data: birthweight; age (months); WHO Child Growth 
Standards  Z-scores;209 hemoglobin; TST; QFT. In evaluating socioeconomic 
variables, factors which indicates low socioeconomic status (SES) are normally 
regarded as exposure, thus higher SES are usually used as reference. In our data, low 
numbers in the high SES categories made it more statistically correct to use low SES 
as reference. The categorizations and definitions of socioeconomic variables are 
described in section 3.9., paper I). WHO Child Growth Standards Z-scores are 
presented as mean/min-max as well as the proportion of children with Z-score <-2. 
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This is the standard cut-off for moderate to severe malnutrition. The adequacy of new 
cut-offs for the dichotomous nutritional variables introduced in univariate and 
multivariate logistic regression analyses (Table 3 and 4, paper I) could be a matter of 
dispute. We argue for this choice in paper I, and more in-depth in section 3.9., paper 
I). In addition to the argument given there, we want to underline that it is unknown 
whether the WHO cut-offs of <-2 or <-3 are adequate in evaluating immunological 
changes in the malnourished individuals. Furthermore, we concluded not to use 
continuous nutritional variables as the relationship between malnutrition and 
immunological outcomes is more likely to be U-shaped than linear. This is because 
over-weight is associated with increased inflammation which implies altered immune 
responses.256 This effect is presumably marginal in our study as only 8 children had a 
BMI-for-age score >2. Nevertheless, as false interactions can be a problem with 
continuous variables, our argument for a dichotomized variable was further 
strengthened.  
 
Regarding malnutrition in children enrolled in the NCS but not referred to the CVW 
and therefore assumed to have lower morbidity, referred children were slightly more 
malnourished. In general, Indian children have lower gestational age-specific 
birthweight257 and reduced growth (height and weight)258 compared to WHO Child 
Growth Standards.209 209, 217 A recent paper analyzed the distribution of the Z-scores 
obtained from the National Family and Health Survey (NFHS) which included 
information on >27,000 children <3 years in rural India in 2005.259 For this population 
the mean height-for-age Z-scores (HAZ) was -1.59, whereas the mean weight-for-
height Z-score (WHZ) was -1.08. The Z-scores tended to be lower with increasing age 
from birth, until stabilization at about 18 months. Children included in paper I, had at 
a mean age of 14.8 months, mean Z-scores of -1.25 (HAZ), -1.80 (WHZ) and -1.95 
(WAZ).  For NCS children not referred to the CVW, we have weight data from the 
children under active surveillance at 14 and 16 months of age. This enables estimation 
of WAZ score for comparison with referred children. Assuming a linear relationship 
between WAZ and age, non-referred children of 14.8 months, would have an 
estimated WAZ about -1.32 (Figure 16). Subsequently, referred children had a WAZ 
score about 30% lower than non-referred children. This confirms the assumption of 
referred children having a poorer health condition than the un-referred despite a low 
threshold for referral. 
90 
 
Plot of mean values
13 14 15 16 17 18
-1.5
-1.4
-1.3
-1.2
age (months)
W
AZ
 
 
5.1.5.2. Selection of variables for adjusted analyses (paper II and III) 
The aim of paper II and III was exploratory. Independent variables listed in Table I 
(paper II and III) were evaluated by their confounding potential and subsequent 
inclusion in adjusted analyses as described in section 3.9 (subtitle; Paper II). Age, 
WHZ, WAZ and NTMs in culture were adjusted for. In the light of the findings in 
paper I, two aspects could have been assessed differently: First, the WHO cut-off (<-
2) for the Z-scores, might not be optimal when adjusting for malnutrition in this 
population. Second, including both WHZ and WAZ in adjusted logistic regression 
could introduce problems related to collinearity as indicated by analyses performed as 
part of paper I (see section 3.9., paper II and III) (Spearman’s rho=0.51, p>0.0005, 
Tolerance=1.0, VIF=1.0). The risk of collinearity might have been less prominent if 
WHZ and HAZ were used for correction (Spearman’s rho =0.21, p=0.0003, 
Tolerance=1.0, VIF=1.0). Alternatively, WHZ could be used alone, as this variable 
was most unevenly distributed.  
 
5.1.5.3.Considerations on multiple testing (paper II and III) 
In paper II and III, no correction for multiple testing was done in single gene analyses 
due to the exploratory nature of the papers. Methods correcting for multiple testing 
(Bonferroni correction and false discovery rate (FDR) control) was applied in the 
initial analyses, but revealed minimal differences between the groups. We consider 
this likely due to large heterogeneity within the groups (see section 5.1.2). Instead, to 
avoid conclusions based on false differences (Type I error); in paper II, we restrict our 
conclusions on differences to immune biomarkers that turn out significant in more 
than one pair-wise comparison. This is true for the transcription of RAB33A which is 
lower in children with clinical TB compared to either MTB infected children or 
Figure 16. Estimate of 
WAZ score in children 
enrolled in the NCS who 
were not referred to the 
CVW, at 14.8 months of 
age. (A linear relationship 
between WAZ and age is 
assumed)
91 
 
controls, and for the transcription of TGFB1 which is higher in children with either 
clinical disease or MTB infection compared to controls. Multiple testing is not 
required in the global test223 nor in lasso regression224. In paper III, we cannot exclude 
type I errors with regard to single biomarkers, but as discussed in the paper, the 
tendencies of the immune biomarker profiles in terms of pro- or anti-inflammatory or 
blunted patterns seem relatively consistent between different comparisons reported in 
the study, and the findings makes sense in the context of current literature. 
 
5.2. Discussion of main results 
 
Sited from section 2: “The general aim of this thesis was to contribute to the 
understanding of current immunological diagnostic and explore the diagnostic 
potential of new immune biomarkers in Mycobacterium tuberculosis infection and 
disease”. This was undertaken in the setting of the two described cohorts studies; 
NCS (paper I-III) and ACS (paper IV). These cohorts represent two important target 
populations for future TB vaccines: neonates as targets for a better pre-exposure 
vaccine (“Improved” BCG), and adolescents as targets for post-exposure vaccines 
when the effect of BCG is waning.260 There are two important distinctions between 
the study subjects selected from the NCS and the study subjects selected from the 
ACS: Firstly, the most obvious difference is in age: NCS children selected for paper I-
III are <3 years, whereas ACS children selected for paper IV are 12-18 years. 
Secondly, the children in paper I-III are symptomatic whereas the adolescents in 
paper IV are healthy.  
 
Another distinction between the papers worth noting: while a clinical TB 
classification of the study participants forms the basis for the analysis approach in 
paper I and II, paper III and IV explore immune biomarkers in study participants 
classified uniquely by their TST and/or QFT results: In paper III, the children are 
classified by their TST and/or QFT. In paper IV, healthy adolescents were classified 
based on 2 QFT results 1 year apart. 
 
Regarding the clinical condition of the study subjects, all the children in paper I-III 
were evaluated for suspected TB due to known TB exposure, symptoms and/or TST 
10mm (see section 3.3.1.). Of the 746 children admitted to the CVW, 655 (88%) 
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were symptomatic with failure to thrive (FTT), persistent fever and/or cough. 
Anthropometric measurements support that these children were in a poorer health 
condition than children within the active surveillance arm of the NCS in whom TB 
was not suspected during the follow-up (mean WAZ -1.95 versus -1.32 at the age of 
14.8 months, see section 5.1.5.1.). With regard to MTB infection; children this young 
are most likely within the course of primary infection as it takes 1-3 years for TB 
lesions to calcify. Calcified lesions are considered the hallmark of a latent stage of 
MTB infection.261 (For paper I, all the 746 children were eligible whereas 210 of the 
746 were selected for the biomarker sub-studies in paper II and III (see section 
3.3.1).) On the other hand, paper IV includes 52 healthy adolescents in whom data 
were collected at pre-scheduled follow-up visits within the active surveillance arm of 
ACS (see section 3.3.2.). These subjects had no symptoms and only one had known 
TB exposure. Therefore, in summary, immune responses in the adolescents can be 
assumed to differ importantly from immune responses in the young children in three 
aspects: 1) the immune system has reached a more mature state,81, 262 2) the immune 
system is not affected by ongoing infectious intercurrent diseases 221 and 3) if MTB 
infected, they are much more likely to have entered a latent stage.22 These 
considerations are important to keep in mind throughout the following discussion. 
 
The results in paper IV are discussed first; this is because healthy MTB infected 
adolescents in many ways represent a referral group when it comes to immune 
responses to MTB; their immunity is neither affected by likely intercurrent disease 
nor immaturity due to young age. Notably, the MTB infected adolescents were 
categorized in two groups assumed to have different risk of TB progression judged by 
their longitudinal QFT results: QFT consistent positives and QFT reverters. QFT 
reversion can be assumed to represent reduced risk of TB progression compared to 
consistent positives.263 This is supported by the following evidence: 1) IGRA-
reversion is more likely in subjects with a negative TST30, 227, 254, 264, 265 and/or IFNȖ-
responses close to the test cut-off.254, 265 2) The risk of TB progression seems to 
increase with the magnitude of MTB-specific IFNȖ-responses (reviewed in65). 3) 
Adults with concordant positive TST and IGRA result have increased TB risk 
compared to subjects positive for either test (discordant test results).232 As expected, 
reverters in our study had significantly reduced QFT and TST responses compared to 
consistent positives. Whereas more than half of the consistent positives showed a 
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positive TST at both time points, all reverters had a negative TST at baseline and one 
reverter only, had a TST 10 mm after 1 year. Therefore, the assumption of reduced 
risk in QFT reverters in this study seems appropriate. (An argument for true test 
reversion in the study subjects have previously been argued for in section 5.1.3.2., 
paper IV.) 
Based on the assumption that the quality (polyfunctionality) of the T cell 
response is of greater importance for TB protection than the total amount of specific 
IFNȖ-production,117, 118 polyfunctional T cells have been suggested to be 
protective.117, 120, 266, 267 We therefore hypothesized that QFT reverters differ from 
QFT consistent positives with regard to the quality and magnitude of MTB-specific T 
cell responses in peripheral blood. Relative frequencies of PPD-specific 
polyfunctional (IFNȖ+IL2+TNFĮ+) CD4+ T cells were high but similar in both QFT 
consistent positives and reverters at baseline. Reverters displayed lower absolute 
frequencies of these cells, which were further reduced 1 year later. Notably, the 
polyfunctional subset was most efficient in terms of cytokine production and their 
absolute frequency correlated well with the magnitude of the QFT-response. 
Subsequently, our data do not support that the relative or absolute frequencies of 
PPD-specific polyfunctional CD4+ T cells in peripheral blood can explain the reduced 
risk of TB progression observed in QFT reverters. PPD is a relatively crude mixture 
of mycobacterial antigens shared by the BCG strain and NTM. Nevertheless, we 
observed a good correlation between absolute frequencies of PPD-specific T cells 
(when assessing either all IFNȖ-producing subsets or the polyfunctional subset) and 
the magnitude of QFT-response. As the IFNȖ-release in the QFT assay depends on T-
cell recognition of RD1-specific antigens (mostly; TB7.7 is not a RD1-antigen) not 
present in the BCG-strain and most NTM, the polyfunctional T-cell responses to PPD 
measured here likely reflects specific anti-MTB immune reactivity. Further 
supporting this: The TST which also applies the PPD, is not affected when the BCG 
vaccine is administered at birth and not repeated.65 The individual BCG status of the 
study subjects in paper IV are given in Table 17. Comparing QFT consistent positives 
with reverters, significantly fewer were vaccinated (16/20 versus 21/21, Fisher’s 
Exact test, p=0.048), whereas there was no difference in the absence of a BCG scar. 
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Table 17. 
BCG status in 
paper IV 
study subjects 
QFT group 
Total 
n=51(%) 
Consistent 
positives 
n=21(%) 
Reverters     
n=21(%) 
Consistent 
negatives 
n=10(%) 
BCG 
vaccinated 16* (80%) 21 (100%) 9 (90%) 46 (90.2%) 
Presence of 
BCG scar 12 (57.1%) 17 (81%) 7 (70%) 36 (69.2%) 
*n= 20; one subject missing due to unknown BCG vaccination status 
 
Moreover, both QFT reverters and controls had negative TST at baseline, and controls 
from the same study-population/vaccine coverage, had negligible absolute frequencies 
of PPD-specific CD4+ T cells. This support little impact of BCG-vaccination on 
mycobacterial-specific T cell responses. In the light of TB risk, we find the close 
correlation between absolute frequencies of PPD-specific polyfunctional T cells and 
the magnitude of the QFT response particularly interesting: In non-human primates 
the magnitude of the IGRA-responses reflects the antigen load.188 There is broad 
consensus that the higher load of MTB bacilli within the organism, the higher the risk 
of TB progression.1, 188 Interestingly, a recent study found no correlation between 
mycobacterial growth inhibition and the magnitude of IFNȖ ELISPOT responses.268 
Notably, no correlation between the frequencies of polyfunctional T cells and 
protection against TB was found in BCG-vaccinated infants.121 Subsequently, rather 
than being markers of protection, we suggest that absolute frequencies of PPD-
specific polyfunctional T-cells reflects antigen load. Our data also supports earlier 
speculations on the requirement for persistent or recurrent MTB exposure to maintain 
specific IFNȖ-responses.30, 53, 227, 264, 269 
 
Even if true in healthy MTB infected subjects, evidence suggests that the relationship 
between antigen load and the magnitude of the IFNȖ-response is altered in subjects 
with severe TB disease.270 This could be explained by sequestration of immune cells 
in the tissue,271, 272 as well as relative immune-deficiency in severely ill individuals.273 
Very few of the young children with clinical TB in our material, had positive 
immunological tests (4 out of 13, TST sensitivity 31%, QFT sensitivity 23%). Both 
tests were negative in the only child with a positive smear (grade 3+ in gastric 
aspirate, MTB confirmed by PCR). Of the 9 unconfirmed TB cases, only one had a 
positive TST (16mm). This child also had symptoms, and was therefore not subject to 
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selection bias by the diagnostic algorithm (see section 5.1.4). Knowing this, we 
hesitate to suggest that TST-/QFT+ discordant children in paper III have reduced risk 
of TB progression compared to concordant positive children as evidence suggests for 
adults.232 Furthermore, in the context of paper IV: While reduced antigen load seems 
to be a reasonable explanation for reduced absolute frequencies of polyfunctional 
mycobacterial-specific CD4+ T cells in adolescents who reverted to QFT negative (all 
were TST-/QFT+ discordant positive at baseline), a TST-/QFT+ discordant result in 
symptomatic children <3 years could be a marker of blunted immune responses from 
young age and/or malnutrition. In that case, these children could have an increased 
risk for TB progression. The findings in paper I support this, but we acknowledge that 
an alternative explanation could be that a TST-/QFT+ discordant test result from a 
more recent MTB infection,268 as the TST response take weeks to develop.68 
 
In paper I, we address a fundamental challenge in diagnosis and adequate 
management of young children; the high proportion of bacteriologically unconfirmed 
TB cases. While TST and QFT are used as supplements in the diagnosis of pediatric 
TB, we report, in consistence with others, a low sensitivity for these tests in clinical 
TB.63, 201, 274 It is rather striking that 8 out of 9 bacteriologically unconfirmed TB cases 
were negative for both tests, but reduced sensitivity of TST and IGRAs in this group 
compared to smear/culture positive TB cases has been observed by others.245 A major 
question is therefore whether bacteriologically unconfirmed TB cases which 
constitute 2/3 of clinical TB cases in most pediatric studies,75 are true TB cases. 
Epidemiological estimates strongly suggest that they are.12 Assessing risk-factors and 
TST/QFT responses in bacteriologically unconfirmed TB cases compared to 
smear/culture positive TB cases would have been the most straight forward approach 
to shed light on clinical and immunological features characteristic for each of these 
groups of patients. Unfortunately, there were a limited number of TB cases in our 
study. Therefore, we explored instead clinical, demographic and nutritional 
(intrauterine and post-natal) factors that might be associated with TST and/or QFT 
outcome. Factors associated with TST and QFT outcomes might indirectly contribute 
to the understanding of host immune responses. We reported that children <2 years 
were less likely to have a positive TST and/or QFT and more likely to have an 
indeterminate QFT. If the sample volume is adequate, indeterminate QFT results are 
most often caused by low mitogen responses (QFT Mitogen minus Nil < 0.5 
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IU/mL),275 which was also the case here, although not reported in paper I: bivariate 
analysis of age and mitogen response as continuous variables, revealed a moderate 
positive correlation between age (months) and the magnitude of the mitogen response 
(Spearmans Rho= 0.34, p<0.0005), an association supported by others,276, 277 but the 
analysis is restricted by the lack of values >10IU/mL, a penalty of the QFT assay. 
Previous studies in young children are contradictory on whether there are positive 
associations between age and TST243, 278, 279 or QFT result,274, 278-280 but the largest 
study support such associations.278 These associations likely reflect a cumulative 
exposure with age, but might also reflect that immunological tests perform differently 
in subjects with an immature immune system. The latter is supported by reports on 
determinants for an indeterminate QFT, where exposure is irrelevant. Many studies 
support that indeterminate results are more frequent at young age.231, 274, 275, 277, 278, 280-
282 In our study, children with stunting due to chronic malnutrition (height-for-age Z-
score within the lowest quartile), seemed more susceptible to MTB infection and 
more prone to indeterminate QFT. Malnourished children are in general more 
susceptible to infections 283 because of altered immune responses,85 but to our 
knowledge, no previous studies have established this for MTB infection by the use of 
height-for-age Z-score. TST proved less reliable in children with wasting (weight-for-
height Z-score within the lowest quartile). The literature on the impact of malnutrition 
on the TST response is contradicting,284-287 but we suggest that this is due to 
considerable variation in how malnutrition is defined. In addition, if the Z-scores are 
used, the WHO cut-offs of <-2 (moderate to severe malnutrition) or <-3 (severe 
malnutrition)209 are not defined with regard to the impact of malnutrition on the host 
immune response. We also found that symptomatic children (fever and cough) were 
more likely to have indeterminate QFT responses. Similar reports exists,221 and this 
findings likely reflects the general impact on the immune response by ongoing disease 
regardless of etiology. Our findings shed light on the poor sensitivity of TST and QFT 
in MTB infection and disease in a pediatric context. Ideally, determinants for the TST 
and QFT outcomes should be evaluated in clinical TB cases, but this is barely doable 
in community-based settings with low to medium TB incidence. The fact that the 
majority of bacteriologically unconfirmed cases in our study (8 out of 9) came from 
the active surveillance arm, suggests that unconfirmed cases represent either an early 
phase in TB disease or a manifestation with diffuse and/or little symptoms. Evidence 
suggest that children <3 years might have little symptoms despite severe disease,22, 288 
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and together with the fact that children with bacteriologically unconfirmed TB in our 
study were younger than children with smear/culture positive TB (median age 14 
months versus 22 months, not statistically tested due to low numbers), different 
disease manifestation in younger children related to immature immune responses are 
likely. Unfortunately, we cannot confirm or reject whether bacteriologically 
unconfirmed cases represent an early disease stage as all children diagnosed with 
clinical TB were referred to the Revised National TB Control Program for treatment. 
An alternative explanation is that young age seen in the bacteriologically unconfirmed 
cases, make MTB infection less likely as a shorter life represents a reduced 
accumulated risk of exposure. Following this, unconfirmed cases in our study would 
represent an over-diagnosis of TB. However, we find this unlikely as smear/culture 
positive TB cases only account for about 30% of clinical TB cases in the majority of 
pediatric settings.75  Moreover, the evidence of an impact of age on the severity of 
disease manifestations22, 26 and immune responses, are compelling. In addition, 
epidemiological estimates strongly suggest that pediatric TB is under-diagnosed.12 
 
As discussed in section 5.1.2.1 and 5.1.2.2 we might have lost discriminatory power 
in paper II due to misclassification of TB status. This might explain why the 
differences in biomarkers exhibited by the dcRT-MLPA are much less pronounced in 
our study compared to the differences between adults with smear/culture positive TB 
or healthy MTB infected adults reported in by Joosten et al.,211 but biomarkers with 
the potential to increase diagnostic accuracy must be robust. In analysis of single 
genes, we report that the expression RAB33A in unstimulated peripheral blood was 
significantly lower in children with clinical TB compared to children with MTB 
infection and controls. Down-regulation of RAB33A in TB is consistent with previous 
findings.289, 290  RAB33A is a small guanosine triphosphatase (GTPase) suggested to 
be involved in the transport and fusion of intracellular vesicles.291 Phagosomal arrest 
is a major survival strategy for MTB (See section 1.2.4), which might be mediated 
through a dysregulation of GTPases.292 Our study also identified RAB33A in the 
adjusted lasso model as the only gene with discriminatory power between children 
with clinical TB and MTB infection (AUC 77.5%). RAB33A was also one of 5 genes 
with a substantial discriminatory power between children with clinical TB and 
uninfected controls (AUC 91.7%), and one of 11 genes with modest discriminatory 
power between children with MTB infection and uninfected controls (AUC 72.2%). 
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RAB33A has previously been identified in the context of biosignatures which enables 
the discrimination of confirmed TB, healthy latently infected and healthy uninfected 
adults of African or Caucasian origin.290, 293 Even though differently expressed in 
single gene analysis, RAB33A was not included in the predictory biomarker signature 
identified by the lasso model on dcRT-MLPA data from African and South American 
adults.211 Identification of RAB33A in Indian children with much less rigorous clinical 
categories strengthens the evidence that this biomarker can be used in the diagnosis 
and discrimination of MTB infection and disease. Another transcriptional marker 
identified by our analyses of unstimulated peripheral blood was TGFB1 which had 
increased expression levels 1) in clinical TB compared to uninfected controls and 2) 
in MTB infection compared to uninfected controls. TGFB1 encodes the cytokine 
TGF-ȕ, which has immune-modulating properties in the priming of T-cells. TGF-ȕ 
alone induces differentiation of Tregs, whereas in the presence of IL-6, the hallmark 
of inflammation, delineation is skewed towards Th17 cells.95 Elevated levels of TGF-
ȕ have been reported in TB patients (peripheral blood) compared to healthy control 
with or without MTB infection.294, 295 In addition, this biomarker took part in the 11-
biomarker signature with modest discriminatory power between children with MTB 
infection and uninfected controls (AUC 72.2%). Increased expression levels of 
TGFB1 in adults with smear/culture positive TB compared to healthy uninfected 
controls have been reported previously when mRNA from freshly isolated monocytes 
was analyzed 296, and compared to healthy latently infected adults.294, 295 TGFB1 was 
also one of 15 genes which discriminated smear/culture positive TB cases from 
uninfected controls (AUC 86%).211 Supported by these findings, TGFB1 is likely to 
have a diagnostic potential in the diagnosis of pediatric MTB infection and disease.  
 
In paper III, we hypothesized that the biomarker data acquired as part of paper II 
could provide some insight into the immunological mechanisms associated with 
concordant and discordant TST and QFT results frequently found in young children. 
In clinical settings, it is unclear how discordant TST and QFT results should be 
interpreted in terms of TB risk and preventive treatment, although the predictive value 
of concordant or discordant results has been addressed in some studies.232, 297 For 
instance; do discordant TST+/QFT- results represent increased specificity or reduced 
sensitivity of the QFT for MTB infection in a given setting (compared to TST)? False 
positive test results are least likely in concordant positive subjects, thus concordant 
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positive children in paper III can be assumed to be the most likely to have true MTB 
infection. This is consistent with known TB exposure being more frequent in these 
children in our study. Regarding discordant positive children, it is likely that a 
proportion of the TST+/QFT- results constitutes false positive TSTs since all the 
children were BCG-vaccinated at birth and <3 years at the time of testing.298 
Regarding the TST-/QFT+ results we find it more likely that these children are truly 
MTB infected as the specificity of QFT is reported to be high in similar 
populations.63, 71 Supporting the assumption of a true positive QFT in these children is 
a median specific IFNȖ-response well above the test cut-off (1.11 IU/mL). Notably, 
the sensitivity of MTB infection of both TST and QFT in our study population is 
unclear due to the lack of a gold standard.299 In a clinical setting where MTB-
infection is suspected in a child aged <5 years either TST, QFT or both test are used 
together with TB exposure to guide the decision on preventive treatment. We 
therefore assessed biomarker differences in children based on either or both tests 
compared to children assumed to be uninfected by MTB (TST-/QFT- concordant 
negative). The main immune biomarker differences between TST/QFT concordant 
positive, concordant negative and discordant positive children are illustrated in Figure 
13.  
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Comparing either concordant positive (TST+/QFT+), discordant positive 
(TST+/QFT-; TST-/QFT+), or TST+ (regardless of QFT result) or QFT + children 
(regardless of TST result) to concordant negatives, concordant positive children only,  
Figure 13.  Immune biomarkers in peripheral blood differentially expressed between 
children with concordant or discordant TST and QFT test results. Biomarkers in 
italics represent transcriptomes analyzed directly ex vivo, whereas normal fonts 
represent proteins in supernatant after MTB-specific stimulation (TB-Ag tube in the 
QFT assay). The triangles illustrate up-regulation (broad end) versus down-
regulation (pointed end) between the different groups.  
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had differentially expressed transcriptomes (unstimulated, direct ex vivo) of FPR1, 
TNFRSF1A (both up-regulated) and BPI (down-regulated), and increased levels of 
IFNȖ in TB-Ag stimulated supernatants (from the QFT assay). Contrary, all test 
positive children had up-regulation of the transcriptomes CD4 and TGFB1 
(unstimulated, direct ex vivo), and increased levels of the cytokines IL-2 and IL-13 
(stimulated; from the TB-Ag tube in the QFT assay), when compared to concordant 
negative children. CD4 and IL-2 are general markers of adaptive immunity: CD4+ T 
cells are known to be crucial in host defence against MTB (see section 1.2.3.1). IL-2 
is secreted by T cells upon antigen recognition and activation through the T cell 
receptor, and is required for the proliferation and maintenance of antigen-specific T 
cell pools (memory T cells).150 Most studies report that IL- 2 in stimulated samples is 
elevated in adults with TB disease compared to controls and the IL-2 levels seem to 
correlate with known TB exposure, but some studies report reduced levels in TB 
patients compared to MTB infected subjects (reviewed in300).The role of TGFB1 has 
been discussed for paper II. IL-13, a Th2 cytokine, seems to inhibit protective IFNȖ-
induced autophagy in MTB infected macrophages162 favouring macrophage 
necrosis104 possibly contributing to disintegration of  the granuloma (see section 
1.2.4.). A previous report on IL-13 release in children with TB disease or MTB 
infection suggests a positive correlation between IL-13 and Th1 cytokines,301 and 
increased levels have been reported in children with TB disease compared to 
uninfected controls.302 Moving on to a more specific assessment; the immune 
biomarker profiles in concordant positive versus discordant positive children, 
concordant positives had higher levels of the transcripts CD4 and TNFRSF1A as well 
as the cytokine IL-2 than both TST+/QFT- and TST-/QFT+ discordant children. 
Furthermore, the transcriptomes TGFB1 and TNFRSF1B as well as the chemokine IP-
10, are interesting: TGFB1 because of an up-regulation in both concordant positives 
and TST+/QFT- discordant children compared to concordant negatives, but also an 
up-regulation in concordant positives compared to TST-/QFT+ discordant children; 
TNFRSF1B because of an up-regulation in concordant positives compared to 
concordant negatives an both the discordant groups; IP-10 because TST+/QFT- 
discordant children had lower levels than both concordant negative and concordant 
positive children, whereas concordant positive children had elevated levels compared 
to concordant negatives, and TST-/QFT+ discordant children had increased levels 
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compared to TST+/QFT- discordant children. This elevated level of IP-10 was, 
together with a down-regulation of the transcriptome SEC14L1 (in TST-/QFT+) the 
only direct difference between the discordant groups. TNFRSF1A and TNFRSF1B 
encodes the membrane-bound TNFĮ-receptors TNFR1 and TNFR2. Binding of TNFĮ 
to these receptors mediate protective apoptosis in MTB infected macrophages,104, 164, 
303 but the receptors can also be shed by proteolysis. Shedding restricts the effect of 
TNFĮ by competing binding and reduced density of TNFRs on the cell surface 
(transient?).304 Evidence suggest a shedding of these reseptors in TB pathogenesis as 
TNFR1 and TNFR2 transcriptomes have been reported higher in whole blood but 
reduced in blood monocytes of TB patients compared to healthy household contacts 
and controls.165 Whether TNFRSF1A and TNFRSF1B represent increased levels of 
membrane-bound or soluble reseptors in our setting cannot be determined as the 
analyses were restricted to whole blood. IP-10, (IFNȖ-inducible protein 10) belonging 
to the CXC-chemokine family (also named CXCL10), is secreted by monocytes and 
APCs upon stimulation by multiple cytokines; main IFNȖ and TNFĮ, following the 
same kinetic pattern as IFNȖ.300 As the IP-10 ligand, CXCR3, seems to be uniquely 
expressed on T cells, IP-10 stimulation mediates a specific effect on lymphocytes,305 
creating a positive feed-back loop resulting in  amplification of IP-10 levels compared 
to IFNȖ. This probably explains why  IP-10 seems to be a more potent marker of 
antigenic stimulus and less influenced by CD4 counts or function than IFNȖ.300 A 
higher amplitude of IP-10 compared to IFNȖ was also demonstrated in our study as 
the difference in IP-10 levels between stimulated (TB Antigen tube) and unstimulated 
(Nil tube) samples was significant in both concordant and discordant positive children 
whereas the difference in IFNȖ levels was only significant in concordant positive 
children. Somewhat surprising, IP-10 levels were higher in concordant negative 
children than in TST+/QFT- discordant children, but little discrimination by IP-10 
when comparing active TB patients with patients with other pulmonary disease has 
been described,306 and likely reflects intercurrent disease in the concordant negative 
children in our study. SEC14L1 might have a role in intracellular vesicular transport 
and was identified by microarray analysis of differences between TB patients and 
healthy TB contacts,293 and took part in the transcriptional 5-biomarker signature 
identified in paper II. In summary for paper III,  when considering the analyses which 
take both TST and QFT results into account, general markers of adaptive immunity 
(CD4, IL-2) seemed to associate with a positive TST, whereas a concordant positive 
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result also associated with an increase in TNFRSF1B, TGFB1, TIMP-2 and IL-13, all 
likely players in the pathogenesis towards TB. Whether they serve host or pathogen in 
this interaction remains unclear. Interestingly, when compared to concordant 
negatives, there was no overlap of differentially expressed biomarkers between the 
discordant groups, suggesting that these phenotypes represents and measures distinct 
immune responses. Futhermore, we were intrigued to find so little difference in IFNȖ 
between the groups as they were categorized based, in part, on MTB-specific IFNȖ-
release as determined by the QFT assay. Instead, IP-10 proved to be more 
differentially expressed between TST+/QFT- and TST-/QFT+ discordant children. 
Notably, TST-/QFT+ discordant children in this study were younger and had a higher 
proportion of wasting (WHZ < 2SD) than the other test positive groups. It is 
reasonable to assume that these factors have contributed to the reduced expression of 
general markers of adaptive immunity (CD4, IL-2) seen in these children compared to 
concordant positives. These markers seem to associate with a positive TST since they 
are also elevated in TST+/QFT- discordant compared to concordant negative children. 
Having a positive QFT, TST-/QFT+ discordant children are very likely to be MTB 
infected.71 Inadequate adaptive immunity is likely to represent an increased risk of TB 
progression and implies reduced sensitivity of T cell based diagnostics in these 
children. IP-10 seems less influenced by CD4 counts300 and for young children, our 
study suggests a potential of increased sensitivity of IP-10 compared to IFNȖ in a 
diagnostic setting and possibly in predicting TB disease.  
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6. CONCLUSIONS 
6.1. What the studies add 
 
6.1.1. Impact on the interpretation of current diagnostic tools in MTB 
infection and disease. 
This thesis highlights the complexity in the interpretation of diagnostic tests in young 
children with suspected TB. This work provides strong arguments to the management 
of children: It is vital to keep in mind the potential for poorer TST and QFT 
performance in the most vulnerable, namely the young and/or malnourished. The 
impact of age and malnutrition on TST and QFT, both tests of cellular immunity, is 
likely to be closely linked to the high proportion of discordant TST and QFT results in 
this population. Consistent with this, concordant and discordant TST and QFT results 
reflect differences in immune biomarker profiles. Reduced risk of TB seen in 
discordant positive adults, can for these reasons, not be assumed to apply to young 
children. For these reasons, the implementation of WHO’s treatment 
recommendations should be intensified.307 
 
Our work also links longitudinal QFT results with polyfunctional mycobacterial-
specific CD4+ T cells in peripheral blood – a hitherto hot candidate when it comes to 
possible immune correlates of protection. Contrary to our starting hypothesis, our data 
do not support that the relative or absolute frequencies of PPD-specific polyfunctional 
CD4+ T-cells in peripheral blood can explain the reduced risk of TB progression 
observed in QFT reverters. Contrary, absolute frequencies of these cells correlated 
with the QFT-response, suggesting that this readout reflects the antigen load, similar 
to that shown for IGRA-responses in non-human primates.188 Our data hereby 
supports earlier speculations on the requirement for persistent or recurrent MTB 
exposure to maintain specific IFNȖ-responses.30, 227, 264, 269 
 
6.1.2. Impact on new diagnostic and predictive tools in MTB infection and 
disease. 
Through our work, we have for the first time confirmed a diagnostic potential 
for RAB33A when disease or infection with MTB is suspected in a pediatric setting. 
RAB33A seems to have a discriminatory potential across all relevant clinical TB 
categories both as a single biomarker and as part of biosignatures. We also suggest a 
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similar potential for TGFB1, but notably, this marker did not discriminate between 
MTB infection and disease, which is likely to be a requirement of a new diagnostic 
tool. Furthermore, it is of importance that the study was conducted on the Sub-Indian 
continent which is a relatively rare site in TB biomarker research. In order to be 
included as recommended diagnostic tools, potential biomarkers would need 
validation in multiple populations.31  
 
A strong belief in a potential for polyfunctional mycobaterial-specific T cell responses 
in predicting TB progression or protection has inspired broad research based on 
resource intensive methods. Based on our finding that absolute frequencies of these 
cells correlated with the magnitude of the QFT response, we question the rationale for 
performing elaborate flow cytometry assays on peripheral blood samples in the search 
for “protective biomarkers”. Notably, the extensive research aiming to identify 
immunologic biomarkers for diagnostic purposes mostly has a strong emphasis on 
cellular immunity. Better diagnostic accuracy is badly needed particularly in young 
children, but based on our work we suggest that age and malnutrition are likely to 
influence the performance of all cellular immunological markers. Future research on 
other approaches than host cell-mediated immune markers might prove more fruitful 
in this population.  
 
6.2. Future research perspectives 
 
Both epidemiological studies and advances in basic science are required to improve 
the tool-box of TB diagnostics. As stated by the Stop TB partnership, research efforts 
will continue to work towards a point-of-care test for active TB, explore 
biomarkers/bio-signatures which allow for accurate identification of patients at 
various stages of disease; from asymptomatic infection to disease, as well as 
biomarkers/bio-signatures capable of predicting protection or increased risk of TB 
progression in MTB infected or vaccinated subjects.199  
 
In addition, findings included in this thesis point to other relevant research questions 
(listed below in unprioritized order):    
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x Further exploration and validation of immune biomarkers of MTB infection 
and disease with diagnostic potential in pediatric settings. Biomarkers suitable 
for point-of-care tests would be preferable.308  
x Exploration of new diagnostic and predictive markers not dependent on 
cellular immunity. This will be particularly useful in young children, HIV 
patients and other immunocompromised individuals. 
x Explore, in children <5 years, whether bacteriologically unconfirmed TB cases 
are different from smear/culture positive TB cases with regard to 
sociodemographic, clinical and nutritional characteristics.   
x Explore host immune responses in smear/culture positive versus 
bacteriologically unconfirmed TB cases. Differences in disease manifestations 
are likely to be reflected in the host immune response or vice versa.  
x What are the adequate Z-score cut-offs for the effect of malnutrition on the 
host immune system? Are the same cut-offs valid for all populations? 
x The prognostic value of concordant and discordant TST and QFT results in 
children <3 years needs further investigation in order to optimize 
recommendations for management and treatment.  
x Is preventive TB treatment required in otherwise healthy young children 
positive for TST and/or QFT in children without ongoing exposure? A close 
monitoring in a randomized study-setting can justify to with-hold treatment in 
these children.309 
x Exploration of reduced cut-off for QFT test positivity in young children.  
x Explore the immunological phenotype associated with indeterminate QFT 
results. 
x Explore whether indeterminate QFT responses/low mitogen responses are 
reflected in more general immune biomarker profiles?  
x Longitudinal studies of QFT reverters in high-endemic settings: Are they 
protected from re-infection? An answer to this question is important for the 
assessment of subjects at repeated risk of exposure: 1) Is repeated 
testing/examination indicated or not? 2) Should a booster vaccine be 
recommended? 
x Longitudinal studies of QFT consistent positives in high-endemic settings to 
determine their risk of TB progression. 
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x Do the levels of polyfunctional mycobacterial-specific CD4+ T cells in the 
blood (or BAL) have the potential to predict TB progression (or MTB 
clearance) in MTB infected subjects?  
 
In evaluating diagnostic tools for active TB, the study design should take into account 
that in real-life, subjects seek health because of symptoms, thus they are rarely 
healthy. The complex network of innate immunity more or less put into play in most 
disease states regardless of acute or chronic infectious, or non-infectious etiology, is 
likely to influence host immune biomarkers. Clifton E. Barry III recently reported that 
the pulmonary lesions in subjects with untreated XDR TB were almost completely 
rearranged within 2 months when assessed by high-resolution computed tomography 
(HRCT) and positron emission tomography (PET) (Clifton E. Barry III, unpublished 
data presented on the Keystone Symposia “Host Response in Tuberculosis”, March 
13-18, 2013, Whistler, BC, Canada). These gross changes were never reflected in 
IGRA responses (QFT and T-SPOT) questioning the ability of these tests and possibly 
specific T cells responses in blood, to reflect changes in extended disease. Notably, a 
very recent report suggests that sputum might be a more appropriate specimen for 
immune biomarker-based diagnostics.306 
 
Regarding correlates of TB protection highly relevant in future TB vaccine trials, 
functional mycobaterial growth-inhibition assays using whole blood or PBMCs from 
study subjects might be both more promising and feasible than phenotyping of 
specific T cells.268, 310 
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ERRATA 
 
 
Please note the following corrections to the thesis: 
 
Table of content.  
Correction between point 3.3.1 and 3.3.2 Clinical outcomes (diagnostic algorithm, 
Figure 9) was wrongly assigned a headline. Likewise: TB Antigen minus Nil (IU/mL) 
between point 3.8.2 and 3.8.3. 
1.1.5 
page 15. The epidemiological numbers are updated according to the Global TB report 
2014, which was not yet published when I submitted my thesis.  
1.1.6.1.1 
page 17. antigen changed to antigens and PPD is an antigen changed to PPD 
contains antigens 
1.2.5.2 
page 36. Added bolded text: the onset of efficient adaptive immune responses 
following infection is crucial in controlling bacterial replication. 
1.3 
page 36. Add bolded text: Invasive procedures in the diagnosis of MTB infection in 
absence of active TB are hardly ethical. 
3.3.1 
Figure 9, page 47. Added bolded text: Clinical entry criteria. 
Figure 10, page 45. Add a conjunction line from the blue box “mixed outcomes” to 
the blue box to the left “clinical TB”. 
3.3.2 
Table 5, page 49. Lay-out adjusted to increase the readability. 
3.4 
Table 6, page 47. Lay-out adjusted to increase the readability. In the row “When 
assessed”, changed Every 3 months to Every 2 (NCS) or 3 (ACS) months. Added text 
in bold: **Failure to thrive (defined in section 3.3.1, point 3.) 
3.8.5.5 
Table 8, page 58. Lay-out adjusted to increase the readability. 
3.8.5.6 
page 59. Add bolded text: lacked a valid positive control (Valid positive control 
defined as >1% cytokine-producing cells when stimulated with SEB). 
page 60: is changed to was 
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3.9 
Figure 14, page 64. Failure to thrive in the lower left box should be in italic. 
5.1.1 
page 74. More specifically, paper I-III cover the clinical setting of young children 
investigated for TB and subsequently shed light on current diagnostic tools (paper I, 
III and IV), potential future diagnostic (paper II) and predictive (paper IV) tools. 
Changed to Paper I, III and IV shed light on current diagnostic tools, whereas 
potential future diagnostic and predictive markers are explored in paper II and IV. 
page 75. If the gradient of TST or IGRA results corresponds to the exposure, changed 
to If the magnitude of TST or IGRA results corresponds to the gradient of exposure, 
5.1.2.1 
page 77. dismissal changed to discharge. 
5.2 
page 88. Final point changed to colon in In paper III, the children are classified by 
their TST and/or QFT: 
page 92: added a parenthesis around the sentence: For paper I, all the 746 children 
were eligible whereas 210 of the 746 were selected for the biomarker sub-studies in 
paper II and III (see section 3.3.1). and deleted (paper I-III)  
page 93: crude mycobacterial antigen changed to crude mixture of mycobacterial 
antigens and deleted  bolded text The TST which also applies the PPD antigen 
page 94. T cell changed to T cells 
page 98. Added bolded text reduced sensitivity of the QFT (compared to TST)  
page 101. Added bolded text but the receptors can also be she and made the font on 
following the same kinetic pattern as uniform: Times new roman 12. 
page 102. Added bolded text and for young children, our study suggests  
6.1.2 
page 104. Deleted in an added bolded text in Notably, in the extensive research 
aiming to identify immunologic biomarkers for diagnostic purposes mostly has a 
strong emphasis  
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ABSTRACT 
Background. Reliable identification of Mycobacterium tuberculosis (MTB) infection or 
tuberculosis (TB) disease in young children is vital to assure adequate preventive and 
curative treatment. The tuberculin skin test (TST) and IFNȖ-release assay (IGRA) may 
supplement the diagnosis of pediatric TB as cases typically are bacteriologically 
unconfirmed. However, it is unclear to what extent the performance of TST and 
QuantiFERON-TB Gold In-Tube (QFT) (Cellestis’ IGRA test) depend on the demographic, 
clinical, and nutritional characteristics of children in whom they are tested. 
Methods. During a 2-year prospective observational study of 4382 neonates in Southern 
India, children with suspected TB were investigated and classified by a standard TB 
diagnostic algorithm. 
Results. Clinical TB was diagnosed in 13 of 705 children referred for case verification 
with suspected TB. TST and QFT had a susceptibility for clinical TB of 31% and 23%, 
respectively, in this group. Children <2 years were more likely to test QFT indeterminate. A 
height-for-age Z-score within the lowest quartile increased the odds ratio (OR) for a positive 
or indeterminate QFT result (OR 2.46 [1.19-5.06], OR 3.08 [1.10-8.58]), whereas the OR for 
a positive TST was reduced with a weight-for-height Z-score within the lowest quartile (OR 
0.17 [0.06-0.47]). 
Conclusion. The sensitivities of the TST and QFT for clinical TB in children <3 years of 
age were equally poor in this population. Stunted children were more susceptible to MTB 
infection, and more prone to indeterminate QFT results. TST was less reliable in children 
with wasting. 
AC
CE
PT
ED
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
 4 
BACKGROUND 
Children <2 years of age at the time of infection, typically develop tuberculosis (TB) 
disease due to primary infection, and not as a result of reactivation. Their risk of progression 
to TB and for developing severe disease is high. Therefore, reliable identification of 
Mycobacterium tuberculosis (MTB) infection or TB in young children is vital to assure 
adequate preventive and curative treatment. Pediatric TB often remains unconfirmed due to 
paucibacillary disease and technical difficulties in obtaining adequate specimens. Therefore, 
evidence of MTB infection by a positive tuberculin skin test (TST) or IFNȖ-release assay 
(IGRA) may be used as a supplement in diagnosis(1). WHO recommends the use of TST 
over IGRAs in children in low- to middle- income countries as TST is cheaper and evidence 
suggests little difference in sensitivity(2). A trend towards lower sensitivity of all tests in 
children <5 years was highlighted in a recent meta-analysis, but the conclusion was limited 
by few included subjects(3). In addition, it is unclear to what extent the performance of TST 
and IGRAs depends on demographic, clinical and nutritional characteristics in young 
children.  
 In this study, we first evaluated the performance of TST and QuantiFERON-TB Gold 
In-Tube (QFT) in diagnosing clinical TB, in a cohort of children <3 years in a rural setting in 
Southern India. We then assessed the associations between TST and QFT results and 
sociodemographic, clinical, and nutritional (intra-uterine and post-natal) characteristics, in the 
same cohort.  
 
METHODS 
Study design and setting 
This study was nested within the Neonatal Cohort Study (NCS), a population-based 
prospective study of 4,382 BCG-vaccinated neonates cluster randomized to active (2,215) or 
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passive (2,167) surveillance for 2 years, in the Palamaner Taluk, India (3.2000N, 72.75000E, 
altitude 683m), from April 2007 to September 2010. Enrollment and consent procedures are 
previously described(4). The NCS covered a total population of ~400,000, with an estimated 
TB incidence of 136/100,000 (Andhra Pradesh, 2010)(5).  
The present study is cross-sectional and included children enrolled in the NCS and 
evaluated for TB at the Case Verification Ward (CVW) at Emmaus Swiss Hospital, during 
the follow-up period. Referral criteria were either 1)exposure to a known TB case within the 
last year; 2)respiratory/infectious symptoms; 3)or failure to thrive (FTT) defined as any of the 
following; a)loss of weight or no weight gain for two consecutive visits; b)downward 
crossing of two percentile lines on the weight-for-age growth chart; or c)weight that tracked 
consistently below the 3rd percentile in the weight-for-age growth chart(6); or 4)a TST 10 
mm at study close-out.  
 The study was approved by the institutional review board at St. John’s Medical 
College, Bangalore, India, an independent ethics review committee, and the Ministry of 
Health Screening Committee, Government of India (No. 5/8/9/60/20006-ECD-1 
dt.10.11.2006).  
 
Diagnostic assessment 
Clinical and anthropometric data were recorded. A chest radiograph (CXR), anterioposterior 
view, was interpreted by 3 independent radiologists. Agreement by 2 radiologists was 
required to classify a CXR as consistent with TB. A TST was performed by a trained 
nurse/doctor (2 TU/0.1mL tuberculin; Span Diagnostics Ltd, India) and read after 48 hours. 
Peripheral blood (3 ml) was drawn for the QuantiFERON®-TB Gold In-Tube (Cellestis, 
Australia) which was performed according to the manufacturer’s instructions.  
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Gastric aspirates and induced sputa were collected on 2 consecutive days for fluorescent 
microscopy (Auramine) and culture on solid (Löwenstein-Jensen) and liquid (Mycobacterial 
Growth Indicator Tube, BD) medium. Positive results were confirmed by Ziehl-Neelsen 
staining and speciated using the HAIN kit (GenoType® MTBC, Ver1, Hain Life Sciences, 
Germany). Direct PCR (The COBAS® TaqMan® MTB Test, Roche 2007) was done on all 
culture-negative specimens in children with CXR consistent with TB. The HIV status was not 
assessed, but data from a house-hold contact study conducted in the same study area in the 
period 2010 to 2012, found a HIV prevalence <1% (TB Trials Study Group, unpublished 
data). 
 
Clinical outcomes 
A structured diagnostic algorithm including TST result (but not QFT), classified the children 
as having definite TB, probable TB or not TB. Clinical TB included definite TB (positive 
culture or PCR) and probable TB (CXR suggestive of TB and 1 of the following: known TB 
exposure, fever and/or cough 2 weeks, FTT and TST 10mm). 
 
Statistical analysis 
Low birthweight (<2500g) and being small for gestational age (SGA: Weight-for-gestational 
age <10th percentile)(7) were used as indicators of intra-uterine nutritional status. The WHO 
child growth standard Z-scores were dichotomized using the cut-off <-2, which defines 
wasting (weight-for-height (WHZ)), stunting (height-for-age (HAZ)) and underweight 
(weight-for-age (WAZ) and BMI-for-age (BAZ))(6). Equal to the WHO definition, 
hemoglobin <10 g/100ml defined the cut-off for moderate-severe anemia(8). TST and QFT 
were handled as categorical variables; TST (binary), cut-off  10mm(9), QFT in 3 categories: 
positive (0.35 IU/mL), negative (<0.35 IU/mL) and indeterminate. Categorical data were 
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compared by Pearson’s chi-square with Yates Continuity Correction or Fisher’s exact test, 
where appropriate. 
Kappa statistics were used in the concordance analyses of TST and QFT result and 
evaluated according to McGinn et al.(10).  
Because malnutrition was left-shifted in the study-population, children within the 
lowest quartile were considered malnourished in new dichotomous variables which were 
included in the univariate and multivariate analyses (cut-offs: WHZ <-2.59, HAZ <-2.14, 
WAZ <-2.63 and BAZ <-2.51). Univariate associations between positive TST and/or QFT 
outcomes  (indeterminate QFT results excluded) and surveillance arm (active or passive), 
gender, birthweight, SGA, age, socioeconomic factors (mothers/fathers education, housing, 
cooking fuel), known TB exposure, symptoms, nutritional status (WHZ, HAZ, WAZ, BAZ, 
anemia) and isolated NTMs, were assessed by logistic regression. Variables with significant 
univariate associations with the TST and/or QFT outcomes were considered for inclusion in 
the multivariate model if they could be assumed to have a casual impact on the outcomes. 
These assumed causal relationships were based on the literature and drawn by principles of a 
directed acyclic graph (DAG)(11). Notably, as the positive TST and/or QFT outcomes are 
imperfect read-outs of the clinical TB outcome (clinical TB disease, MTB infection or no 
infection/disease) for which there is no gold standard, we chose to illustrate the variables 
relationship both to the clinical TB outcome and the positive TST and/or QFT outcomes 
(Figure 1) (Causal relationships are indicated with arrows.) The variables’ impact on clinical 
TB influence on the child’s susceptibility for MTB infection and disease, whereas the 
variables impact on a positive TST and/or QFT result influence on the ability of the tests to 
correctly reflect the clinical TB outcome (test performance). Following the DAG principle, 
ancestor variables (variables that is a cause of another variable more closely linked to the 
outcome) and descendants of the outcome, were not included in the multivariate models(11). 
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These considerations left age, TB exposure, WHZ, HAZ and NTM presence in the 
multivariate model together with gender which is routinely included. WHZ and HAZ 
represent different entities of malnutrition, and important collinearity or interaction was not 
found when all possible 2-way interactions in each of the multivariate models were tested. 
Regarding the indeterminate QFT outcome, the assumed causal relationship is different 
(Figure 2). Being primarily the result of inadequate mitogen responses, this outcome is not 
specific for clinical TB outcome, but rather affected by all physiological conditions 
interfering with T-cell responses in general (Figure 2). Accordingly, known TB was not 
considered relevant whereas symptoms of any duration (categories defined in Table 6) were 
included because of previous reports(12). Missing data for each variable can be deduced from 
Table 1.  
All p-values were calculated using two-tailed tests and a p-value of <0.05 was 
considered significant. Analyses were conducted using PASW Statistics version 18.0, 2009. 
SPSS Inc. Chicago, IL. 
 
RESULTS 
Characteristics of the study population 
Of 746 children investigated at the CVW, 86 children (11.5%) had known TB exposure. Two 
or more referral criteria were present in 123 (16.5%). Of 623 children with a single referral 
criteria present, 452 (60.6%) had FTT, 80 (10.7%) had persistent cough and/or fever and 40 
(5.4%) had known TB exposure. Among the 51 (6.8%) children admitted based on TST 
10mm alone, 44 (86.3%) were referred at study closure. Of the 746 children, 41 where 
excluded from further analyses as missing data prevented classification by the diagnostic 
algorithm (40), or loss to follow-up (1) (Figure 3). None of these children had a CXR 
suggestive of TB, and only one child had known TB exposure. Subsequently, 705 children 
AC
CE
PT
ED
Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
 9 
were included in further analyses. Their clinical characteristics are provided in Table 1. 
Except for CXR changes, TST and QFT test results, there were no significant differences in 
sociodemographic, clinical or nutritional variables between children with or without clinical 
TB. The mean age was 14.8 months, about 50% of the mothers and fathers had primary or 
secondary school, 76.6% lived in brick houses but only 7% of the families used gas to cook. 
Known TB exposure was present in 12.1%. A striking 76.2% had FTT. Poor nutritional status 
was also reflected in the WHO growth-chart Z-scores (40-50% had wasting/underweight and 
30% had stunting) and in the proportion of children with moderate-severe anemia (32.8%).   
 
Performance of TST and QFT in clinical TB cases 
Thirteen clinical TB cases, (4 definite and 9 probable) were identified; 4 were TST positive 
and 3 QFT positive. The sensitivity of TST and QFT for clinical TB was 31% and 23%, 
respectively (Table 2). Among children with definite TB, 3 had negative smears but positive 
cultures, and were TST and QFT positive. The fourth child with definite TB was TST and 
QFT negative (sensitivity for definite TB: 75%). This 18 months old boy was the only child 
in our study with a positive smear (gastric aspirate grade 3+), illustrating the shortcomings of 
TST and QFT also in definite TB cases despite an adequate T-cell response to mitogen (>10). 
He had been initiated on anti-TB treatment 2 weeks prior to admission which likely explains 
the negative culture, but MTB was confirmed by PCR. Of 9 children classified as probable 
TB, one infant was TST positive, 7 were QFT negative and 2 QFT indeterminate (Table 2).  
 
Overall TST and QFT results 
In the 705 children, 69 of 702 (9.8%) were TST positive. QFT was positive in 36 and 
indeterminate in 22 of 691 (5.1% and 3.1%, respectively). Of the children with an 
indeterminate QFT, 19 (86.4%) were aged <12 months and the remaining 3 (13.6%) were 
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aged 12-23 months. The difference in the distribution of indeterminate results within the 3 
age categories were thus highly significant (Fisher’s Exact test, p<0.0005). Low mitogen 
response was the predominant cause of an indeterminate QFT result in 21 children (95.5%). 
Notably, indeterminate QFT was more frequent in children with clinical TB (15%) compared 
to children without (3%). 
 
TST and QFT agreement 
Valid results for both TST and QFT were obtained in 666 children. The 39 children without 
corresponding TST and QFT results were thus omitted from this analysis. Agreement 
between the tests was only fair (ț=0.30, 95%CI 0.18-0.42), indicating that exchanging one 
test for the other is unlikely to provide the same information. When restricted to those with 
known TB exposure, which increases the pretest probability of the tests, the agreement was 
substantial (ț=0.75, 95%CI 0.42-0.95) (Table 3). This highlights the importance of focusing 
on TB exposure rather than immunological tests in young pediatric populations.  
 
Determinants for a positive TST and/or QFT 
Unadjusted odds ratio estimates for the variables: surveillance arm (active or passive), 
gender, birthweight, SGA, age, socioeconomic factors (mothers/fathers education, housing, 
cooking fuel), known TB exposure, symptoms, nutritional status (WHZ, HAZ, WAZ, BAZ, 
anemia) and isolated NTMs, were performed by logistic regression. If significant, these 
estimates, with 95% confidence intervals, are presented in Table 5 and 6 together with 
unadjusted and adjusted analyses for all variables included in the final multivariate model: 
gender, age (categorical), known TB exposure, nutritional status (WHZ, HAZ) and NTM 
isolated from culture. Data not shown are available on request.  
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Adjusted for the other factors, boys had increased OR for a positive TST. Younger 
age associated negatively with a positive TST and/or QFT, more prominently with TST than 
QFT, both in children <12 and 12-23 months compared to children 24 months. TB exposure 
was a determinant for a positive TST and/or QFT. Within the study population, having a 
WHZ<-2.59 reduced the OR for a positive TST whereas having a HAZ<-2.14 increased the 
OR for a positive QFT and positivity for both tests, but not for TST alone. Birthweight 
<2500g and SGA were included in the models one at a time, but no significant associations 
was present and the other coefficients remained unchanged (data not shown). All possible 2-
way interactions in the models were tested, but only a slight interaction between WHZ and 
HAZ (p=0.048) for a positive QFT was found. The model including the interaction gave a 
better fit (Likelihood Ratio test Statistics: X²=5.34, p<0.025), but did not change the 
coefficients. Stratified analyses indicated that the effect of having a HAZ<-2.14 on a positive 
QFT, was not evident in children with WHZ<-2.59 (OR 0.55, 95%CI 0.06-5.13 versus OR 
4.0, 95%CI 1.71-9.35).  
 
Determinants for an indeterminate QFT 
Results from unadjusted and adjusted analyses are given in Table 7.  
The multivariate model included gender, age (continuous), fever and/or cough of any 
duration, nutritional status (WHZ and HAZ) and NTM isolated from culture. Adjusted for the 
other factors, the OR of an indeterminate result was reduced by 0.83 with every month of age 
(95%CI 0.76-0.90). Fever and cough as well as a HAZ within the lowest quartile increased 
the OR for an indeterminate QFT. Neither birthweight <2500g nor SGA showed any 
association or changed the other coefficients, and were therefore omitted in the final model.  
 
The impact of alternative nutritional variables on TST and QFT outcomes 
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WAZ and BAZ are alternative markers of nutritional status and indicate underweight if the Z-
score is <-2)(6). Exchanging WHZ and HAZ for WAZ or BAZ in the multivariate models, 
WAZ (cut-off<-2.63) and BAZ (cut-off<-2.51) acted similarly by reducing the OR for a 
positive TST (ORWAZ 4.00, 95%CI 1.61-9.95, ORBAZ 3.02, 95%CI 1.23-7.44) and increased 
the OR for an indeterminate QFT result (ORWAZ 0.35, 95%CI 0.16-0.77, ORBAZ 0.20, 95%CI 
0.07-0.54) in children with Z-scores below the cut-off.  
 
DISCUSSION 
To our knowledge, this is the first extensive study of TST and QFT performance in 
young Indian children. The sensitivities of TST and QFT test for clinical TB were equally 
poor, which may be attributable to the influence of younger age and malnutrition. QFT results 
did not add significantly to the information already provided by TST, supporting current 
WHO guidelines in high-burden TB settings(2). We report for the first time that a low HAZ 
score, which indicates stunting, a result of chronic malnutrition, is a determinant for an 
indeterminate QFT result when corrected for other factors.  
The sensitivities of TST and QFT for clinical TB were 31% and 23%, which is 
comparable to studies conducted in young African children(13-16). The diagnostic criteria in 
this study are slightly less stringent than recently recommended by an expert panel(17), but 
the proportion of confirmed TB cases (30%) is similar to other studies of pediatric TB(18). 
The lack of a gold standard for MTB infection and the diagnosis of smear and culture 
negative TB complicates the evaluation of TST and QFT performance.  
Determining the clinical relevance of bacteriologically unconfirmed TB is an 
important issue in pediatric TB. Because pediatric TB is often paucibacillary(1), it can be 
argued that false negative QFT results could be expected as increasing evidence supports a 
positive association between the antigen load and the magnitude of MTB-specific IFNȖ-
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responses(19;20). Accordingly, children with sputum-negative TB could simply be in the 
early stages of TB. Given that cases in this study were identified by active case finding, this 
is very likely(1). While published studies indicate an increased risk of TB disease in subjects 
with TST indurations 12mm(21), or high IFNȖ-responses following recent infection(19;20) 
these studies were conducted almost entirely in adults. Interestingly, adults with discordant 
TST and IGRA results had the lowest rates of TB in a household contact study in the 
Gambia(20). From this perspective one could argue that there is an over-diagnosis of TB in 
young children. However, epidemiological estimates suggest the opposite(1) and TST and/or 
QFT negativity is not restricted to unconfirmed TB cases(13;15;16;22), as shown in this 
study. Furthermore, we report increased OR for indeterminate QFT in children with 
intercurrent disease (fever and/or cough of any duration). This questions the validity of 
extrapolation of immune responses in asymptomatic, latently infected adults, to immune 
responses in sick children. Moreover, unlike adults, children <2 years at time of infection 
who progress to TB, can almost universally be assumed to do so after a primary infection(1). 
The nature of a primary and/or immature immune response(23), could cause MTB-specific 
IFNȖ-producing T-cells to be present in lower numbers in young children.  
Ideally, determinants for TST and QFT outcomes should be evaluated in clinical TB 
cases, but this is possible only in prospective community-based settings where the TB 
incidence is high. Therefore, we evaluated associations between determinants and TST/QFT 
results regardless of TB disease status. As expected, known TB exposure associated with a 
positive TST and/or QFT when corrected for other factors. Our study indicates that there 
might be factors which mask the true relationship between known TB exposure and a positive 
TST since this association was evident only in adjusted analysis.  
 Boys were more likely to be TST positive than girls when corrected for other factors. 
Basu et al., recently reported that boys were more likely to be QFT positive, but found no 
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such association with TST(24). There are well-known gender differences in TB 
epidemiology, but it is unclear to which extent these are attributable to genetic as opposed to 
socioeconomic and cultural factors(25).  
 Children <2 years were less likely to be TST and/or QFT positive and more likely to 
have an indeterminate QFT result than children aged 2-3 years. This is not surprising as the 
immune responses in infancy are considered immature and evolving(23). Previous findings in 
young children are contradictory with regard to a positive association between age and a 
positive TST(14;24). Regarding QFT, some studies reported no association with age, but few 
young children were included(16;26). In a large study of children <5 years, age associated 
positively with a positive TST and QFT after adjusting for BCG vaccination and gender(24). 
Many studies have suggested indeterminate QFT to be more frequent in young individuals 
(16;22;24).  
 The burden of malnutrition in this study was considerable. Malnourished children are 
more susceptible to infections because of altered immune responses(27), and would thus be 
expected to have increased susceptibility to MTB infection and subsequently an increased 
rate of positive TST and/or QFT. On the other hand, blunted immune responses by 
malnutrition are likely to cause suboptimal performance of immunological tests as reported 
for immunocompromised children(28). We report that HAZ <-2.16 increased the OR for a 
positive TST and/or QFT, when corrected for other factors. A HAZ <-2 is a marker of 
stunting, the result of chronic malnutrition. Our findings therefore confirm the increased 
susceptibility to MTB infection in children with chronic malnutrition. At the same time, these 
children were more prone to indeterminate QFT (overwhelmingly due to lower mitogen-
driven responses), which together with a substantially reduced OR for a positive TST when 
WHZ was <-2.61, is suggestive of a blunted immune response in these children. The clinical 
consequences of blunted immunity are demonstrated by a higher mortality in hospitalized 
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children with indeterminate QFT, regardless of the underlying disease(16). Studies on the 
effect of malnutrition on TST are conflicting(29;30), but reduced sensitivity of TST for 
clinical TB in children with WAZ <-2 have been reported(13). Few studies (all evaluating 
WAZ <-2 without considering other Z-scores) have evaluated malnutrition as a determinant 
for QFT results(16;26). The definitions of malnutrition in studies vary considerably, and 
conflicting results might be attributed to different effects of chronic and sub-acute 
malnutrition. Furthermore, the standard Z-score cut-off <-2 has not been evaluated with 
regard to immunological changes related to malnutrition. We have demonstrated that the 
effect of malnutrition depends on the variable used. When WAZ or BAZ replaced WHZ and 
HAZ in our adjusted models, the effect of chronic malnutrition on a positive QFT result was 
lost. 
 Children with at least one NTM isolated from culture (23.5%), but had no increased  
OR for being TST positive when corrected for other factors, suggesting that reduced 
specificity of TST by NTM cross-reactivity plays little role in this setting. Similarly, no 
apparent impact of NTM on TST was reported in Gambian children(31). QFT 
(positive/indeterminate) was not influenced by the presence of NTM, and all children with 
RD1-positive NTM (M. kansasii) were QFT negative. No child fulfilled the ATS/IDSA 
criteria(32) for NTM disease, suggesting that NTMs were commensals in this setting.  
The strength of this study is the community-based prospective design with a 
considerable number of enrolled children in a country with high TB burden but low HIV 
prevalence (<1%) (TB Trials Study Group, unpublished data). This “real-life” context makes 
our findings very clinically-relevant. The high prevalence of malnutrition and colonization by 
NTMs may limit the generalizability to other settings, but these conditions are typical for 
many areas with high-to-moderate TB burden. The prevalence of helminth infection is 
presumably high(33) and might interact with host immune responses(34;35), but we were 
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unable to collect stool samples in this cohort. Well-quantified TB exposure is a reliable 
surrogate measure of MTB infection(36), as reflected in this study by the increased kappa 
agreement between TST and QFT when the analysis was restricted to TB exposed children. 
Unfortunately graded data on TB exposure was not available in this study. TST 10mm 
outcome was both a referral criteria and 1 of 4 diagnostic criteria (1 criteria in addition to 
characteristic CXR changes) required for a diagnosis of clinical TB. The TST estimates could 
therefore be subject to selection bias, which is a limitation in our study. This compromise in 
design was required in order to avoid losing TB cases; the primary aim of the NCS was to 
establish the true incidence of TB in this cohort as part of preparing the site for future vaccine 
trials. This selection bias could result in an overestimation of the TST’s sensitivity for clinical 
TB, but as none of the probable TB cases depended on a positive TST for their diagnosis, this 
does not affect the TST sensitivity estimate. Furthermore, compared to the OR estimates of 
the associations between a positive TST and the assessed variables, the OR estimates for a 
positive QFT outcome may be overestimated because TST-QFT+ discordant positives 
children within the NCS were only referred if they had known TB exposure or were 
symptomatic, whereas TST+QFT- children might have had no other referral criteria. Notably, 
referral based on a positive TST only was present in 51 of 746 children, which limits this 
effect. 
 
CONCLUSIONS 
This study highlights that in assessing children with suspected TB, it is vital to keep in 
mind the potential for poorer TST and QFT performance in the most vulnerable, namely the 
young and/or malnourished. Accordingly, the implementation of WHO’s treatment 
recommendations should be intensified(37). Withholding treatment in exposed and/or 
TST/IGRA positive but otherwise healthy children can only be justified if careful clinical 
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follow-up is possible. TST and QFT are immunological tests of cellular immunity which 
provide indirect evidence of MTB infection. Currently, extensive research is aimed at 
identifying immunologic biomarkers for diagnostic purposes, with a strong emphasis on 
cellular immunity. Better diagnostic accuracy in this population is badly needed, but based on 
the results of this study, we suggest that age and malnutrition are likely to influence the 
performance of all cellular immunological markers. Future research on other approaches than 
host cell-mediated immune markers might prove more fruitful in this population.  
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FIGURE LEGENDS 
Figure 1. 
A Directed Acyclic Graph (DAG) illustrating the causal relationships between the 
determinants for the outcomes clinical TB and positive TST and/or QFT. A causal 
relationship between a determinate (variable names listed in parenthesis) and an outcome is 
indicated with arrows. Ancestors (variables that is a cause of another variable more closely 
linked to the outcome) and descendants of the outcome not included in the multivariate 
models, are in italic. Variables significantly associated to the outcomes in univariate analysis 
are in bold. Dashed arrows indicate more uncertain relationships. 
 
Figure 2. 
A Directed Acyclic Graph (DAG) illustrating the causal relationships between the 
determinants for the outcome indeterminate QFT. A causal relationship between a 
determinate (variable names listed in parenthesis) and an outcome is indicated with arrows. 
Ancestors (variables that is a cause of another variable more closely linked to the outcome) 
and descendants of the outcome not included in the multivariate models, are in italic. 
Variables significantly associated to the outcomes in univariate analysis are in bold. Dashed 
arrows indicate more uncertain relationships. 
Figure 3. 
Flow-chart for the 746 study participants. The diagnostic procedures applied at the *Case 
Verification Ward (CVW) are listed.  
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Table 1. Characteristics of children referred to the Case Verification Ward (CVW) classified 
according to the diagnostic TB algorithm (n=705).ª 
Total Clinical TB¹ No TB  
  
n=705 (%) n=13 (%) n=692 (%) 
p value 
 
Surveillance arm (N=705)       
  
   Active 609 (86.4) 10 (76.9) 599 (86.6) 0.40 
  
No of visits to the CVW (N=705)    
 
 1 visit 663 (94.0) 10 (76.9) 653 (94.4) 0.07 
 2 visits 40 (5.7) 3 (23.1) 37 (5.3)  
 3 visits 2 (0.3) - 2 (0.3)  
Sex (N=705)    
 
 Male 374 (53.0) 7 (53.8) 367 (53.0) 1.00 
Birthweight (g) (N=703)    
 
 Mean 2807 2735 2809 0.13 
 Min-Max 1500-4500 (1500-4000) (2000-4500)  
 Small for gestational age 72 (10.2) 3 (23.1) 69 (10.0) 0.14 
Age (months) (N=705)                                   
 
 Mean 14.8 16.8 14.8 0.84 
 Min-Max (1-35) (8-28) (1-35)  
 0-11 months 220 (31.2) 4 (30.8) 216 (31.2) 0.53 
 12-23 months 392 (55.6) 6 (46.2) 386 (55.8)  
  24 months 93 (13.2) 3 (23.1) 90 (13.0)  
Mothers education (N=705)    
 
 High school or higher 143 (20.3) 1 (7.7) 142 (20.5) 0.37 
 Primary, secondary 351 (49.8) 9 (69.2) 342 (49.4)  
 Illiterate 211 (29.9) 3 (23.1) 208 (30.1)  
Fathers education (N=701)    
 
 High school or higher 195 (27.7) 1 (7.7) 194 (28.0) 0.18 
 Primary, secondary 372 (52.8) 8 (61.5) 364 (52.6)  
 Illiterate 134 (19.0) 4 (30.8) 130 (18.8)  
Housing (wall) (N=705)    
 
 Bricks 540 (76.6) 11 (84.6) 529 (76.4) 0.74 
 Other 165 (23.4) 2 (15.4) 163 (23.6)  
Cooking fuel (N=705)    
 
 Electricity(none) or gas 49 (7.0) - 49 (7.1) 1.00 
 Other 656 (93.0) 13 (100.0) 643 (92.9)  
Known contact with TB case (N=705)    
 
 Yes 85 (12.1) 2 (15.4) 83 (12.0) 0.66 
Symptoms (fever and/or cough) (N=705)    
 
 2 of 2 symptoms 145 (20.6) 3 (23.1) 142 (20.5) 1.00 
 1 of 2 symptoms 142 (20.1) 2 (15.4) 140 (20.2)  
 None 418 (59.3) 8 (61.5) 410 (59.2)  
Fever and/or cough  2weeks (N=705)    
 
 Yes 175 (24.8) 4 (30.8) 171 (24.7) 0.75 
Failure to thrive (FTT) (N=705)    
 
 Yes 537 (76.2) 8 (61.5) 529 (76.4) 0.20 
Chest X-ray (AP) (N=704)    
 
 Consistent with TB 11 (1.6) 11 (84.6) - <0.0005 
 Abnormal, not TB 12 (1.7) - 12 (1.7)  
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 Normal 681 (96.6) 2 (15.4) 679 (98.1)  
Non-tuberculous mycobacteria  (NTM) 
(N=705)     
 1 positive specimen 166 (23.5) 2 (15.4) 164 (23.7) 0.74 
Weight-for-height Z score (WHZ) (N=703)    
 
 Mean -1.80 -1.86 -1.80 0.38 
 Min-Max -4.93-3.61 (-4.06-1.59) (-4.93-3.61)  
 < -2 (wasting) 305 (43.3) 7 (53.8) 298 (43.1) 0.57 
Height-for-age Z score (HAZ) (N=703)    
 
 Mean -1.25 -2.23 -1.24 0.81 
 Min-Max -6.32-3.13 (-2.95-0.35) (-6.32-3.13)  
 < -2 (stunting) 197 (27.9) 6 (46.2) 191 (27.6) 0.21 
Weight-for-age Z score (WAZ) (N=705)    
 
 Mean -1.95 -2.11 -1.95 0.47 
 Min-Max -5.00-1.67 (-3.99-1.33) (-5.00-1.67)  
 < -2 (underweight) 354 (50.2) 8 (61.5) 346 (50.0) 0.58 
BMI-for-age Z score (BAZ) (N=703)    
 
 Mean -1.70 -1.70 -1.70 0.44 
 Min-Max -4.95-4.63 -3.86-1.55 -4.95-4.63  
 < -2 (underweight) 284 (40.3) 7 (53.8) 277 (40.0) 0.40 
Hgb (g/100ml) (N=601)    
 
 Mean 10.7 10.0 10.7 0.16 
 Min-Max 4.0-18.9 8.0-11.6 4.0-18.9  
 
<10 g/100ml (moderate-severe 
anemia) 197 (32.8) 6 (54.5) 191 (32.4) 0.11 
Tuberculosis Skin Test (TST) (N=702)    
 
 Median 4.0 7.5 4.0 0.07 
 Positive (cut-off 10mm) 69 (9.8) 4 (30.8) 65 (9.4) 0.031 
QuantiFERON Gold In-Tube (N=691)    
 
 Positive ( 0.35IU/mL) 36 (5.1) 3 (23.1) 33 (4.8) 0.003 
 Negative (< 0.35IU/mL) 633 (89.8) 8 (61.5) 625 (90.3)  
 Indeterminate 22 (3.1) 2 (15.4) 20 (2.9)  
 Mitogen minus Nil (median) 10 10 10 0.40 
  TB-antigen minus Nil (median) 0.01 0.02 0.01 0.29 
ªComparison of distribution between infants with and without clinical TB disease perforemd by T-test, 
Mann-Whitney U test or Fisher's Exact test where appropriate. 2-sided p-values <0.05 are shown in 
bold. ¹No missing data among infants with clinical TB disease. 
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Table 3. The performance of the Tuberculin skin test (TST) and the QuantiFERON TB Gold In-
Tube (QFT) in the diagnosis of clinical TB disease. 
  
TB status Sensitivity Specificity PPV NPV ț (95%CI)* 
 
Clinical 
TB 
No 
TB      
  N N         
  
Tuberculin Skin Test             
  10mm 4 65 30.8% 90.6% 5.8% 98.6% 0,07 
  <10mm 9 624 (4/13) (624/689) (4/69) (624/633) (-0.02, 0.16) 
QuantiFERON TB Gold In-Tube      
  0.35IU/mL 3 33 23.1% 92.2% 8.3% 98.7% 0,11 
  <0.35IU/mL 8 625 (3/13) (625/678) (3/36) (625/633) (-0.02, 0.27) 
  
Indeterminate 2 20           
*Indeterminate QFT results are excluded from analysis of kappa agreement. Confidence intervals 
that do not overlap the null value ț=1 are shown in bold. 
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Table 4. Kappa agreement (ț)* between the QuantiFERON TB Gold 
In-Tube and the Tuberculin skin test (TST) in  A: all children tested 
with both tests; B: children with known TB exposure. 
  
A: Tuberculin skin 
test, all (N=688) 
B: Tuberculin skin test,  
children with known TB 
exposure (N=79) 
  
10mm, 
N (%) 
<10mm, 
N (%) 
10mm, N 
(%) 
<10mm, N 
(%) 
QuantiFERON TB Gold In-Tube   
  0.35IU/mL 18 (26.9) 18 (2.9) 7 (63.6) 1 (1.5) 
  <0.35IU/mL 48 (71.6) 
582 
(93.7) 3 (27.3) 65 (95.6) 
  
Indeterminate 1 (1.5) 21 (3.4) 1 (9.1) 2 (2.9) 
ț (95%CI) 0.30 (0.18, 0.42) 0.75 (0.42, 0.95) 
*Indeterminate QFT results are excluded from analysis of kappa 
agreement. Confidence intervals that do not overlap the null value 
ț=1 are shown in bold. 
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